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Abstract of the Dissertation
The Degenerating Star Clock: Circadian Clock Regulation of Astrogliosis and Implications for
Alzheimer’s Disease
by
Brian V. Lananna
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2019
Assistant Professor Erik S. Musiek, Chair

Sleep disruption and circadian dysfunction are common symptoms of aging and
neurodegenerative diseases, including Alzheimer’s disease (AD). The molecular rhythms in
transcription/translation that govern these behavioral processes are mediated by clock genes and
can be abrogated by deletion of the master circadian transcription factor Bmal1 (Arntl). We have
shown that disruption of clock gene function in the mouse brain causes astrogliosis, synaptic
damage, oxidative stress, and exacerbated neurodegeneration. However, the molecular
mechanisms linking the circadian clock to these phenotypes and their implications for AD
pathology remain largely unknown. Astrocyte activation occurs in response to diverse insults,
and plays a critical role in brain health and disease. We report that deletion of Bmal1 specifically
in astrocytes causes a pronounced and unique astrogliosis phenotype both in vitro and in vivo,
mediated in part by suppression of glutathione-s-transferase signaling. Functionally, loss of
Bmal1 in astrocytes promotes neuronal death in vitro. This clock-controlled astrogliosis is
characterized by a robust upregulation of a number of known astrocyte activation markers and a
xi

hyperinflammatory phenotype, including almost complete loss of the astrocytic inflammatory
regulator and AD cerebrospinal fluid biomarker, Chi3l1 (YKL-40). The function of
Chi3l1/YKL-40 in the setting of AD is unknown. Mutation of the BMAL1 repressors Per1 and
Per2 increases expression of Chi3l1, reinforcing the idea that Chi3l1 is regulated by the
circadian clock. The astrocytic clock also gates inflammatory induction of Chi3l1, while Chi3l1
deletion exaggerates LPS-induced astrocyte inflammation in vitro and neuroinflammation in
vivo. These data suggest that BMAL1 may regulate neuroinflammation through Chi3l1.
Surprisingly, Chi3l1 deletion mitigates astrocyte activation, promotes peri-plaque expression of
the microglial lysosomal marker CD68, and leads to a significant suppression of Aβ deposition
in a β-amyloidosis AD mouse model. Finally, in a large observational cohort of AD patients, we
found that a variant in the human CHI3L1 gene, which decreases CSF YKL-40, was significantly
associated with slower AD progression. In a preliminary study, we show that the microglial
circadian clock may also contribute to regulation of the neuroinflammatory and neuroimmune
responses. Together, our findings demonstrate that the core clock protein BMAL1 regulates
astrocyte activation and function in vivo and reveal Chi3l1/YKL-40 as a clock-regulated
modulator of AD pathogenesis both in mice and humans. Thus, we have elucidated a novel
mechanism linking the circadian clock with neuroinflammation and AD.
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Chapter 1: Introduction to the Dissertation
Brian V. Lananna

1

Historically characterized as neuronal support cells, the crucial role of astrocytes in regulating
neuroimmune function has become increasingly appreciated1. Although a common feature of
diseases from Alzheimer’s and other dementias to stroke, traumatic brain injury, viral and
bacterial infections, and autoimmune disease, astrocyte activation, or “astrogliosis” remains
ambiguously defined and its consequences elusive2. Meanwhile, changes in behavioral circadian
rhythms such as disrupted sleep/wake activity patterns and sleep fragmentation are also common
in a wide range of neurodegenerative diseases such as Huntington’s3,4, Parkinson’s5–8 (PD), and
Alzheimer’s9–14 (AD). Dysfunction of the molecular clock, which regulates the sleep/wake cycle
along with many other systemic and cellular processes, has been shown to drive inflammation
and reactive oxygen species (ROS) production in the brain15 and peripheral immune system16,17.
However, the capacity for the molecular clock to regulate astrocyte immune function and the
implications for such a role in AD has not been investigated.
Thus, I will begin with a brief overview of known and emerging astrocyte functions, circadian
rhythms in health and disease, and the pathogenesis of AD with a particular focus on the role of
glia. The original work presented thereafter will ultimately theorize a role for the molecular
circadian clock in cell-autonomously regulating a previously undescribed form of astrogliosis
and propose targeting the astrocytic protein YKL-40 (gene name Chi3l1), a key downstream
effector of this pathway, to modulate glial function as a potential therapeutic for AD. This work
will be followed by presentation of a preliminary and ongoing investigation into microglial clock
function in the neuroimmune system and a possible role in AD pathogenesis. This dissertation
will conclude with a discussion of the implications for these investigations and possibilities for
future directions.

2

1.1 A star with many faces
Michael von Lenhossék first coined the term “astrocyte” in 1895 as he described a “star-shaped”
cell with a multitude of long, fine processes in the spinal cord of a young boy (Fig. 1.1)18,19.
Shortly thereafter, Santiago Ramón y Cajal impressively hypothesized complex interactions
between astrocytes and neurons as he optimized staining methods for detection of astrocytes and
other glia (Fig. 1.2)19. Observing clear contacts between astrocytic end feet and blood vessels,
Cajal correctly inferred astrocytic regulation of blood vessel dilation. Indeed, astrocytes can
respond to neuronal glutamate by releasing internal Ca2+20, which, in an O2 dependent manner,
leads to the release of arachadonic acid, inducing vessel dilation21,22. In addition to modulating
blood flow, these astrocyte-vessel contacts play an integral role in regulating the blood brain
barrier23 and the purported glymphatic CSF recycling/waste clearance network24,25.

Figure 1.2. Astrocytes from Ramón y Cajal’s
original slides.
Figure 1.1. The first astrocyte.
"’Astrocytes’, star-shaped cells, are the small
elements which form the supporting system of
the spinal cord, in fact (Fig. 20), no other
comparison gives their peculiarity as aptly.”
From von Lenhossék, 189518. Translated from
German by Google translate.

C. Astrocyte stained by formol-uranium nitrate
method. ef = endfeet, bv = blood vessel.
F. Astrocyte stained by silver carbonated method.
From García-Marín et al., 200719.
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Cajal’s intricate drawings depicting intimate connections between astrocytes and neurons (Fig.
1.3) as well as his resultant insight also predicted an active and dynamic role for astrocytes in
modulating neuronal signaling26. It is now thought that astrocytes envelope synapses to form a
“tri-partite synapse” where they respond to neurotransmission by upregulating internal Ca2+.
This Ca2+ change induces astrocytic release of neurotransmitters and neuromodulators thereby
modifying synaptic strength and neuronal activity27. For example, astrocyte release of glutamate
in response to hippocampal granule neuron activity can induce presynaptic strengthening through
NMDAR-dependent upregulation of mEPSC frequency28, or induce post-synaptic strengthening
through an NMDAR-independent mechanism29.
Figure 1.3. Reproduction of
original drawing of neuroglia
from Ramón y Cajal in
hippocampus of adult man
autopsied 3 hours after death.
A, B = astrocytes, C, D = neurons, a
= “third element” (satellite cell), E =
cell undergoing “autolysis”. Stained
via sublimated gold chloride
method. From Navarrete and
Araque, 2014 taken from Instituto
Cajal26.
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Cajal even surmised a relationship between astrocyte/neuronal signaling and the sleep/wake
cycle19. As is discussed later in this text, only in the last few years has the impressive extent to
which astrocytes regulate sleep/wake rhythms been revealed30–33. The nature of this relationship
is in fact quite different than that originally envisioned by Cajal who proposed astrocytes as an
off-switch to daytime neuronal activity19. However, his mere suggestion that astrocyte signaling
could be important for sleep/wake is exceptionally precocious and speaks to the value he placed
on the role of astrocytes in regulating brain function.
Despite his astute inferences emphasizing the importance of glial function in the CNS, Cajal
predicted a major obstacle toward progress in the field of glial research, suggesting,
The prejudice that the relation between neuroglial fibers and neuronal cells is similar to
the relation between connective tissue and muscle or gland cells, that is, a passive for
merely filling and support (and in the best case, a gangue for taking nutritive juices),
constitutes the main obstacle that the researcher needs to remove to get a rational concept
about the activity of the neuroglia.
-Santiago Ramón y Cajal, 189926
While this statement proved eerily prophetic for the majority of the 20th century, glial research
has received renewed vigor over the past couple of decades. Accordingly, our knowledge of the
breadth and fundamental necessity of astrocyte function has grown substantially since the time of
Cajal.
Evidence now suggests that astrocytes begin differentiating from neural stem cells between
E11.5-12.5 in the spinal cord and E16-18 in the cortex of mice34–36 and just prior to 17-20 weeks
gestation in humans37. Astrocyte proliferation increases dramatically after birth and, reinforced
via prolific post-differentiated self-renewal in the cortex38, astrocytes become the most abundant
glial cell39, contributing to an eventual glia:neuron ratio of approximately 1:1 in the brain40.
5

Astrocyte maturation continues through approximately 6-12 months in humans37 or the third
postnatal week in mice38,41–43 as astrocytes across every region of the brain assume residence of
primarily discrete, tiled domains, which they cover with an intricate array of fine processes42,44.
While similar in morphology, human astrocytes display an even more complex meshwork of
processes, containing ~27 times greater volume than mouse astrocytes45. Despite ubiquitous
coverage of the brain by astrocytes, substantial region specific diversity in astrocytic gene
expression, which may be even more pronounced in aging46,47, suggests heterogeneous
functional populations37,48,49.
Astrocytes regulate axon guidance50,51, axon branching52, dendrite morphology,53 and
synaptogenesis52 during development. They secrete factors, such as thrombospondins54,
glypicans55, and chordin-like 156, that are region specific57, and essential for the development of
functional and mature synapses. Astrocytes shape circuit development by phagocytosing
synapses58 and mediating microglial phagocytosis58,59. Synapses enveloped by astrocytic
processes also benefit from neurotransmitter recycling services60 and a lactate shuttle system61–63
helps ensure neuronal nutrition64. Astrocytes are capable of generating complex, microdomainspecific, calcium transients, both spontaneous and evoked by neuronal signaling65. Although
still controversial66,67, this astrocyte Ca2+ signaling may play important roles in regulating
neuronal circuits65,68–71 with potential consequences for cognition69,72 and neurovascular
coupling73. Despite the myriad astrocytic functions outlined, many details on the regulation,
interactions, and heterogeneity of these functions are yet to be elucidated. Perhaps the most
underappreciated and poorly defined role for astrocytes is that of immune regulation including
the dynamic range of astrocyte function during disease.

6

1.2 Toward a working definition of astrogliosis
The gene expression and morphological changes induced in astrocytes in an abnormal brain state
are collectively referred to as “astrogliosis”2. Some reports cogently claim that the term
“astrocyte activation” should remain a distinct label as it potentially encompasses homeostatic
alterations in astrocyte signaling or function2. However, as is common practice in the literature,
these two designations are used synonymously in this text. Visibly distinct due to upregulation
and hypertrophy of glial fibrillary acidic protein (GFAP) positive processes74, astrogliosis is
complex and, in truth, refers to a spectrum of genetic and functional changes2. Astrogliosis can
be induced by neuronal injury, inflammatory factors from microglia or the periphery, protein
aggregates, lipopolysaccharide (LPS), and many other stimuli1,75,76. The exact functional change
resulting from activation of an astrocyte depends on the type77 and severity of the
perturbation2,78, the brain region79,80, the astrocyte subpopulation within a region81, and on the
age of the subject in question46,47,82. For instance, LPS induces astrocytic production of proinflammatory cytokines and chemokines83,84. Reactive astrocytes can secrete factors that inhibit
remyelination85 and neuronal outgrowth86 in multiple sclerosis models, or drive inflammation87
and dopaminergic neuron toxicity in models of Parkinson’s disease (PD)87. Astrogliotic
neurotoxicity can be promoted by inflammatory factors77,84,88 or suppressed in response to
growth factors secreted by microglia89 or T-cells90. Conversely, activated astrocytes can secrete
complement and other factors, which markedly affect microglia and monocyte function in a
context dependent manner91–95. Activation also alters astrocyte Ca2+ signaling82,96 and neuronal
excitability97.
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On the other hand, glial scars consisting of newly proliferated as well as resident, activated
astrocytes81,98 can substantially limit the spread of inflammation and neuronal injury in models of
stroke,99,100 spinal cord injury,101,102 or traumatic brain injury103,104. Activated astrocytes can
exert dramatic anti-inflammatory effects in autoimmune disease105,106 while autoimmune
diseases targeting astrocytic aquaporin-4 are more severe107,108. Transplanting astrocytes into a
model of PD can improve therapeutic outcomes109 and astrocytes can provide protein
degradation services in neurodegenerative disease110,111. Additionally, modulating, but not
resolving astrogliosis rescued dopaminergic cell loss and behavioral deficits in a PD mouse
model112 suggesting that astrogliosis is not inherently detrimental. The astrocytic response in
AD is, in itself, complex and multifaceted and will be discussed later in this text. The disparate,
context-dependent regulation and downstream consequences of documented astrogliosis
highlight two central themes in the field. First, despite common alterations in GFAP, astrogliosis
does not exist as a single state. Second, there is much work ahead before we are to better predict
and/or manipulate astrocyte function in a given condition.
Recent efforts have attempted to classify differential astrocyte activation phenotypes according
to activation markers upregulated during LPS treatment (A1 or neurotoxic phenotype), stroke
(A2 or neurotrophic phenotype) or both (pan-reactive)77,84. Such work aims to begin associating
the different functions of activated astrocytes with particular gene signatures. Thus, we might
eventually be able to use gene expression changes as proxies to recognize, understand, and
potentially skew changes toward a beneficial outcome. This strategy can be an important step
forward if employed thoroughly and judiciously. However, as the catalogue of astrocyte
activation states inevitably expands, it is vitally important to keep in mind that unless the
function of a particular gene change in astrocytes is clearly defined, the altered expression of a
8

single “activation marker” among many alterations is essentially meaningless. The utilization of
genetic marker expression in settings of “astrogliosis” is valuable only when paired with
measured, not assumed, astrocyte functional outcomes.
These efforts will prove even more valuable when gene expression changes common to multiple
settings of astrogliosis correspond to shared functional changes. This overlap will allow the
inference that a particular genetic signature is not unique to a perturbation, but potentially
reflects a functional astrocyte state change. Oversimplification of astrogliotic classification by
forcing a binary choice between neurotoxic and neurotrophic (A1 or A2) would be a mistake,
creating a distracting and artificial rift in the astrocyte field akin to the M1/M2 controversy in the
field of microglial activation113. With these caveats in mind, the work described herein will
utilize changes in GFAP as a default marker of astrogliosis in that it identifies a non-homeostatic
astrocyte state. Importantly, changes in GFAP measurements will be accompanied by
complementary assays in an effort to more completely describe the consequences of the
described astrogliosis. Only with this accompanying information will the term “astrogliosis”
mean anything beyond “altered”.

1.3 The daily grind: Circadian rhythms from sleep/wake to
the astrocyte molecular clock
Organisms from plants114 to bacteria115 and fruit flies to mammals, including humans116, have
evolved to synchronize their physiology and behavior to the approximately 24-hour rotation of
the earth. Governed by the suprachiasmatic nucleus of the hypothalamus (SCN), mammalian
circadian rhythms in such parameters as sleep, physical activity, and endocrine function
accommodate this 24-hour cycle117. The SCN receives environmental input primarily from light
9

via its direct connection to the retina117–119, but can also be synchronized via temperature120 and
other behaviors121. The SCN then communicates the rhythmicity of these cues to the rest of the
brain and body through mechanisms such as rhythmic neuronal firing122–125 and release of
neuropeptides such as vasoactive intestinal polypeptide (VIP)126 among others127. The SCN is
both necessary and sufficient for circadian rhythm generation in mammals128,129.
The rhythmic output of the SCN is both dependent on130–132 and feeds back into133 a molecular
clock125, which is composed of a series of transcription-translation feedback loops (TTFLs). The
positive limb of the core molecular clock TTFL consists of heterodimers of the bHLH
transcription factor BMAL1 (gene name Arntl, aryl hydrocarbon receptor nuclear translocatorlike protein 1) with either CLOCK (circadian locomotor output cycles kaput) or NPAS2
(neuronal PAS domain protein 2). To avoid confusion, “Bmal1” will be used to refer to both the
protein and the gene throughout this text. The negative limb includes Period (PER),
Cryptochrome (CRY), and REV-ERB (gene name Nr1d1, nuclear receptor subfamily 1, group D,
member 1) family genes, which are transcriptional targets of BMAL1 and provide negative
feedback inhibition of BMAL1 function117. Although an individual cell is capable of
maintaining intact circadian clock TTFLs134, synchronization of these clocks between cell
populations requires input from the SCN135,136. As all other genes have family members or
stand-ins with overlapping function, deletion of Bmal1 is the only single gene manipulation that
completely abrogates both behavioral and molecular rhythms121. The core clock regulates
transcription of thousands of genes in a highly tissue-specific manner with as much as 40% of
the genome regulated by the clock in at least one tissue137,138. Across various tissues, the clock
regulates a wide range of cellular functions including metabolism, inflammation, and redox
homeostasis139.
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Molecular clocks are expressed and oscillate in cells throughout the body138 and brain136
including in astrocytes140 and microglia141,142. In the SCN, astrocytic clocks are synchronized by
VIP143 and can be altered by immune factors such as TNFα144. Astrocytic extracellular ATP
release145, which has potential implications for allodynia146 and gliotransmission147, and
glutamate uptake148 are regulated by the clock. Additionally, astrocytes play a substantial role in
maintaining behavioral circadian rhythms. For instance, under certain conditions, glial clock
dysfunction can cause behavioral arrhythmicity in flies149. Several recent studies have
independently documented an even more impressive role for the clock in SCN astrocytes in
determining the phase and period of mouse circadian rhythms30,32,33. Surprisingly, it was also
shown that SCN astrocytes are capable of generating population-wide circadian clock
oscillations and mouse activity rhythms in the absence of intact neuronal clocks31. Despite the
robustness of the astrocytic clock in the SCN, relatively little is known about its function
elsewhere in the brain and outside of behavioral rhythm maintenance.
Maintaining the integrity of circadian rhythms is crucial for optimizing a large host of
physiological outputs including, but not limited to long-term potentiation150,151 and associated
cognition152,153, metabolic health154, reaction time155,156, and muscle performance157,158.
Accordingly, the perturbation of rhythms, for instance with nighttime light exposure141, circadian
misalignment (shift work)159 or jetlag160, can impair these functions. Circadian disruption also
increases risk factors161–164 and worsens outcomes165 for acute neurological and cardiovascular
events, which already display daily rhythms in occurrence166–169.
Deterioration in behavioral rhythms such as the sleep/wake cycle early in
neurodegeneration14,170,171 and mild-cognitive impairment9, and in the robustness of SCN firing
rhythms with age172 have been documented. While these changes could simply represent a
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global breakdown of all brain function in these conditions, the more intriguing possibility that
changes in the circadian system could drive or contribute to pathology remains relatively
unexplored. Circadian dysfunction can occur as one of the earliest symptoms in
neurodegenerative models13 and the circadian phase can dramatically affect the efficacy and
toxicity of drug treatments173–175. The potent regulation of the peripheral immune system by the
circadian clock will be discussed in the next section. In combination, these findings suggest that
investigation into the interaction between the circadian clock and disease pathogenesis could be a
boon to our understanding of diseases such as AD as well as to the development of therapeutics.

1.4 It’s all about timing: Circadian regulation of the immune
system
The association between circadian rhythms and disease risk and progression is indicative of an
intimate connection between the circadian clock and the immune system176. Indeed, the
circadian clock regulates inflammatory and oxidative stress responses. For example, both lesion
of the SCN177 and light induced rhythm disruption178 can exacerbate release of cytokines
TNFα177 and IL-6177,178 in response to LPS, while LPS can differentially activate SCN neurons
based on time of day177. Chronic circadian phase shifts (chronic jet-lag)179 or merely varying the
time of day180,181 can heighten both inflammation and LPS-induced endotoxemic death in mice.
Global and brain-specific Bmal1 KO as well as Clock/Npas2 double KO mice have agedependent increases in ROS damage, chronic inflammation15,182 including increased Tnfa,
microglia and astrocyte activation, and synapse degeneration15. Global Bmal1 KO mice also
suffer from reduced lifespan as well as a number of other aging-associated impairments182. In
monkeys, Bmal1 KO can induce immune system activation and depression-like symptoms183.
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Importantly, clock genes including Clock, Per2184, Bmal1, and the BMAL1 target Nr1d1
oscillate in peripheral macrophages16,184 and lymphocytes185. In humans, the LPS-induced blood
levels of cytokines Interferon-γ (IFN-γ), Interleukin-10 (IL-10)186, and TNFα187,188 vary
consistently based on time of day while IL-6 levels vary inconsistently187,188. In mice,
lymphocyte trafficking185, LPS-induced monocyte recruitment, cytokine levels including TNFα,
IL-6184, IL-1217, inducible nitric oxide synthase (iNOS - reactive NO-producing enzyme)16,
chemokines including CCL517, and mortality189 exhibit time of day dependence with a reduction
during late wake/early rest periods16,184. This reduction can be abolished upon monocyte
Bmal116 or Nr1d117 KO indicating an immune-suppressive role for these proteins. Accordingly,
Bmal1 KO in monocytes reduces survival in response to infection and exacerbates chronic
inflammation and glucose intolerance in a mouse model of diet-induced obesity16. Deletion of
Bmal1 also induces an Nrf2-dependent increase in ROS and IL-1β in macrophages190.
Disruption of BMAL1-regulated neutrophil aging can impair immune defense and vascular
protection in mice191.
In vitro, Bmal1 KO can cause increased neuronal degeneration, death, and susceptibility to
oxidative damage15. Additionally, it was found that the BMAL1/CLOCK complex binds
chemokine Ccl2 and Ccl8 promoters16 while BMAL1 binds the promoters of genes protective
against oxidative stress, which are also downregulated in Bmal1 KO mice15. Nr1d1 KO
increases IL-6 secretion while REV-ERBα (Nr1d1) agonist GSK411217,192 and Nr1d1
overexpression192 suppresses IL-6 release. In further support of BMAL1-mediated immune
suppression, KO of two repressors of BMAL1 activity, Per2193 and microRNA miR-155, can
reduce TNFα180, IL-1β, and IFN-γ193 secretion upon LPS treatment. Taken together, these and
similar studies make a strong case for the circadian clock as an important immune regulator,
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providing a limiting check on immune over activation in the periphery.
The neuroimmune system, primarily under the purview of glia, may also be subject to regulation
by the molecular clock. In addition to the astrocytic clock discussed in the previous section, a
few recent reports have documented oscillating clock gene expression including Bmal1, Per2,
and Nr1d1 in microglia141,142,194. Cytokine levels including Il-6, Tnfa, and the critical
inflammasome component Nlrp3 (only measured after LPS), among others, show circadian
variation in unstimulated and LPS-stimulated whole hippocampus and microglia141. Aging
abolishes these differences, clamping the microglial inflammatory response to LPS at its highest
level in younger mice195. Little is known about astrocyte clock function in the immune system.
However, BDNF and Nrf2-dependent oxidative stress protection provided by astrocytes to
neurons196 and NF-κB-mediated inflammation may both be regulated by the astrocytic clock197.
Nr1d1 KO induces microgliosis and astrogliosis in vivo and exacerbates the neuroinflammatory
response to LPS treatment, including NF-κB signaling, in vivo as well as in cultured microglia198.
However, one study demonstrated a surprising depression of Il-6 expression in microglia and a
mitigation of stroke damage in vivo after deleting Bmal1199. The varied results from glial clock
manipulations suggest a more nuanced clock regulation of the glial immune response and
underscore the need for further investigation.
The general finding of an upregulated immune system at the rest to wake transition16,17,141 is
likely preemptive, preparing the body for increased possibilities of infection exposure during
“morning” foraging and conservationist, minimizing both energy expenditure at unneeded times
and collateral damage induced by a constitutively active immune system200. These studies in the
peripheral and central immune systems as well as the pro-inflammatory, pro-ROS phenotypes of
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Bmal1 mutants support the possibility that the circadian clock gene could regulate the CNS
immune response in microglia and astrocytes.

1.5 Stars and time in Alzheimer’s disease
Alzheimer’s disease (AD) is the 6th leading cause of death in the United States where it and other
dementias will cost an estimated $290 billion in 2019201. There is currently no treatment that can
cure, prevent, or slow the progression of AD201. As astrocytes1,92,111,202–205 and microglia206–212
are tightly intertwined with immune regulation, protein aggregation, and resultant synaptic
damage in AD, understanding the mechanisms connecting these processes is critical for the
development of effective therapeutics213. Circadian dysfunction in AD and other dementias on
both behavioral10–14,214 and molecular215–217 levels is well documented and can occur early in
disease progression. Thus, investigating the ability of the astrocytic and microglial clocks to
regulate neuroimmune responses and resultant disease progression could be foundational steps in
understanding the pathogenesis of AD.
AD is characterized by an accumulation of amyloid-beta (Aβ) plaques and hyper-phosphorylated
tau neurofibrillary tangles (NFTs). Aβ is a fragment resulting from cleavage of the amyloid
precursor protein by β- and γ-secretases, which can aggregate to form Aβ plaques. While the
deposition of NFTs more closely correlates with the progression and severity of the clinical
disease course, the accumulation of Aβ is the initiating event of AD and begins approximately
10-20 years before the presentation of clinical symptoms213,218,219. The hallmark gliosis
surrounding AD protein aggregates was drawn and described by Alois Alzheimer in his original
work classifying the disease (Fig. 1.4)220–222. Alzheimer was fascinated by the pronounced glial
phenotype and hypothesized that they played a role in plaque formation223.
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Figure 1.4. Drawing of
AD pathology and
associated gliosis by
Alois Alzheimer.
Drawing of pathology in
Alzheimer’s second
patient, Johann F. Credit
in 1911. glz = glia, gaz =
ganglion neuron, P1 =
plaque core, P2 = plaque
halo. “The glia had
abundant formed fibers; in
addition, many glial cells
showed large deposits.” –
Alois Alzheimer220. From
Dahm, 2006221. Originally
from Alzheimer, 1911222

Astrocytes and microglia surround Aβ plaques in both human AD224,225 and mouse models of
AD202,226–228. When exposed to Aβ, astrocytes upregulate and release cytokines and chemokines
which attract and activate microglia203,208. Astrocytes also produce ROS and complement
proteins such as C3 in AD, which both directly damage neurons92,203 and induce microglial
synaptic pruning211. The astrocytic protein, YKL-40 (Chi3l1) is a documented inflammatory
regulator229–231 and a biomarker of AD232 and other inflammatory conditions233–236, but its
potential role in the pathogenesis of AD is unknown.
Despite data that temporary ablation of microglia failed to influence pathological progression in
an AD mouse model237, recent evidence suggests that microglia-driven neuroinflammation and
oxidative stress contribute significantly to AD pathogenesis and neurodegeneration238–246. An
extensive microarray study of 1647 post-mortem human brain samples found that immune
system and microglia-specific genes involved in the inflammatory, phagocytic, microglial
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activation, and ROS-producing pathways were significantly upregulated in sporadic AD244.
Increased NOX2, ROS damage209, and inflammasome activation207 in the brain as well as
increased levels of circulating cytokines including IL-6239 and TNFα have also been observed in
human AD patients238 with increased TNFα 242 and NOX2209 being predictive of cognitive
decline. In AD mouse models, increased levels of oxidative stress247 and pro-inflammatory
cytokines including TNFα 240,241, IL-6, and IL-12240, among others have been observed.
However, discovery of significant AD risk conferred by mutations in genes that modulate
microglial phagocytosis of Aβ such as triggering receptor expressed on myeloid cells 2
(TREM2)248,249 and CD33250,251 suggests that microglia can also play a beneficial role in AD.
Additionally, reports that microglia limit plaque formation228, ingest252,253 and clear Aβ early in
AD227,253, release Aβ degrading enzymes254,255, and that impairing microglial accumulation
accelerates pathology226 further illustrate the constructive actions of microglia in AD. Astrocytes
release Aβ degrading enzymes, ingest and degrade Aβ110, facilitate clearance of soluble Aβ by
bulk flow24 and enhance microglial degradation of Aβ through lipidation of APOE256. Altering
astrocyte activation has variable effects on Aβ plaque deposition depending on the mechanism of
perturbation202,204,205,257. Thus, pushing the balance of astrocytic and microglial actions toward
the beneficial end of the spectrum could serve as a therapeutic strategy for AD206. However, the
inconsistent results of clinical trials for anti-inflammatory drug therapy in AD indicate that a
more specific approach is likely required208.
While sleep dysfunction can be both a predictor of AD development and exacerbate AD
pathology, the precise roles of circadian rhythm dysfunction and clock proteins such as BMAL1
in AD remain nebulous10. For example, in a study of 1282 cognitively normal women,
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behavioral circadian dysfunction carried an increased risk of 50-83% for developing AD over a
five-year period9. ISF and CSF levels of Aβ protein oscillate in a circadian manner in both
humans258 and mouse models of AD259. Deposition of Aβ can disrupt the sleep/wake cycle260
while disrupting circadian rhythms can induce Aβ deposition261. CSF tau also varies with the
sleep/wake cycle in mice and humans while sleep deprivation can increase CSF tau and tau
deposition262. These effects could be due to either sleep irregularities10 or changes in SCN
output as decreases in both arginine vasopressin (AVP) expression12 and the number of VIPproducing, synchronization neurons11 have been shown in the SCN in AD. The role of cell
autonomous clocks in these phenomena is unknown10.
A study using the 5xFAD mouse model of AD reported highly disrupted behavioral and body
temperature rhythmicity that correlated with age215. The study also found that Aβ induced
changes in the cellular oscillations of BMAL1 and PER2 as well as changes in post-translational
modification (sumoylation) and activity of these proteins, respectively215. Additionally, three
studies in Han Chinese populations found distinct polymorphisms in the CLOCK gene that
significantly increase risk of developing AD263–265. Overall, these studies provide evidence that
AD could impact the molecular circadian rhythms of AD patients, but determining the precise
nature of that influence, its consequences, and the possibility that changes in circadian rhythms
could precede, or even drive AD pathology require further investigation.

1.6 Everything’s connected: Circadian regulation of the
astroglial immune response in AD
Astrogliosis, microgliosis, impaired circadian function, and immune dysfunction coexist
consistently across aging and pathological conditions, including Alzheimer’s disease1,200,214,266.
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Despite documented regulatory overlap between several combinations of these areas of active
inquiry, the idea that they are all connected via a single unifying thread has not been explored.
That is, astrocyte function is crucial for maintaining brain homeostasis, including circadian
rhythm integrity, which breaks down in AD. At the same time, the circadian clock is vital in
optimizing immune function, which is also compromised in AD. Additionally, astrocytes and
microglia play substantial, highly integrated roles in neuroimmune regulation and in the
pathogenesis of AD. Thus, this dissertation will evaluate a potential function of the astrocytic
molecular clock in regulating astrogliosis and the consequences of such regulation for the
pathological progression of AD. A complementary, in-progress study will begin to parse an
emergent role of the microglial clock in neuroimmune modulation, eventually in the setting of
AD. This investigation is therefore in the unique position of linking unanswered questions in
several fields simultaneously, revealing both innovative possible therapeutic targets for treating
AD and potential avenues for prolific future study.
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Figure 2.1. Graphical Abstract.

2.1 Summary
Circadian clock dysfunction is a common symptom of aging and neurodegenerative diseases,
though its impact on brain health is poorly understood. Astrocyte activation occurs in response to
diverse insults, and plays a critical role in brain health and disease. We report that the core
circadian clock protein BMAL1 regulates astrogliosis in a synergistic manner via a cellautonomous mechanism, and a lesser non-cell-autonomous signal from neurons. Astrocyte21

specific Bmal1 deletion induces astrocyte activation and inflammatory gene expression in vitro
and in vivo, mediated in part by suppression of glutathione-s-transferase signaling. Functionally,
loss of Bmal1 in astrocytes promotes neuronal death in vitro. Our results demonstrate that the
core clock protein BMAL1 regulates astrocyte activation and function in vivo, elucidating a
mechanism by which the circadian clock could influence many aspects of brain function and
neurologic disease.

2.2 Introduction
Changes in behavioral circadian rhythms are common in many neurodegenerative diseases8,170,214
and can occur early in disease progression14. In addition to disrupted activity and sleep rhythms,
dysregulated circadian gene expression patterns are also observed in neurodegenerative disease
models and patients8,215,267. However, the impact of clock dysfunction on neurologic diseases of
the brain remains poorly understood.
Astrocytes and astrocyte activation play critical roles in brain health and neurodegenerative
disease, as dysfunctional astrocytes can drive neurodegeneration92,268,269. Recent work has begun
to elucidate the diversity of astrocyte activation phenotypes beyond GFAP, as astrocytes
activated by different stimuli express unique transcriptional profiles which can be associated
with divergent phenotypes, ranging from neurotoxic to neurotrophic77,84. However, a further
understanding of astrocyte activation mechanisms is needed in order to effectively target
astrocyte function therapeutically.
Astrocyte activation and circadian clock dysfunction are two pervasive, often co-existent features
of neurological diseases, though their interaction is unknown. We previously observed that
deletion of the core clock gene Bmal1, which abrogates all circadian clock function, caused
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severe, spontaneous astrogliosis throughout the mouse brain, which was accompanied by
increased oxidative stress, synaptic damage, and inflammation15. However, the cellular and
molecular mechanisms linking BMAL1 to astrocyte activation and function remain uncertain.
Thus, we sought to characterize the astrocyte activation induced by circadian clock disruption
and evaluate whether the clock protein BMAL1 might regulate astrogliosis in a cell-autonomous
manner.

2.3 Results
We first asked if non-genetic disruption of circadian rhythms could influence Gfap levels in the
brain. Exposure of wild type (WT) C57Bl/6 mice to a 10hr:10hr light:dark cycle induces
circadian desynchrony and eventually arrhythmicity, as well as loss of detectable circadian
transcript oscillations in the cerebral cortex (Fig. 2.2A and S2.1A). After 6 weeks of circadian
disruption, Gfap transcript levels were increased throughout the circadian cycle (Fig. S2.1B),
with an average increase of 19.7% (Fig. 2.2B). Thus, light-induced behavioral circadian rhythm
disruption promotes astrocyte Gfap expression.
We previously observed that abrogation of circadian function by deletion of Bmal1 in mice
induced striking increases in GFAP+ astrocytes throughout the brain15,270. We asked if the
astrocyte activation observed following Bmal1 deletion was simply a response to neuronal
injury, or a cell-autonomous process regulated by the core clock in astrocytes. To address this,
we examined the brains of neuron-specific Bmal1 KO mice (Camk2a-iCre;Bmal1f/f). These mice
express Cre recombinase in a pan-neuronal manner under the control of a BAC-CaMKIIa
promoter, yielding widespread neuronal deletion of Bmal1 (Fig. S2.1C) and loss of behavioral
circadian rhythms271.
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Figure 2.2. Light-induced circadian disruption or neuron-specific Bmal1 deletion partially
recapitulate the astrocyte activation phenotype observed following brain-specific Bmal1
deletion.
A. Cortical qPCR from 6-week old WT mice housed in 12h:12h or 10h:10h light:dark cycles for 6 weeks,
harvested every 6 hours from CT0-CT18 reveals blunting of circadian gene oscillations in 10h:10h mice.
B. Total Gfap mRNA levels for mice from (A). **p<0.01 by 2-tailed T-test.
C. Representative images showing GFAP immunostaining of hippocampus (upper panels) and cingulate
cortex (lower panels) of neuron-specific Bmal1 KO mice (Cam2a-iCre+;Bmal1f/f ) and brain-specific
(neurons+astrocytes) Bmal1 KO mice (Nestin-Cre+;Bmal1f/f) at 4mo. Scale bar = 100 μm.
D. Quantification of GFAP immunoreactivity in two brain regions of Cre-, Cam2a-iCre+;Bmal1f/f, and
Nestin-Cre+;Bmal1f/f mice. N=3-4/genotype. Each data point=1 mouse. *p<0.05 by 1-way ANOVA.
E. Quantification of astrocyte activation transcripts by qPCR in cortex of Cre-;Bmal1f/f, Cam2aiCre+;Bmal1f/f, and Nestin-Cre+;Bmal1f/f mice. The clock-controlled gene Nr1d1 is shown to illustrate
loss of BMAL1-mediated transcription. *p<0.05 by 2-way ANOVA with Dunnett’s post-test for multiple
comparisons.
All data represent mean±SEM.

At 4mo, Camk2a- iCre+;Bmal1f/f mice exhibited a modest increase in astrocyte activation, as
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assessed by GFAP immunostaining (Fig. 2.2C,D) and qPCR (Fig. 2.2E), in the cortex and
hippocampus. However, similarly-aged Nestin-Cre+;Bmal1f/f (referred to as NBmal1 KO) mice,
in which Bmal1 is deleted in neurons and astrocytes, have much more prominent astrogliosis
throughout the brain and higher expression of activation-related transcripts Aqp4 and Serpina3n
(Fig. 2.2C-E). While NBmal1 KO mice exhibit large increases in GFAP+ astrocytes in the
cortex, this did not appear to be due to increased astrocyte division, as NBmal1 KO mice had no
significant increase in dividing Ki67+, GFAP+ double-positive cells (Fig. S2.1D), or in
immunoreactivity for the pan-astrocyte marker S100B (Fig. S2.1E). This finding suggests that
while a small component of astrogliosis observed following Bmal1 deletion may be a response to
neuronal injury, BMAL1 within astrocytes appears to play a critical cell-autonomous role in
astrocyte activation.
To assess the potential cell-autonomous effects of Bmal1 on astrocyte activation, we generated
primary astrocyte-enriched cultures from Bmal1 KO mice and WT littermates, and examined
activation markers in vitro. Bmal1 KO astrocytes were viable and appeared to have normal
morphology, but had significantly elevated expression of Gfap and Aqp4 mRNA and GFAP
protein (Fig. 2.3A,B), suggesting spontaneous activation in the absence of neuronal influence. In
order to exclude a developmental influence of BMAL1, we used siRNA to knock down Bmal1
expression in WT primary astrocyte cultures. This method resulted in a 95% decrease in BMAL1
protein (Fig. 2.3C,D) and a 66% decrease in expression of the BMAL1 target Nr1d1 (which
encodes REV-ERBα)(Fig. S2.2A). Bmal1 knockdown (KD) in astrocytes induced a highly
consistent (across 14 independent experiments) 36% increase in Gfap mRNA expression (Fig.
S2.2A) as well as a 68% increase in GFAP protein (Fig. 2C,D). We also saw a significant
increases in the astrocyte activation marker S100a6 (1.7 fold), the cytokine Il6 (2.4 fold), and
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Il33 (1.6 fold) (Fig. S2.3A), an astrocytic cytokine implicated in astrocyte-microglia signaling94.
Bmal1 KD in primary astrocytes from Per2-luciferase reporter mice caused a loss of circadian
Per2 rhythms (Fig. 2.3E). Thus, disruption of circadian function via knockdown of Bmal1 in WT
astrocytes induces a cell-autonomous reactive phenotype in vitro.
We next sought to confirm these findings by specifically deleting Bmal1 in astrocytes in
vivo. We found that intracerebroventricular injection of an AAV8 viral vector expressing eGFP
under a Gfap promoter (AAV8-GFAP-eGFP) on postnatal day 2 led to widespread eGFP
expression in resting astrocytes throughout the cerebral cortex, with almost no neuronal labeling
(Fig. 2.3F,G, S2.2B). Thus, we injected P2 Bmal1f/f mice either with AAV8-GFAP-GFP, or with
an identical virus expressing a Cre-GFP fusion protein (AAV8-GFAP-CreGFP). At 5mo, we
observed Bmal1 deletion and increased GFAP expression specifically in astrocytes expressing
AAV8-GFAP- CreGFP (Fig. 2.3F). The GFAP-CreGFP vector exhibits very weak nuclei-restricted
fluorescence, making it more difficult to see than that of the AAV8-GFAP-eGFP vector. Mice
treated with the eGFP control vector had widespread astrocyte labeling throughout the cingulate
and retrosplenial cortices, intact BMAL1 expression, and very little astrocyte activation as
defined by GFAP immunoreactivity (Fig. 2.3F,G). Mice injected with the CreGFP vector showed
astrocytic nuclear GFP expression and 3.4- and 3.1-fold increases in GFAP immunoreactivity in
the cingulate and retrosplenial cortices, respectively (Fig. 2.3G).
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Figure 2.3. Bmal1 deficiency induces cell-autonomous astrocyte activation in vitro and in
vivo.
A. qPCR of Gfap and Aqp4 mRNA in primary astrocyte-enriched cultures from WT or global Bmal1 KO
mice. N=8-12 samples from 3 independent experiments.
B. Western blot showing increased GFAP protein levels in cultured astrocyte cell lysates from Bmal1 KO
mice. In (B) and (C), p42/44 ERK protein is shown as a loading control.
C. Western blot showing knockdown of BMAL1 and increased GFAP protein in WT astrocyte cultures 7
days after treatment with non-targeting siRNA (siSCR) or siRNA targeting Bmal1 (siBmal1).
D. Densitometric quantification of blots in (C). N=4 samples/group.
E. Representative trace depicting detrended circadian oscillations in luminescence seen in primary
astrocyte cultures from Per2-Luc reporter mice treated with siRNA (siSCR, blue or siBmal1, red).
Similar results were obtained in 3 separate cultures.
F. Representative confocal images from cerebral cortex of Bmal1f/f mice 5 mo after i.c.v. injection at age
P2 with viral vectors inducing astrocyte-specific expression of eGFP (AAV8-GFAP-eGFP) or Cre
(AAV8-GFAP-CreGFP). AAV8-GFAP-GFP-infected cells show whole-cell GFP expression and persistent
colocalized nuclear BMAL1 staining, while AAV8-GFAP-Cre infected cells show nuclear GFP
expression, increased GFAP expression, and loss of nuclear BMAL1. Scale bar= 30µm.
G. Representative images (left) and quantification (right) illustrating increased percent area covered by
GFAP+ astrocytes in cortex in mice from (F) injected with AAV8-GFAP-Cre, as compared to AAV8-
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GFAP-GFP-injected controls. Note that AAV8-GFAP-Cre virus encodes a CreGFP fusion protein which is
nuclear-localized and more difficult to see (F). Scale bar= 100µm. Each data point = 1 mouse.
H. Representative images and quantification of % area of GFAP staining from hippocampus of Aldh1l1CreERT2+;Bmal1f/f and Aldh1l1-CreERT2+;Bmal1wt/flox mice at 3 mo (2 months after tamoxifen treatment),
CAG-CreERT2+;Bmal1f/f mice at 4 mo (2 months after tamoxifen treatment), and Bmal1f/f controls. Scale
bar = 100µm.
All data represent mean+SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by 2-tailed T-tests (C)
and (G) or 1-way ANOVA (H) with Holm-Sidak correction for multiple comparisons when applicable.

Finally, we generated tamoxifen- inducible astrocyte-specific Bmal1 KO mice using an Aldh1l1CreERT2 driver line (Aldh1l1- CreERT2; Bmal1f/f mice)272. We treated Cre+ and Cre- mice with
tamoxifen at 1mo, and examined astrocyte activation at 3mo. We observed specific deletion of
Bmal1 in astrocyte nuclei of the hippocampus and cortex (Fig. S2.2D,E). Aldh1l1-Cre+ mice had
significant increases in astrogliosis, as assessed by GFAP immunostaining in the hippocampus
(Fig. 2.3H) and a nearly significant (p=0.055) increase in the retrosplenial cortex (Fig. S2.2C).
While it is difficult to directly compare tamoxifen-inducible and constitutive Cre lines, Aldh1l1Cre+ mice had similar levels of astrogliosis to tamoxifen inducible global Bmal1 KO mice
(CAG- CreERT2+; Bmal1f/f)270(Yang et al., 2016) also harvested 2mo after TAM treatment (Fig.
2.3H, S2.2C). Astrogliosis was not caused by Cre expression, as Cre+; Bmal1flox/WT mice had no
phenotype (Fig. 2.3H, S2.2C). Ald1l1-Cre+ mice also had spontaneous and significant increases
in a number of additional astrocyte activation transcripts including S100a6 (2.5 fold), C4b (2.6
fold), Cxcl5 (7.5 fold), and Mmp14 (3.1 fold) (Fig. S2.2F). In total, these experiments
demonstrate that Bmal1 deletion in astrocytes can induce activation in a cell-autonomous
manner.
While activated astrocytes generally exhibit morphologic changes and increased GFAP
expression, the transcriptional profile of activated astrocytes is heterogeneous and can define
their function77,84. In order to examine the transcriptional profile in the brain following Bmal1
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deletion, we performed microarray analysis of cortical tissue from 11mo NBmal1 KO mice, Crecontrols, and Per1Brdm/Per2Brdm (Per1/2mut) mice, placed in constant dark conditions for 36 hours
then harvested at CT 6:00 and 18:00. Per1/2mut mice were included because they have a
dysfunctional circadian clock, but have no astrogliosis phenotype as well as tonically increased
levels of BMAL1 transcriptional targets (Fig. 2.4A, S2.3A). To understand astrocyte
transcriptional changes in NBmal1 KO brain, we examined the overlap between the 200 most
upregulated transcripts in NBmal1 KO, with the 200 most astrocyte-enriched transcripts,
according to the Barres Lab RNAseq database273 (Fig. 2.4A). Thirty genes overlapped, including
Gfap, Aqp4 (encoding the astrocytic water channel Aquaporin-4), and Megf10, a gene involved
in astrocyte-mediated synaptic elimination58. C4b, a complement cascade component also
implicated in synapse elimination and a marker of astrocyte activation and aging46,47, was
strongly upregulated (4-fold) in NBmal1 KO brain. Several other disease- associated astrocytic
genes were increased in NBmal1 KO brain, including inflammatory mediators such as Cxcl5 and
Ccr7 and matrix metaloproteinases Mmp14 and Mmp2. Nearly all of these transcripts were either
unchanged or decreased in Per1/2mut mice, demonstrating the key role of decreased BMAL1
function in this phenotype. We next performed microfluidic qPCR profiling of global Bmal1 KO
hippocampal samples for markers of astrocyte activation and polarization84, which demonstrated
that Bmal1 deletion increased most pan-reactive markers but did not clearly polarize astrocytes
toward a neurotoxic or neurotrophic profile (Fig. 2.4B). These genetic profiling studies suggest
that Bmal1 deletion induces a unique state of astrocyte activation.
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Figure 2.4. BMAL1 regulates astrocyte activation via a glutathionylation-dependent
mechanism.
A. Astrocyte-specific genes upregulated in Nestin-Cre+;Bmal1f/f (NBmal1 KO) cortex and changes to the
same genes in Per1/2mut mice. Transcripts upregulated at least 2-fold in NBmal1 KO were compared to
the top 200 astrocyte-specific genes (Zhang et al, 2014), and overlapping genes are displayed. Bottom other notable genes implicated in astrocyte activation and function which were upregulated in NBmal1
KO cortex. The clock-controlled genes Dbp and Nr1d1 are direct Bmal1 transcriptional targets.
B. Expression of neurotoxic, neurotrophic, and pan-reactive astrocyte activation genes (Liddelow et al.,
2017) in 5 mo global Bmal1 KO vs WT littermate hippocampus assayed by microfluidic qPCR. Each
datapoint represents the average of 4 Bmal1 KO mice normalized to the average of 4 WT littermates.
C. Results from Ingenuity Pathway Analysis Canonical Pathway Analysis of NBmal1 KO microarray
data. Pathways related to glutathione homeostasis are colored blue.
D. Expression levels for downregulated glutathione-S-transferases in NBmal1 KO cortex vs. Bmal1f/f
controls. Expression levels in Per1/2mut cortex included for comparison. Based on microarray data.
E. qPCR illustrating effect of glutathione manipulation on Gfap transcript levels following Bmal1
knockdown. WT primary astrocytes treated with control siRNA (siSCR, grey bars) or siBmal1 (blue
bars), +/- N-acetyl-cysteine (NAC, striped bars) to increase glutathione levels, or buthionine sulfoxime
(BSO, speckled bars) to deplete glutathione. N=9 samples/condition from 3 separate experiments.
F. WT astrocytes transfected with siSCR, siBmal1, or siSCR +BSO (BSO) were treated with biotin-linked
glutathione ethyl ester (bioGEE) to assess glutathionylation. Increased band intensity indicates decreased
endogenous glutathionylation. Arrows denote altered bands. NT = not treated with bioGEE, showing
non-specific labeling.
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G. qPCR depicting effects of NAC treatment on Gfap transcript levels in cortex of inducible Bmal1 KO
mice (CAG-CreERT2+;Bmal1f/f). Inducible Bmal1 KO mice and Cre- control littermates were treated with
NAC prior, during, and after 5-day tamoxifen treatment to delete Bmal1. Mice were harvested 9 days
after start of tamoxifen. N=6-10 mice per group.
All data represent mean+SEM. *p<0.05, ***p<0.001 by T-test with Holm-Sidak correction for multiple
comparisons.

Although Per1/2mut and NBmal1 KO mice are both behaviorally arrhythmic, expression of
BMAL1 transcriptional targets Nr1d1 and Dbp are elevated solely in the Per1/2mut mice, due to
loss of inhibition of BMAL1 (Fig. 2.4A, S2.3A). Gfap is not elevated in Per1/2mut mice (Fig.
2.4A, S2.3A), suggesting that loss of BMAL1 activity, or at least blunting of BMAL1 oscillation
(as in Fig. 2.2A), is needed to induce astrocyte activation. In order to determine if Gfap and other
selected activation markers are clock-controlled genes, we harvested cortex from 4mo NBmal1
KO and Cre- controls at 4-hour intervals across one circadian cycle in constant darkness. Gfap
mRNA levels showed no circadian oscillation in control or Cre+ mice, and were elevated across
the circadian cycle in Cre+ mice. These findings were duplicated in other markers of astrocyte
activation, including Aqp4 and Mmp14 (Fig. S2.3B). Thus, the astrogliosis phenotype in Bmal1
KOs is not likely due to direct regulation of Gfap or other activation markers by the clock.
To address potential mechanisms linking BMAL1 to astrocyte activation, we performed pathway
analysis on our NBmal1 KO transcriptomic data using two bioinformatics tools: Ingenuity
Pathway Analysis (IPA) and DAVID Bioinformatics Resources 6.8274. We analyzed an inclusive
list consisting of all transcripts that differed between control and NBmal1 KO at 6pm with
uncorrected p values<0.01 (Table 2.1). IPA Canonical Pathway Analysis identified Glutathionemediated detoxification as the top hit (Fig. 2.4C, p= 0.000013). Functional Annotation
Clustering with DAVID showed that the most enriched gene cluster focused on glutathione-stransferase (GST) activity, and 4 of the top 5 KEGG pathways identified were related to
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glutathione metabolism (Fig. S2.3C). GST enzymes catalyze the phase II detoxification of
reactive intermediates in cells via adduction to glutathione and can alter cellular signaling via
glutathionylation of proteins275. We found that expression of several GST isoforms was
suppressed in NBmal1 KO cortex, and were increased in Per1/2mut cortex (Fig. 2.4D), suggesting
reciprocal regulation by the positive and negative limbs of the circadian clock. In support of our
microarray analysis, we observed significant decreases in 2 of the 3 GST isoforms probed in
cortex from 3mo CAG-Cre+;Bmal1f/f mice 9 days after tamoxifen treatment (Fig. S2.3D) and in
1 of the 3 GST isoforms probed in hippocampus from 3mo Aldh1l1-Cre+ mice 2 months after
tamoxifen treatment (Fig. S2.3E). We next asked if altered glutathione homeostasis within
astrocytes linked Bmal1 deficiency with astrocyte activation. Our data clearly show that Bmal1
deletion induced changes in both Gfap mRNA and GFAP protein, which are very closely
correlated across all models (See Fig S2.4A), so Gfap mRNA was used as a marker for
astrogliosis in subsequent experiments. Treatment with N-acetyl cysteine (NAC), a glutathione
precursor, completely prevented increased Gfap expression in astrocytes following Bmal1
knockdown (Fig. 2.4E). Conversely, incubation of WT astrocytes with buthionine sulfoxime
(BSO), which blocks glutathione production, lowered cellular glutathione levels (Fig. S2.3F) and
caused a similar increase in Gfap mRNA to that observed with Bmal1 KD (Fig. 2.4E). Treatment
of Bmal1 deficient astrocytes with BSO did not induce a further increase in Gfap suggesting that
BSO and Bmal1 knockdown are causing increases in Gfap through overlapping pathways.
Interestingly, neither Bmal1 KO nor knockdown of Bmal1 in cultured primary astrocytes altered
glutathione levels (Fig. S2.3F). Additionally, the oxidation state of glutathione (ratio of reduced
GSH to oxidized GSSG) was not altered in cortex from NBmal1 KO or Per1/2mut mice (Fig.
S2.3G). As glutathione levels and oxidation state remained unchanged with loss of Bmal1, we
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next examined glutathione signaling via glutathionylation, which has been shown to oscillate in a
circadian manner in the SCN276 (Wang et al., 2012). Western blot analysis of WT astrocytes
treated with biotin-linked glutathione ethyl ester (bioGEE) revealed widespread changes in the
pattern of s-glutathionylated proteins in Bmal1 KD cells, which are similar to changes seen in
BSO treated controls (Fig. 2.4F). In general, numerous bands showed increased biotin labeling,
indicating decreased glutathionylation, as would be expected with decreased GST expression.
These data suggest that the observed astrogliosis may be due at least in part to altered protein
glutathionylation resulting from impaired expression of specific GSTs.
We next examined whether bolstering glutathione signaling can prevent astrogliosis following
Bmal1 deletion in vivo. We previously showed that tamoxifen-inducible global Bmal1 deletion
in mice (CAG-Cre+;Bmal1f/f mice) causes astrocyte activation270. We treated CAGCre+;Bmal1f/f mice with NAC in their drinking water (40mM beginning 5 days before
tamoxifen) and via intraperitoneal injection (150mg/kg, daily beginning 2 days before
tamoxifen), and induced Bmal1 deletion via tamoxifen administration for 5 days. Both
administrations of NAC were continued for the duration of the experiment. Cortex was harvested
9 days after the start of tamoxifen treatment and analyzed by qPCR. Tamoxifen treatment
induced an 87% loss in Bmal1 and a 79% loss in expression of the BMAL1 target Nr1d1 (Fig.
S2.3H), as well as a 64% increase if Gfap expression (Fig. 2.4G). Administration of NAC was
able to provide a significant, but partial rescue of the Gfap increase seen in CAG-Cre+;Bmal1f/f
animals (Fig. 2.4G). These results suggest that BMAL1 regulates Gfap expression at least in part
through modulation of glutathione signaling in vivo.
Finally, we examined potential pathogenic consequences of Bmal1 deletion in astrocytes. We
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generated primary astrocyte-enriched cultures from CAG-Cre+;Bmal1f/f mice and Crelittermates and treated them with tamoxifen in vitro to delete Bmal1. These cultures are primarily
astrocytes, but this methods yields cultures which contain ~2% microglia and/or oligodendrocyte
precursor cells277. Primary WT cortical neurons were then co-cultured on these astrocytes for up
to 12 days and a subset were subjected to oxidative stress by hydrogen peroxide exposure
(100μM H2O2) for 24 hours (Fig. 2.5A). We found no difference in the number of neurons
surviving on Cre- and Cre+ astrocyte cultures 1 day after plating (as quantified by staining for
neuronal nuclei with NEUN, as these cells do not yet have many MAP2 positive neurites) (Fig.
2.5B). At day 7 after plating, there was a 45% decrease in NEUN+ nuclei (Fig. 2.5B,C), a trend
toward a decrease in MAP2 staining, and a trend toward an increase in cleaved-caspase-3
staining (Fig. S2.4B,C) in the Cre+ astrocyte condition. The decrease in MAP2 staining in
cultures containing Cre+ astrocytes became significant after 12 days (Fig. 2.5D,E). H2O2
exposure at day 12 decreased MAP2 levels in Cre- cultures, and the combination of Bmal1
deletion and H2O2 killed nearly all neurons (Fig. 2.5D,E). This finding shows that Bmal1deficient astrocytes are less able to sustain neuronal viability, particularly in the face of oxidative
stress.
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Figure 2.5. Loss of Bmal1 impairs astrocytic support of neurons.
A. Diagram depicting co-culture experimental design. DIV; days in vitro. TAM; tamoxifen.
B. Representative images showing NEUN+ WT neuronal nuclei at DIV 1 and 7, grown on primary
astrocytes from Cre- control mice, or inducible Bmal1 KO mice (iCAG-Cre+), treated with tamoxifen in
vitro. Scale bar = 100μm.
C. Quantification of NEUN+ nuclei from (B) normalized to NEUN counts from Cre- condition. N=8
replicates from 2 independent experiments.
D. Representative images of MAP2+ WT neurons grown as in (B) at DIV 12. Lower panels show
neurons from adjacent wells treated for 24 hours with hydrogen peroxide at DIV 11 (H2O2, 100µM).
Scale bar = 100μm.
E. Quantification of MAP2 immunoreactivity (% area) from (D). N=9 replicates from 3 independent
experiments.
All data are represented as mean±SEM. *p<0.05, **p<0.01 by 2-tailed T-test.
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2.4 Discussion
Despite a large body of evidence describing circadian disruptions in both aging and
neurodegenerative disease, little is known about the implications of circadian dysfunction on the
brain. Here, we provide evidence that behavioral circadian disruption or disruption of the
astrocytic molecular clock via manipulations of the master clock gene Bmal1 induce astrogliosis
and astrocyte dysfunction. The critical but complex role of astrocytes in brain pathologies and
neuroinflammation underscores the importance of elucidating mechanisms of astrocyte
activation, and our data illuminate BMAL1 as a potent regulator of astrocyte activation by both
cell-autonomous and non-autonomous mechanisms.
The existence of the astrocyte circadian clock has been well documented140, and the critical role
of the astrocyte clock in maintaining circadian rhythms in the SCN has recently been
described30,32,33. Clock genes have been shown to regulate astrocytic glutamate uptake and ATP
release145,148, but the function of the core clock in astrocytes is otherwise unexplored. We have
shown here, using several in vitro and in vivo methods, that loss of Bmal1 function in astrocytes
causes cell-autonomous astrocyte activation. However, deletion of Bmal1 specifically in neurons
also induces a partial astrocyte activation phenotype, suggesting a coexistent cell nonautonomous mechanism. Bmal1 deletion in cultured neurons causes toxicity15, implicating a
possible damage signal from Bmal1-deficient neurons which activates nearby astrocytes.
Alternatively, the neuron-specific Bmal1 KO mice used in this study are behaviorally
arrhythmic271, and this loss of rhythms could induce astrocyte activation, as seen in 10h:10h L:D
exposed animals (Fig. 2.2). Thus, cell non-autonomous influences on glial activation in the brain
must be examined in the future.
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One important question is whether the loss of rhythmic function of the circadian clock plays a
key role in this phenotype, or if this is a “non-circadian” function of BMAL1. Our data suggest
that arrhythmicity in the setting of increased BMAL1 expression, as in Per1/2mut mice, does not
induce astrocyte activation, as these mice express increased levels of GSTs. Thus, astrocyte
activation appears to be dependent on suppression of BMAL1-mediated transcription. However,
BMAL1 DNA binding is highly rhythmic and regulated by the clock278, making it difficult to
separate entirely from circadian rhythms. Bmal1 knockdown in astrocytes abrogates circadian
Per2-luc oscillations, which could contribute to increased Gfap expression in cell culture.
Moreover, we show in Fig. 2.2 that circadian disruption by exposure of mice to 10h:10h L:D
conditions, which blunts Bmal1 oscillations in the brain, can induce Gfap expression. Thus,
dampening the rhythmicity of BMAL1 expression through circadian clock disruption likely plays
a role in mediating astrogliosis, perhaps by restricting BMAL1 levels at certain key times of day.
BMAL1 levels can be suppressed by several factors such as aging279, inflammation180, or
amyloid-beta215, all of which could potentially influence astrocyte activation and function in a
BMAL1-dependent manner.
The activation profile induced in Bmal1-deficient astrocytes encompasses upregulation of a
variety of genes across the pre-defined neurotoxic, neurotrophic, and pan-reactive categories84.
However, it is important to remember that these astrocyte phenotypes are thought to be induced
by cytokine release from microglia, whereas activation due to loss of Bmal1 can be cellautonomous. Our findings contrast with those of Nakazato et al, who found that S100bCre+;Bmal1f/f mice did not develop astrocyte activation, and attributed the astrocyte activation
phenotype of Nestin-Cre+;Bmal1f/f mice to pericyte dysfunction280. While our data does not
exclude a contribution of blood-brain barrier dysfunction to the Nestin-Bmal1 phenotype, we
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provide multiple lines of evidence demonstrating cell-autonomous astrocyte activation. While
Bmal1-deficient astrocytes do not assume a clear neurotoxic (“A1”) phenotype, they are less able
to support neuronal survival in a co-culture system and express numerous transcripts associated
with inflammation and neurodegeneration. These include C4b, a complement component and
marker of astrocyte activation and aging46,47, Megf10, which mediates astrocytic synapse
elimination58, and Pla2g3, a phospholipase implicated in ROS-induced neuronal damage281.
Activation marker Lcn2 (Lipocalin 2), an anti-inflammatory mediator in the brain282, was not
increased, again suggesting a pro-inflammatory state.
Our data support a mechanism in which loss of BMAL1 induces astrogliosis through disruption
of GST-mediated protein glutathionylation. In addition to its role in quenching oxidative stress,
glutathione can form adducts on cysteine residues in a process termed glutathionylation, which is
catalyzed by glutathione-s-transferases and can serve a signaling function275,283. Circadian
rhythms of protein s-glutathionylation in the SCN may regulate neuronal excitability276. Because
Bmal1-deficient astrocytes have normal total glutathione levels, it is likely that disruption of
GST-mediated glutathione signaling or utilization, not glutathione depletion, mediates BMAL1controlled astrogliosis. Accordingly, we observed an altered pattern of protein sglutathionylation in Bmal1-deficient astrocytes, which resembled that seen in BSO-treated cells.
Thus, supplementing Bmal1–deficient astrocyte cultures or mice with NAC presumably prevents
astrogliosis by promoting non-enzymatic glutathionylation of protein targets, thereby
circumventing the loss of GSTs. Further studies are needed to identify specific glutathionylation
targets that mediate astrocyte activation, and to understand regulation of astrocyte glutathione
signaling in health and disease.
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In summary, our data identify the circadian clock protein BMAL1 as a cell-autonomous regulator
of astrocyte activation and neurotrophic function, and posit altered GST-mediated protein
glutathionylation as a mediator of this effect. Our findings suggest that BMAL1 serves as a link
between the core circadian clock and astrogliosis, and provide insights into how the circadian
clock might influence neurodegeneration.

2.5 Materials and Methods
2.5.1 Experimental model and subject details
Mice. Nestin-Cre+, CAG-CreERT2+, Global Bmal1 KO, Aldh1L1-CreERT2+, and Bmal1f/f mice
were obtained from The Jackson Laboratory (Bar Harbor, ME) and were bred at Washington
University. Camk2a-iCre+;Bmal1f/f mice were bred at University of Texas Southwestern. All
cohorts of mice were mixed sex with ages specified in figure legends. All mice were backcrossed
at least 10 generations and were maintained on a C57Bl/6 background and housed under 12-hour
light/12-hour dark conditions. In all cases, a Cre+; Bmal1f/f male mouse was bred with Bmal1f/f
females to generate an equal mix of Cre- and Cre+ mice, all on the Bmal1f/f background. All
littermates were thus used for experiments. Aldh1L1-CreERT2+ and CAG-CreERT2+ mice (Cre- and
Cre+ littermates from several litters) were given tamoxifen (Sigma, dissolved in corn oil,
2mg/mouse/day for 5 days) by oral gavage at 1mo or 2mo, respectively, to induce Bmal1
deletion in the applicable tissue. Behavioral circadian desynchronization experiments were
performed at Washington State University, using adult male C57BL/6N mice (age 5-6 weeks on
arrival, Harlan Envigo). All mice were group housed for gene expression experiments (N=4-5
per cage), or singly housed for actigraphy, with food and water available ad libitum. All mouse
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experiments were conducted in accordance with protocols approved by the Washington
University Department of Comparative Medicine, or by the IACUCs at UTSW or WSU.
Primary cell cultures: Primary cells were extracted from mixed sex P1-3 (astrocytes) or E16-17
(neurons) CD1 WT, Bmal1f/f, or iCAG-Cre+;Bmal1f/f mice per experimental designation.
Wildtype (WT) CD1 mice for culture experiments were obtained from Charles River
Laboratories (Wilmington, MA). Mice were briefly anesthetized by cooling on ice, cleansed with
ethanol, then decapitated with scissors, and the brain placed in ice-cold DMEM (Life
Technologies). Cortices were dissected, stripped of meninges in ice-cold DMEM, and incubated
in 0.05% Trypsin-EDTA (Life Technologies) at 37oC for 15 (neurons) or 20 (astrocytes)
minutes. 37oC DMEM plus 10% FBS (Gibco) was then added to neutralize trypsin, cortices were
spun down for 5 minutes at ~300g and gently triturated in 37oC DMEM plus 10% FBS (Gibco).
For astrocytes cultures, cells were then plated on 10cm or T75 tissue culture plates (coated for 2
hours at 37oC with 50 μg/mL poly-D-lysine (PDL- MP Biosciences, Santa Ana, CA), then rinsed
twice with ddH2O) at a concentration of 2 cortices (1 brain) per plate. Astrocytes were then
grown to confluence (~10 days), then shaken at 37oC in a heated shaker at 225 rpm for 2 hours,
followed by media change to remove adherent microglia. Cells were later lifted using Trypl-E
dissociation reagent (Life Technologies) for 5 minutes at 37oC, washed with DMEM plus 10%
FBS, and replated on 12-well (mRNA experiments), 48-well (neuronal co-cultures), or 96-well
(GSH experiments) plates (coated with PDL as above) at a 1:2 dilution. Astrocyte-enriched
cultures were then grown in DMEM+ 10% FBS + penicillin/streptomycin until used for
experiments.
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2.5.2 Method details
Behavioral Desynchronization: Activity was monitored by implanted Mini-mitter telemetry
device (Star BioSciences). For circadian desynchronization, mice were transferred into a 20h
light/dark cycle, with 10h of light (~200 Lux) and 10h of dark for 6 weeks then harvested as
described below at CT0, 6, 12, and 18; N=4-5/group/time.
Intracerebroventricular injections: Bmal1f/f mice were injected on postnatal day 2 (P2) with
either AAV8-GFAP-GFP or AAV8-GFAP-CreGFP viral vectors (2μL, bihemispheric, from UNC
viral vector core), using a 30g Hamilton syringe (10ul, 45 degree bevel) with a cuff to ensure
proper depth (1.5mm). The injection site was 1mm lateral and 1mm posterior to bregma. Mice
were housed as described above, harvested at 5 months of age and analyzed as described in the
immunohistochemisty section.
Immunohistochemistry: Mice were anesthetized by i.p. pentobarbital (150mg/kg), followed by
perfusion for 3 minutes with ice-cold Dulbecco’s modified PBS (DPBS) containing 3 g/l heparin.
One hemisphere was post-fixed in 4% paraformaldehyde for 24 hours (4°C), then cryoprotected
with 30% sucrose in PBS (4°C) for 48 hours. 50-micron serial coronal sections were then cut on
a freezing sliding microtome and stored in cryoprotectant solution (30% ethylene glycol, 15%
sucrose, 15% phosphate buffer in ddH20). Sections were washed in Tris buffered saline (TBS),
blocked for 30 minutes in TBSX (TBS with 0.25% Triton X-100 (Sigma-Aldrich, St. Louis,
MO)) containing 3% goat serum, then incubated overnight in TBSX containing 1% goat serum
plus primary antibody at 4°C. Sections were then washed in TBS, incubated for 1 hour at room
temperature in TBSX with 1:1000 fluorescent secondary antibody, and mounted on slides using
Fluoromount G. Epiflourescent images were obtained on a Nikon Eclipse 80i fluorescent
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microscope. A Nikon A1Rsi scanning confocal microscope was used at 20x for Ki67/GFAP colocalization, at 40x for Aldh1L1-Cre BMAL1/GFAP quantification, and at 60x for viral injection
and representative Aldh1L1-Cre co-localization pictures.
Culture experiments: For neuronal cultures, triturated cells were transferred to a second tube to
remove debris, then diluted in Neurobasal+B27+glutamine (Life Technologies) and counted
prior to plating on astrocyte beds. For co-culture experiments, astrocytes were grown to
confluence after replating in 48-well plates and neurons were added immediately following
primary dissection at a concentration of 37,500 cells/well in Neurobasal media plus B-27
supplement and glutamine. After 48 hours, 50% of the media was changed to Neurobasal plus
antioxidant-free B-27 (AOF B-27, Life Technologies) and glutamine. Subsequently, 50% media
changes were performed using Neurobasal plus AOF B-27 and glutamine every 3 days until
neuronal DIV 7 or 11. In cultures grown to DIV 11, half of the wells received 100μM H2O2 for
24 hours. All wells were then fixed with 4% paraformaldehyde for 15 minutes, washed 3x with
TBS and stained for MAP2, Cleaved-Caspase-3 or NEUN and quantified using protocol in
immunoreactivity quantification section.
Immunoreactivity quantification: GFAP and MAP2 staining were quantified from 10x images
using ImageJ software (NIH). GFAP 8-bit images were thresholded by hand to encompass all
GFAP immunoreactivity, and a threshold value was set and maintained for all sections. GFAP
percent area coverage was then calculated for each image. In general, 1 image from each section
and 2-3 sections/mouse were averaged, and the average from each mouse used as a data point.
For Ki67/GFAP co-localization, puncta were hand-counted from maximal intensity projections
of z-stacks in each region of interest. GFAP, BMAL1, and DAPI co-localizations were hand
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counted by 2 independent, blinded experimenters in 6 images/mouse (3 hippocampus, 3 cortex)
with the average for each mouse reported. Cleaved-Caspase-3 puncta co-localizing with MAP2
were hand counted by 2 independent, blinded experimenters in 3-5 images/well over 11 wells
from 3 independent experiments with averages/well reported.
qPCR: Flash-frozen brain tissue was homogenized with a mechanical homogenizer for 20
seconds in RNA kit lysis buffer (PureLinkTM RNA Mini Kit, Life Technologies, Carlsbad CA)
plus 1% β-mercaptoethanol. RNA was then purified using the kit protocol. Cell lysates were
homogenized in TRIzol (Life Technologies). The aqueous layer was then utilized, after
chloroform extraction (added 1:5, sample then spun at 13000xg for 15 minutes), in RNA
isolation using the kit protocol. RNA concentration was then measured by Nanodrop
spectrophotometer and cDNA was made using a high capacity RNA-cDNA reverse transcription
kit (Applied Biosystems/Life Technologies) with 1 μg RNA used per 20μL reaction. Real-time
quantitative PCR was performed with ABI TaqMan primers and ABI PCR Master Mix buffer on
either the ABI StepOnePLus or QuantStudio 12k Real-Time PCR thermocyclers. During
analysis, mRNA measurements were normalized to β-actin (Actb) mRNA levels. All Taqman
qPCR primers were obtained from Thermo/Fisher. Microfluidic qPCR was performed on flash
frozen hippocampal tissue from 6mo Global Bmal1 KO and WT littermates mice at Stanford
University using a BioMark Real-Time PCR system (Fluidigm, South San Francisco, CA) and
analyzed as previously described84.
Western blotting: Tissue samples were homogenized by sonication radioimmunoprecipitation
(RIPA) buffer (Cell Signaling Technologies, Danvers MA) containing cOmplete protease
inhibitors (Roche Lifesceinces USA, Indianapolis IN). Invitrogen nuPAGE Novex gels, SDS
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running buffer, and an iBlot transfer device were utilized per the manufacturer’s instructions
(Life Technologies). Bands were visualized using Lumigen TMA-6 chemiluminescence reagents
(Lumigen, Southfield MI) on a Syngene GBOX imaging system. Band density was calculated
using ImageJ software and normalized to ERK as a loading control.
Microarray: 11mo NBmal1 KO, Cre- littermate, and Per1/2mut mice were placed in constant
darkness for 36 hours, then anesthetized with i.p. pentobarbital in the dark, followed by
perfusion. Mice were harvested at CT 6 and 18 (6am and 6pm), 2-4 mice/genotype/timepoint.
RNA was isolated from flash frozen cortex samples as above and submitted to the Genome
Technology Access Center at Washington University for quality control, MessageAmp RNA
library preparation, and Agilent 4x44k mouse v2 microarray. Raw data was normalized and
analyzed using Partek Genomics Suite v6.6. For DAVID analysis, version 6.8 was used. The
gene list from Table S1 was uploaded using Official Gene Symbol as the identifier, species=mus
musculus, and 692/842 genes were recognized. Two analyses were run: Functional Annotation
Clustering (stringency: high), and KEGG pathway analysis. For Ingenuity Pathway Analysis
(Qiagen, Venlo, Netherlands), content version 28820210, build version 400896 was used, and
the same gene list was employed (with ratios and p values). Cannonical Pathway analysis was
performed. Dataset will be uploaded to GEO Datasets website
(https://www.ncbi.nlm.nih.gov/gds/).
siRNA transfections: Astrocytes were transfected with siRNA using lipofectamine RNAiMAX
(Life Technologies) in Optimem (LifeTechnologies) according to manufacturer’s instructions 24
hours after replating. After 48 hours, media was changed to DMEM plus 10% FBS. SiRNAs
targeting mouse Bmal1 or non-targeting (designed to target no known mouse gene) were
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obtained from Dharmacon (Lafayette, CO). ON-TARGETplus SmartPool siRNA was used,
which contains 5 separate siRNAs targeting the gene of interest which are pooled together
(Bmal1: product L040483-01-005, non-targeting: D-001210-01-05). An siRNA:RNAiMAX
ratio of 1:1.25) was used, and 40 pmol of siRNA (2uL of 20uM stock) was added to each well,
using 12-well plates. Media was changed 24-48 hours later.
BSO and NAC experiments: For NAC experiments, astrocytes were incubated in growth media
supplement with 1mM N-acetylcysteine (Sigma) starting 24 hours after transfection with siRNA,
and for the remainder of the experiment. 72 hours before harvest, media was changed to DMEM
plus 2% FBS and, where indicated, containing 250 μM buthionine sulfoxime (BSO, Sigma) and
cells were harvested as described above at day 8 after siRNA treatment. CAG-Cre+;Bmal1f/f
mice and Cre- littermates (age 2-3 mo) used for in vivo NAC experiments were given either
control drinking water or water containing 40mM NAC starting day 0 until sacrifice. Beginning
on day 3 and continuing until sacrifice, mice were also given daily intraperitoneal injections of
NAC (150mg/kg) or sterile DPBS for controls. Tamoxifen (Sigma, dissolved in corn oil,
2mg/mouse/day for 5 days) was administered by oral gavage to all mice beginning day 5 after
water treatment. Water was refreshed once at day 7. Mice were perfused at day 14 (4 days after
completion of tamoxifen) and tissue was prepared as described above.
Per2:luciferase Bioluminescence Recording: Primary astrocyte cultures were prepared from P12 PER2::LUC transgenic mice, and transfected with siRNA as above. 48 hours later, cells were
synchronized by media change, and PER2::LUC activity was continuously monitored from a
photomultiplier tube (HC135-11MOD, Hamamatsu) from transfected cortical astrocytes plated
on a sealed 35mm Primaria dish (BD Biosystems, San Diego, CA) with 1 ml of serum-free
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DMEM supplemented with 2% B27 (Invitrogen), pen/strep, 10 mM HEPES, 0.35 g/L NaHCO3,
4.5 g/L D-glucose, 2% L-glutamine, and 0.1 mM beetle luciferin (Promega,Madison,WI).
Acquired in vitro bioluminescence traces were detrended by division over a 24h running average
and fitted with a damped sine function (Chronostar 2.0, PMID: 19299560). Only traces with a
coefficient of correlation >0.80 and period between 18-30h were considered circadian and
rhythmic.
BioGEE glutathionylation assay: Primary astrocyte cultures were prepared and transfected with
siBmal1 and siSCR siRNA as described above. At day 5 post-transfection media was changed to
DMEM, +2% FBS, +penicillin/streptomycin. Also at day 5, 250uM BSO (Sigma) was added to
a subset of wells to block glutathione synthesis. At day 7 post-transfection all media was
refreshed (DMEM, +2% FBS, +penicillin/streptomycin, +250uM BSO where appropriate) and
100uM BioGEE Glutathiolation Detection Reagent (Invitrogen, G36000) was added to each well
except for one (non-treated control). After 3 hours, cells were lysed in RIPA buffer and
processed as in western blotting section. As the entire size range of membrane was needed to
blot for glutathione ethyl ester linked biotin, a parallel gel was run using the same sample mix in
order to blot for loading control (p42/44 ERK). After transfer, the loading control membrane was
blotted and imaged as above in the western blotting section. The membrane for detection of
glutathionylation was washed and blocked as above except that TBS-T (tris buffered saline
+0.125 tween) was replaced with PBS-T (phosphate buffered saline +0.125% tween) per method
recommendation. After blocking, membrane was placed in 5% milk in PBS-T +streptavidin
poly-HRP40 conjugate (Fitzgerald, Boston, MA, 65R-S104PHRP, 1:2000) for 1 hour, washed 5
times in PBS-T and imaged as in western blotting section.
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Glutathione Measurements: GSH and GSSG levels were quantified in mouse cortex samples
using the Glutathione Assay Kit (Cayman Chemical, Ann Arbor, MI). In cell culture
experiments, glutathione measurements were obtained at day 7 using the Intracellular
Glutathione Detection Assay Kit (Abcam, Cambridge, MA) by kinetic read (beginning
immediately upon adding reagent and then every 5 minutes for 60 minutes) on a Tecan Infinite
M1000 Pro fluorescent plate reader (Tecan, Switzerland).

2.5.3 Quantification and statistical analysis
Statistical analyses were performed using GraphPad Prizm v7.02. In general, data are
represented by mean +/- SEM. In mouse experiments, “n” represents the number of mice and in
cell culture experiments “n” represents the number of biological replicates. Specific statistical
tests used, p-value level definitions, and additional details are listed in figure legends. When
multiple t-test were performed, Holm-Sidak correction test for multiple comparisons was applied
unless otherwise noted.

2.5.4 Data and software availability
Agilent Microarray was performed and full data is publicly available on the ArrayExpress server,
accession E-MTAB-7151.
Array available at https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7151/
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2.6 Supplementary Materials
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Figure S2.1. Related to Figure 2.2; Characterization of mouse models with astrogliosis
induced by loss of Bmal1.
A. Representative actigraph of a WT mouse housed in 12h:12h light:dark, then switched to 10h:10h
light:dark at black arrow, leading to behavioral arrhythmicity.
B. Cortical qPCR showing mRNA levels from 10h:10h light:dark WT mice from Fig. 2.2A, S2.1A
reveals increased Gfap expression at most timepoints throughout the circadian day.
C. Hippocampal (top, scale bars = 150μm) and cortical (bottom, scale bars = 50μm) staining of NEUN
(red) and BMAL1 (green) from 4mo Camk2a-iCre+;Bmalf/f mice and Cre- controls shows complete loss
of neuronal BMAL1 in Cre+ animals.
D. Representative images (top) and quantification (bottom) illustrating minimal localization of the cell
division marker Ki67 staining with GFAP+ astrocytes in cerebral cortex from 4 mo Nestin-Cre+;Bmal1f/f
(NBmal1 KO) mice (left graph), despite large increases in GFAP+ cells as compared to Cre- controls
(right graph). Scale bar= 50μm.
E. NBmal1 KO mice have increased GFAP+ activated astrocytes in the cerebral cortex without major
changes in number of total (S100B+) astrocytes. Scale bar = 50μm.
All data represent mean+SEM. *p<0.05 by 2-tailed T-test.
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Figure S2.2. Related to Figure 2.3; Characterization of astrogliosis seen with loss of Bmal1
in vitro and in vivo.
A. qPCR showing mRNA levels of several astrocyte activation and inflammatory genes 7 days after
treatment of WT astrocytes with non-targeting siRNA (siSCR) or siRNA targeting Bmal1 (siBmal1).
N=12-15 experiments.
B. Representative cortical images from mice in Fig. 2.3F-H. Top row. AAV8-GFAP-GFP-infected cells
(solid arrows) show whole-cell GFP expression, persistent colocalized nuclear BMAL1, and fail to
colocalize with neuronal nuclei (hollow arrows). Bottom row. AAV8-GFAP-Cre infected cells show only
nuclear GFP expression (solid arrows, CreeGFP fusion protein), loss of nuclear BMAL1 and fail to
colocalize with neuronal nuclei (hollow arrows). Scale bar= 30µm.
C. Representative images, quantification of %GFAP area in retrosplenial cortex of mice in Fig. 2.3H.
Scale bar = 100µm.
D. Representative confocal images of Aldh1l1-Cre+;Bmalf/f mice and Cre- controls. DAPI+, GFAP+
(solid arrows) astrocytes colocalize with BMAL1 in Cre- mice, but not in Cre+ mice. Scale bar= 30µm.
E. Quantification of DAPI/GFAP/BMAL1+ cells (top) or GFAP+ cells per field of view (bottom) in
Aldh1l1-Cre+;Bmalf/f mice vs Cre- controls in hippocampus. Each data point = 1 mouse. 6 fields/mouse
with an average of 24.5 GFAP+ cells/field, totaling 1,176 cells counted. Note that there is not an increase
in GFAP+ cells in hippocampus, just the size and shape of these cells.
F. mRNA levels of astrocyte activation markers in hippocampus from Aldh1l1-Cre+;Bmalf/f mice vs Crecontrols.
All data represent mean+SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by 2-tailed T-tests (A),
(E), and (F) or 1-way ANOVA (D) with Hom-Sidak correction for multiple comparisons when applicable.
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KEGG_PATHWAY
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KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY
KEGG_PATHWAY

D

Term
Count %
mmu00982:Drug metabolism ‐ cytochrome P450
11
mmu00980:Metabolism of xenobiotics by cytochrome P450
9
mmu05414:Dilated cardiomyopathy
9
mmu00480:Glutathione metabolism
7
mmu05204:Chemical carcinogenesis
9
mmu00062:Fatty acid elongation
5
mmu00350:Tyrosine metabolism
5
mmu04916:Melanogenesis
8
mmu05410:Hypertrophic cardiomyopathy (HCM)
7
mmu05200:Pathways in cancer
20
mmu04390:Hippo signaling pathway
10
mmu05222:Small cell lung cancer
7
mmu04925:Aldosterone synthesis and secretion
7
mmu04020:Calcium signaling pathway
11

1.590
1.301
1.301
1.012
1.301
0.723
0.723
1.156
1.012
2.890
1.445
1.012
1.012
1.590

PValue
2.76E‐05
6.84E‐04
0.00370693
0.00634706
0.0069225
0.00749553
0.03032123
0.03153854
0.03336309
0.03488911
0.04160489
0.04310029
0.04744608
0.04901976

Genes
Fold Enrich Benjamini FDR
GSTM1, GSTA2, FMO6, UGT1A6B, UGT1A6A, MAOB, AOX1, GSTT1, GSTT2, GSTT3, GSTM7
5.4290
0.0064
0.0355
GSTM1, GSTA2, UGT1A6B, UGT1A6A, HSD11B1, GSTT1, GSTT2, GSTT3, GSTM7
4.5807
0.0766
0.8746
ADCY3, ADCY2, ITGB8, CACNG5, IGF1, ITGA3, CACNA1F, TTN, CACNA1S
3.5321
0.2506
4.6591
GSTM1, GSTA2, IDH2, GSTT1, GSTT2, GSTT3, GSTM7
4.1458
0.3099
7.8544
GSTM1, GSTA2, UGT1A6B, UGT1A6A, HSD11B1, GSTT1, GSTT2, GSTT3, GSTM7
3.1866
0.2765
8.5376
ACAA2, ELOVL2, ECHS1, ACOT1, ACOT5
6.2642
0.2534
9.2133
DCT, TYRP1, MAOB, AOX1, TPO
4.1761
0.6412 32.6699
DCT, ADCY3, EDNRB, TCF7, WNT4, TYRP1, ADCY2, WNT3A
2.6322
0.6068 33.7477
ITGB8, CACNG5, IGF1, ITGA3, CACNA1F, TTN, CACNA1S
2.8863
0.5846 35.3335
BMP4, TRAF1, ADCY3, TCF7, COL4A2, COL4A1, ADCY2, WNT3A, IGF1, FGF23, ITGA3, BDKRB2, R 1.6410
0.5628 36.6328
BMP4, TCF7, WNT4, CCND2, WNT3A, GDF5, TEAD3, WWTR1, GLI2, BMP6
2.1572
0.5935 42.0699
TRAF1, MAX, COL4A2, COL4A1, ITGA3, RB1, LAMB1
2.7145
0.5749 43.2204
ADCY3, ADCY2, CAMK1G, CAMK4, MC2R, CACNA1F, CACNA1S
2.6514
0.5816 46.4455
ADCY3, EDNRB, ADCY2, CAMK4, CYSLTR2, PHKG2, PLCD1, CACNA1F, BDKRB2, ITPKA, CACNA1S
1.9906
0.5668 47.5711

F

G

E

H

Figure S2.3. Related to Figure 2.4; Pathway analysis, GSTx, and GSH with Bmal1
deficiency.
A. Expression of BMAL1 transcriptional targets and Gfap from microarray in Fig. 2.4A at CT 6 and 18.
B. Expression of astrocyte activation transcripts Gfap, Aqp4, and Mmp14 in cortex of NBmal1 KO (Cre+,
red) and Cre- control mice (black) at 4 hour timepoints across the circadian cycle. No clear circadian
oscillations were observed in Cre- or Cre+ mice. N=3-4 mice/genotype/timepoint.
C. KEGG pathway analysis of NBmal1 KO microarray data. Blue = pathways related to glutathione
homeostasis.
D. qPCR of mRNA expression of glutathione transferases in the cortex of iCAG-Cre+;Bmal1f/f mice (Fig.
2.4F), 9 days after tamoxifen treatment, normalized to Cre-, Bmalf/f controls.
E. qPCR of mRNA expression of glutathione transferases in hippocampus of Aldh1l1-Cre+;Bmal1f/f mice
(Fig. 2.3H).
F. GSH levels in Bmal1 KO (top) and siBmal1 treated WT (bottom) astrocyte enriched cultures along
with appropriate controls as measured by fluorometric intracellular glutathione detection assay.
G. Quantification of GSH and GSSG levels in cortical tissue (CT 10) from control, NBmal1 KO, and
Per1/2mut mice. None of the averages were significantly different.
H. mRNA expression of Bmal1 and Nr1d1 in the cortex of iCAG-Cre+;Bmal1f/f mice used in Fig. 2.4G, 9
days after tamoxifen treatment, normalized to Cre-, Bmalf/f controls.
All data represent mean±SEM. *p<0.05, ****p<0.001 by 2-tailed T-test with Holm-Sidak correction for
multiple comparisons when applicable.
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Figure S2.4. Related to Figures 2.4 and 2.5; Comparison of Gfap mRNA and GFAP protein
across experiments; Further characterization of neuronal support deficits observed with
loss of Bmal1.
A. Comparison of Gfap mRNA (quantified by qPCR) and GFAP protein (quantified by
immunofluorescence) across experiments in this manuscript. Note that in both cultures cells and two
distinct Cre-Lox mouse models, Gfap mRNA and GFAP protein are very closely related. Data is shown
separately in Figs. 2.2 and 2.3.
B. Representative images showing MAP2+ (green) and cleaved-Caspase-3+ (CASP-3, red, arrows) WT
neurons (grown as in Fig. 2.5A) at DIV 7. Scale bar = 100μm.
C. Quantification of MAP2 percent area (top) and cleaved-Caspase-3+ (bottom) neurons from (C) shows
non-significant trends toward decreased MAP2 and increased cleaved-Caspase-3+ neurons when neurons
are plated on BMAL1-deficient astrocytes (Cre+).
All data represent mean+SEM.
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Table 2.1: Related to Figure 2.4; Transcripts altered in NBmal1 KO cortex.
Microarray data was sorted by ratio of mean expression in Nestin-Bmal1 KO cortex/control cortex. All
transcripts which differed from controls at 6pm by >2 fold with an uncorrected p value <0.01 by 2-tailed
student’s t-test were included. The ratio (con/NBmal1 KO), p value, Agilent Gene ID, and Gene name
are listed. N = 3 WT and 3 NBmal1 KO mice. IPA and DAVID analysis were performed with this gene
list. Full dataset is publicly available on ArrayExpress, accession E-MTAB-7151.
Gene name
Ratio
pvalue
Agilent Gene ID
A_55_P2043237
A_51_P391616
A_55_P2141058
A_52_P63343
A_51_P258493
A_51_P520639
A_55_P2073248
A_55_P2034340
A_55_P2032081
A_55_P2173626
A_51_P512306
A_52_P2710
A_51_P362066
A_55_P2032079
A_52_P303891
A_51_P223776
A_51_P127297
A_52_P249733
A_55_P2167269
A_51_P270213
A_55_P2148534
A_55_P1973818
A_55_P2034341
A_55_P2173629
A_55_P2170454
A_55_P2001078
A_55_P2084691
A_55_P2019447
A_51_P373393
A_55_P2054673
A_51_P479230
A_52_P483959
A_55_P1972872
A_55_P2059357
A_51_P440092
A_55_P2154719
A_55_P2176748
A_55_P2100485
A_55_P2080021
A_55_P2066173
A_51_P377856
A_52_P376460
A_55_P2057168
A_66_P136102
A_55_P1960526
A_55_P2011026
A_55_P2037141
A_55_P2148016
A_55_P2034655
A_51_P407984

Rpe65
Etnppl
Gm11128
Gm129
Per3
Mslnl
Slc25a34
Qrfpr
Dbp
Samd3
Kirrel2
Cml5
Chi3l1
Dbp
Nr1d2
Nr1d1
Hsd11b1
Tcap
Pcsk4
Ceacam11
Nr1d2
Mmel1
Qrfpr
Samd3
Gsta2
Mmel1
Hist1h2ac
Ano2
Lce3c
Gpld1
Nat8
C1ql2
I830012O16Rik
Myo7a
Fam187b
ENSMUST00000131176
Prss50
Epha8
Papss2
ENSMUST00000103420
Gstt3
Spag16
A_55_P2057168
Lefty2
Wisp3
Zfp296
Jsrp1
BC039966
AK007918
Grifin

0.024060355
0.061828451
0.119181125
0.137749555
0.139579314
0.152011976
0.157367893
0.158829865
0.169192972
0.171126782
0.19428052
0.198282947
0.201546756
0.202946377
0.219164834
0.225206306
0.225550421
0.23155423
0.233815658
0.239397526
0.244658097
0.245861914
0.248213044
0.260384421
0.263762173
0.26441075
0.2737514
0.275428596
0.279093801
0.287389927
0.290107114
0.292698887
0.300197966
0.306863067
0.309235122
0.322408618
0.326620842
0.326735881
0.328895979
0.329757265
0.333770471
0.34187188
0.345050781
0.349577899
0.35651893
0.357838563
0.365838984
0.366285695
0.369650912
0.375416816

52

0.000251698
0.007902685
0.009911556
0.007307617
0.000132703
0.00031769
0.008573713
3.68969E-05
0.000106896
0.001005607
9.61456E-05
7.02107E-05
0.000128249
0.000141892
0.003954516
0.00011625
0.001663194
3.2698E-06
0.001468289
0.004154597
0.005533589
0.004051247
0.008224279
0.008487559
0.00043127
0.005404809
0.004209427
0.003695005
0.006975218
0.00297564
5.25149E-05
0.009368311
0.001430741
0.00065435
0.008260409
0.000850712
0.001228242
0.005019557
0.000488915
0.000139235
0.003119303
0.004158168
0.009115244
0.000598838
0.000972875
0.00335755
0.007672954
0.000188942
0.000839465
0.001934357

A_51_P419286
A_52_P447439
A_51_P125260
A_55_P1994194
A_55_P2079787
A_52_P332513
A_51_P289107
A_55_P1994447
A_55_P1956598
A_52_P169982
A_55_P2008830
A_55_P2021084
A_55_P1964368
A_55_P2172440
A_52_P155805
A_51_P470851
A_51_P144531
A_55_P2149535
A_55_P2020331
A_52_P366525
A_51_P359570
A_55_P2068560
A_51_P380432
A_66_P105319
A_51_P117739
A_55_P2056571
A_51_P130727
A_55_P1963965
A_51_P259631
A_52_P167278
A_51_P194503
A_55_P2155946
A_51_P403243
A_55_P2004716
A_51_P452768
A_55_P2384521
A_55_P2149774
A_51_P354003
A_55_P2005946
A_55_P2171168
A_52_P143346
A_55_P2091147
A_55_P2219174
A_51_P136303
A_51_P117581
A_55_P2125013
A_55_P1953008
A_51_P350048
A_55_P2070451
A_52_P67212
A_52_P51786
A_55_P2361731
A_51_P427674
A_55_P2158697
A_55_P2036580
A_55_P2051778
A_55_P1953301
A_51_P217498
A_55_P1956093

Batf3
Prss43
Acaa2
Heph
Prss50
Gm9798
Hrh3
Sowahd
BC019489
Atp6v1b1
TC1674279
ENSMUST00000103416
Kctd14
Scarf2
2010204K13Rik
Cplx3
Slc22a29
ENSMUST00000098484
Camk1g
Coq10b
Ifit3
Lyzl4
Scx
Gm15706
Figf
A_55_P2056571
Fkbp11
Hcrtr1
Tsks
Mthfd1l
Olfr433
Hcrtr1
Ccdc116
Gm765
Cyp4f14
Ankrd33b
Vasn
Pou3f4
Lyzl4
A_55_P2171168
Otud6a
Hist1h4k
2010013B24Rik
Cyp4f15
Cables1
Hist1h4j
Ccser1
Gstt2
BU961056
2900052N01Rik
Sec1
AW047481
Cpt1a
Hist1h4i
Gm13547
Sult2b1
Sord
Slc2a4
TC1586030

0.381938682
0.385717693
0.387273626
0.387940347
0.390021446
0.399236189
0.401615602
0.407290166
0.407724871
0.408734347
0.418477861
0.421407185
0.425587047
0.426878776
0.427247469
0.428337208
0.429343014
0.432751762
0.436502286
0.437552494
0.442275962
0.452762218
0.459888705
0.461175395
0.463979869
0.464093717
0.465794937
0.473575918
0.474874935
0.474907192
0.475644624
0.478799505
0.479398146
0.479534393
0.480902587
0.487969027
0.490016806
0.490173127
0.494421563
0.496119327
0.501321449
0.501507097
0.505941016
0.509300192
0.512873267
0.517272048
0.521506552
0.523464099
0.524254834
0.5256741
0.52915283
0.53100235
0.533387144
0.535813733
0.539762892
0.545967282
0.551230085
0.551254039
0.556730074
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0.008181191
0.002459354
0.001039053
0.000699974
0.00103467
0.003634396
2.4018E-06
0.003975428
0.00845519
0.001967124
0.003309502
0.000819679
7.3392E-05
0.006659204
0.007070983
0.002874567
0.002781907
0.004010549
0.000291936
0.004686733
0.00192367
0.000661168
0.000335082
0.003576929
0.000858672
2.29632E-05
0.008137041
0.001976369
0.002896605
3.69676E-05
0.006962711
0.00232683
8.49045E-05
0.007152427
0.001340737
0.002120402
0.00559103
0.001032736
0.004312828
0.004110363
0.003845134
0.006965549
0.009411246
0.00014096
0.001159745
0.007925816
0.004724255
0.005994267
0.008773694
0.003757188
0.001572954
3.97756E-05
0.009363534
0.00693191
0.002895266
0.008583238
0.003303625
0.008311302
0.00558637

A_55_P2041738
A_55_P1976655
A_51_P185869
A_55_P2062617
A_55_P2040276
A_51_P505521
A_55_P2091161
A_55_P2274378
A_55_P1957413
A_55_P2121176
A_55_P2063462
A_55_P2165534
A_52_P116134
A_51_P435321
A_55_P2153221
A_51_P435339
A_51_P161946
A_55_P2229137
A_51_P352303
A_51_P239766
A_51_P114634
A_51_P338443
A_55_P2150962
A_55_P2114626
A_55_P2024841
A_51_P378381
A_52_P84347
A_55_P1973848
A_51_P249286
A_55_P1961014
A_51_P130475
A_55_P2055920
A_55_P2055432
A_55_P2055854
A_55_P2091468
A_55_P2072115
A_55_P2092671
A_51_P344008
A_51_P153053
A_51_P288558
A_51_P479548
A_55_P2006345
A_51_P235726
A_52_P85774
A_55_P1962404
A_55_P1985788
A_55_P2126269
A_55_P2121856
A_55_P2177632
A_55_P2120856
A_51_P406466
A_66_P109002
A_66_P127070
A_55_P2083988
A_55_P2064741
A_52_P89683
A_55_P1994504
A_52_P400831
A_51_P451409

Il15ra
Fgf23
Hbq1a
BC030499
Gm11744
Hist1h4i
Arr3
AW549542
Lsp1
Efcc1
ENSMUST00000051253
Mettl11b
Aldh2
Ap1s2
TC1612904
Epor
E130012A19Rik
Tmem116
Homer2
Plcd1
Amz1
Angptl4
Cpne7
A_55_P2114626
Gstt1
4933436C20Rik
4931419H13Rik
Sema4b
Rgs16
Selenbp1
Wnt4
Kcnd3os
A_55_P2055432
Ppara
Dio3
AW011738
Nppc
Slc25a20
Smpdl3a
Wdr16
Gpr150
Ccdc85b
Icam4
Trim6
Ugt1a6b
Usp2
Nmb
Ier5l
Zfyve28
ENSMUST00000066461
Ankrd35
Kcng2
Gdf5
Lmo2
Nmb
NAP005064-002
Sptbn5
Adamts13
Ttll13

0.556884956
0.556937263
0.558749813
0.562526866
0.564020753
0.567679999
0.569562224
0.571443833
0.572443157
0.573635929
0.57684558
0.579289652
0.582105104
0.585762259
0.596551126
0.598135579
0.598589693
0.600821464
0.61361782
0.616377224
0.6188194
0.620416458
0.621559066
0.622163043
0.623280549
0.627067416
0.628259032
0.628352894
0.628429191
0.629348531
0.629616773
0.630691988
0.63218872
0.632301569
0.633121987
0.63635204
0.636457192
0.640977272
0.64119919
0.641705885
0.641783339
0.642665218
0.643747235
0.644328886
0.646926338
0.648562935
0.649263625
0.650304694
0.651698022
0.652896074
0.654276984
0.655001433
0.655216782
0.655633756
0.659534636
0.664721822
0.664919079
0.66504178
0.665066516
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0.007925058
0.007106549
0.001063392
0.002903892
0.000712525
0.003861471
0.004604113
0.002209236
0.001303095
0.005612067
0.001155115
0.007711835
0.004453523
0.002589465
0.001851044
0.003291254
0.004804123
0.007437067
0.008110239
0.005716274
0.009742811
0.007326134
0.004291269
0.009533796
0.005066307
0.007174706
0.003543583
0.001822371
0.007140957
0.003536439
0.008286803
0.001927277
0.000569524
0.002408504
0.003626917
0.002240406
0.002487722
0.009998593
0.008843073
0.004685282
0.00496468
7.74883E-05
0.002132859
0.002351979
0.009040126
0.003894129
0.001674481
0.007628481
0.007859365
0.007272287
0.006806637
0.001205273
0.006612064
0.002812401
0.003454588
0.007600836
0.000861394
0.008276343
0.007546037

A_55_P1984487
A_51_P307082
A_51_P437478
A_55_P2101055
A_55_P1987670
A_51_P213099
A_55_P1983733
A_55_P2070641
A_51_P302566
A_55_P2021089
A_52_P319438
A_55_P1986680
A_55_P2148385
A_51_P199135
A_51_P155458
A_55_P2342264
A_51_P223724
A_55_P2163561
A_55_P2022074
A_51_P226269
A_55_P2048110
A_55_P1968099
A_51_P516133
A_52_P143037
A_66_P103493
A_52_P53906
A_51_P424878
A_65_P20174
A_55_P2117664
A_55_P2277475
A_55_P2087911
A_66_P100798
A_55_P2159289
A_66_P104814
A_51_P429366
A_52_P668071
A_66_P122699
A_55_P2321468
A_51_P393305
A_55_P2177488
A_55_P2178152
A_55_P1996479
A_55_P1978258
A_55_P2078460
A_55_P2170847
A_51_P255682
A_51_P333111
A_55_P2150757
A_55_P2107155
A_55_P2077664
A_55_P2077515
A_55_P1999800
A_55_P2241488
A_55_P1973130
A_51_P273609
A_51_P122425
A_55_P2079506
A_66_P122060
A_55_P2069765

Adra2c
Hey2
Zfp566
Alpk1
Gm2002
Ntng1
Aldh1l1
Ngb
Maob
AF466698
Ankrd37
A_55_P1986680
A_55_P2148385
Cd83
Dok7
2610008G14Rik
Khdrbs2
Sytl1
Klf10
Rgcc
Tmem97
Pla2g2c
Hist1h1c
Gabra5
AA387883
Ccnd2
Fam213b
Jade1
Rnf165
9330179D12Rik
Mthfsd
Gm5468
Ap5s1
Trak1
Hes6
Asb1
Cux2
C130030J05
Sidt1
Hist2h2be
Ccsap
Nphs1
A_55_P1978258
NAP111472-1
Fbxo27
Mfge8
Aox1
Gzmm
Rasd2
Gm5458
A_55_P2077515
TC1639085
5330439K02Rik
ENSMUST00000051330
Itpka
Ctf1
Ankrd33b
4833418N02Rik
Kiss1

0.666402564
0.667937119
0.668393713
0.669473271
0.671090003
0.67410381
0.676525728
0.677415051
0.681862433
0.682074006
0.682752631
0.683448527
0.683749358
0.686821159
0.686959794
0.688492757
0.689161894
0.690193776
0.694082235
0.696734653
0.697981984
0.698962337
0.700208411
0.703167784
0.703317135
0.706699158
0.70861832
0.709866748
0.71187981
0.712459441
0.712866573
0.712894298
0.715854464
0.716435563
0.71733992
0.718516435
0.719922066
0.722206545
0.722876333
0.723871271
0.724780255
0.725044341
0.725541231
0.730337606
0.731210056
0.731720444
0.731953975
0.732151937
0.732291698
0.73328928
0.737366901
0.739241312
0.742591663
0.742920869
0.7451081
0.745131674
0.745943265
0.747212579
0.749129501
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0.008049514
0.007563061
0.001553307
0.007672018
0.005896637
0.005670444
0.000410163
0.003882699
0.00616182
0.000120297
0.009558269
0.007454627
0.006721731
0.000115126
0.006309803
0.007772423
0.00574482
0.007808678
0.001290967
0.001445652
0.000192778
0.00528789
0.009063137
0.000549138
0.001284383
0.007964257
0.00066838
0.002845691
0.007784423
0.003443596
0.009035053
0.000803341
0.006612928
0.008671346
0.003948432
0.004467498
0.005023549
0.002690434
0.006209807
0.002158201
0.002620544
0.002743674
8.57079E-05
0.000704019
0.006079425
0.00816107
0.007118246
0.007107669
0.004679339
0.001149921
0.007668046
0.002723513
0.008687121
0.006053036
0.000603492
0.006167823
0.004787958
0.005222399
0.00914607

A_55_P2059936
A_51_P386612
A_55_P2007566
A_55_P2064862
A_55_P2016986
A_55_P2033250
A_51_P185247
A_55_P2118684
A_51_P208931
A_52_P162298
A_52_P355084
A_51_P238183
A_55_P2024555
A_66_P108178
A_55_P2017140
A_55_P2098591
A_55_P2012011
A_51_P113195
A_55_P2083252
A_52_P278154
A_51_P163694
A_51_P356055
A_52_P516097
A_55_P2080248
A_51_P414706
A_55_P2054437
A_52_P138967
A_51_P320980
A_52_P512553
A_51_P106488
A_51_P395050
A_55_P1991160
A_55_P2141241
A_55_P2165299
A_55_P2075469
A_55_P2059527
A_66_P118329
A_55_P2181419
A_55_P2062190
A_66_P107038
A_52_P199633
A_51_P121031
A_51_P246066
A_55_P1968448
A_52_P609334
A_51_P317673
A_55_P2024337
A_51_P195215
A_55_P2161595
A_51_P480881
A_51_P409039
A_55_P2000329
A_66_P125722
A_66_P106421
A_51_P323180
A_55_P1958230
A_55_P2077263
A_55_P2058691
A_51_P204913

Zfp383
Pir
Trmt61b
Ica1
CJ159614
Fdft1
Gdf10
Idh2
N4bp3
Ydjc
Metrnl
Etnk2
Ppap2a
Lin52
Vmn2r88
2610318N02Rik
Tceal7
Upk1b
Mtus2
Eif1ad
Rufy1
Grp
Leng9
Cyp2j8
Ddt
Ttpal
Trpm4
Sfxn4
Atg16l2
Speg
Wdtc1
Mrrf
Mb21d1
Mybpc1
Baalc
Gon4l
Ntrk3
Tcf4
Gstm1
Prcp
Trim30d
1-Mar
Slamf9
NAP059069-1
Klhdc8b
Zfp764
Tmem53
Fam149a
Hpca
Thap11
Echs1
Gskip
Cyb5
Ccdc30
Gbp9
Dhodh
Cenpk
Gm10817
Bag2
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0.751484461
0.754856695
0.755191616
0.756358416
0.758086187
0.762189489
0.762715837
0.763520073
0.764410463
0.764820324
0.769005612
0.770616227
0.772688904
0.777580516
0.779112388
0.780736499
0.7808402
0.783647381
0.794024594
0.795319278
0.797227166
0.79869348
0.799455952
0.799831744
0.801227516
0.801392698
0.801821623
0.80250099
0.803779359
0.804530706
0.804819547
0.808665648
0.812522988
0.813208142
0.814490269
0.815455324
0.818792538
0.81995958
0.820745819
0.821162408
0.823025549
0.824178586
0.82485111
0.825293991
0.827722626
0.830333605
0.830409375
0.831293608
0.833952875
0.834440042
0.836091941
0.838638994
0.840604671
0.841513071
0.844986766
0.845359401
0.847518275
0.849869218
0.850147722

0.006042749
0.005811703
0.009095141
0.009935629
0.006951493
0.008103595
0.002227547
0.004802573
0.002814222
0.001132792
0.002909483
0.005883173
0.004959655
0.00818391
0.006975191
0.005470665
0.001128816
0.005284976
0.000628757
0.003835291
0.007497083
0.000297043
0.003459765
0.003015764
0.008356999
0.003797555
0.00930034
0.003772902
0.000438736
0.002943553
0.001060956
0.000311217
0.008331839
0.009035014
0.008252315
0.004122292
0.009345984
0.003003794
0.007083769
0.005049441
0.003449852
0.001059553
0.000817942
0.007970721
0.007037159
0.00035459
0.008901833
0.00095372
0.004344239
0.000417013
0.008298619
0.004204285
0.008880226
0.007499478
0.004447768
0.008467665
0.006952729
0.003882419
0.008607783

A_66_P127432
A_66_P126313
A_55_P2055217
A_51_P482029
A_51_P330213
A_55_P2340101
A_51_P106527
A_55_P1987483
A_66_P106375
A_51_P201661
A_55_P2134877
A_51_P133582
A_55_P2002466
A_55_P1962801
A_51_P150430
A_55_P2000182
A_52_P270164
A_55_P2052936
A_55_P2017640
A_52_P478444
A_51_P245275
A_51_P153486
A_52_P558368
A_55_P2176145
A_51_P161362
A_55_P2080703
A_55_P2030225
A_51_P521176
A_66_P108567
A_55_P2017312
A_51_P369971
A_51_P484671
A_66_P117578
A_51_P373609
A_55_P1972852
A_51_P421303
A_55_P2051874
A_55_P2167451
A_55_P2062627
A_52_P539310
A_52_P408690
A_55_P1970655
A_51_P103975
A_55_P2108579
A_55_P2102175
A_51_P249118
A_55_P2117425
A_55_P2315366
A_55_P2084152
A_55_P2132907
A_55_P2057577
A_55_P2087448
A_55_P2059200
A_55_P2281733
A_55_P2399499
A_55_P2118259
A_52_P94021
A_55_P2120099
A_55_P2068260

Tial1
Rhof
A_55_P2055217
Mcoln1
Asf1b
BC062258
Fam195a
Pgm2
Strap
Xrcc5
Eml1
Cbx4
Zfp747
Max
Mkrn2
Slc5a6
E2f6
CB237565
Phf7
ENSMUST00000064591
H2afx
Dnajb1
Zdhhc1
Rgs17
Gnl2
Cstf2
A_55_P2030225
Rassf7
Xrcc6
Eapp
Fra10ac1
Adcy3
Mtmr7
Yars2
Mcrs1
Caly
Psmc2
Cnnm2
Tmem238
Serp2
Sft2d2
Kdm3b
Mpc2
Phkg2
Lztr1
Abcb4
Syt5
D630022N01Rik
NAP061298-1
Anxa4
Ugt1a6a
Oprm1
Olfr1218
A_55_P2281733
B930025P03Rik
Olfr1349
Spam1
Gm15217
Hist1h3g

0.850557286
0.85120267
0.852111801
0.852706554
0.856392642
0.85703997
0.857974169
0.860480319
0.861125724
0.862221619
0.863295368
0.864624284
0.865316423
0.86891111
0.869042087
0.869421127
0.870139284
0.870936854
0.872389264
0.876461806
0.876674456
0.877030767
0.8778116
0.878124944
0.879601167
0.88023228
0.883187245
0.883231538
0.885634401
0.888784452
0.891880698
0.896926246
0.901627215
0.904034878
0.904827879
0.906163683
0.90762438
0.908004773
0.911540942
0.913350584
0.914306778
0.916980263
0.920023731
0.921480413
0.93249828
0.936018338
0.93617558
0.96804655
0.968665654
0.969189057
0.970080921
0.970621899
0.970958465
0.971118734
0.971203733
0.972609615
0.973028294
0.973121016
0.973124695

57

0.004252839
0.001237847
0.005495315
0.004023762
0.004728062
0.000931495
0.008698179
0.005884071
0.000452245
0.003537039
0.000914749
0.005636916
0.001238859
0.008153285
0.007371147
0.002357898
0.003481092
0.00014393
0.002217096
0.00872092
0.009418408
0.001646138
0.007921729
0.007477526
0.009812719
0.005688421
0.001575675
0.007362939
0.007823609
0.007935022
0.00665621
3.35726E-05
0.001581729
0.001936606
0.003993869
0.00427893
0.005769027
0.002095978
0.004630147
0.005875568
0.005317386
0.004236549
0.005166637
0.002000774
0.003296792
0.007551932
0.007427645
0.008606708
0.004913366
0.004399708
0.005504838
0.002995576
0.0088853
0.002913951
0.008569397
0.009156113
0.003754436
0.009568949
0.001071439

A_55_P2054315
A_51_P245533
A_55_P2117853
A_55_P2139942
A_55_P1985344
A_52_P654703
A_52_P285975
A_55_P2120493
A_55_P2008860
A_55_P2159139
A_52_P678206
A_55_P1989658
A_55_P1989787
A_55_P2141757
A_55_P2094094
A_66_P131152
A_55_P1999616
A_55_P2273929
A_55_P2053824
A_55_P1987352
A_55_P1969486
A_51_P229759
A_55_P2130208
A_55_P2351465
A_55_P2073035
A_55_P2113379
A_55_P2207110
A_55_P2100335
A_55_P2288524
A_51_P361588
A_55_P1968848
A_55_P2153116
A_55_P2243157
A_55_P2026465
A_55_P2091916
A_55_P2100209
A_52_P290783
A_52_P546200
A_55_P2156436
A_52_P765764
A_55_P1988937
A_55_P2317575
A_65_P10174
A_55_P2154337
A_55_P1956537
A_55_P2056388
A_55_P2148684
A_51_P233072
A_66_P130528
A_55_P2159746
A_52_P515869
A_55_P2148416
A_52_P642432
A_55_P2173350
A_55_P2049373
A_52_P508999
A_55_P2052340
A_55_P1959022
A_55_P2053978

Mcpt2
Tex19.1
Lhx9
Calca
A_55_P1985344
Trim69
Plekhg1
Fanca
ENSMUST00000132097
Olfr984
9830107B12Rik
Slco1a1
ENSMUST00000171257
A_55_P2141757
A_55_P2094094
A630073D07Rik
Gm10830
Gm20558
Iqcf4
LOC101056312
Gm4984
Pxdn
A_55_P2130208
Tmem150cos
1700091H14Rik
A_55_P2113379
6430710M23Rik
AA183857
Gpr112
Rai1
Gm4312
Tsix
ENSMUST00000130218
Pramel1
NAP058266-1
Kif2c
BC016579
Glis3
NAP062047-1
AF316510
Gm21292
1700016F12Rik
CO808875
NAP112752-1
Dach2
A_55_P2056388
Best1
E030002O03Rik
Olfr582
Mfsd2b
Rgmb
Gm14347
Gm9059
Vmn2r5
Pde3a
Evi2a-evi2b
Hyal4
Bmp4
Bdkrb2

0.973702094
0.973925036
0.974155345
0.974191018
0.974325355
0.974515267
0.974578634
0.974670249
0.974748219
0.97481717
0.974839717
0.975102432
0.97530064
0.975382583
0.975452362
0.975609696
0.975617976
0.975701856
0.975983332
0.976092648
0.97621728
0.976218327
0.976430167
0.976432687
0.976471599
0.976478252
0.976672342
0.976704131
0.976850476
0.976883622
0.976916326
0.976921209
0.976933999
0.976951832
0.976963057
0.977026314
0.977163138
0.977242059
0.977245493
0.977278992
0.977287666
0.977298889
0.977424004
0.977509642
0.977554509
0.977591839
0.97767976
0.977724052
0.977823716
0.97784192
0.977845761
0.977926866
0.978069766
0.97810692
0.978198154
0.978224466
0.978291694
0.978302683
0.978311594
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0.001252872
0.001147255
0.001100848
0.001502155
0.000583228
0.000219874
0.000601384
0.000224982
0.000724853
0.002816814
0.000317381
0.00896138
0.000280569
0.000454702
8.2833E-05
7.22784E-05
0.004225265
0.000900161
0.000313151
0.000420798
2.47704E-05
0.002634066
0.000533432
0.000142178
5.02725E-05
0.000375686
0.008094419
8.08625E-05
0.008156713
2.88404E-06
0.000199597
0.008129509
0.006578311
0.000358193
4.96326E-06
0.000126336
4.43376E-05
2.02637E-05
0.009591397
0.004726062
3.95026E-05
0.000178519
0.000165034
0.000131326
0.000560583
0.009513415
6.44861E-05
6.97929E-06
0.004731695
0.003231107
0.006952098
0.000267169
0.004157557
0.00335011
0.00389529
0.0076533
0.000502773
3.03357E-05
0.000183359

A_52_P347691
A_55_P2005195
A_55_P1960683
A_55_P2005307
A_55_P2045048
A_55_P2022629
A_55_P2369534
A_55_P2137452
A_51_P144157
A_51_P317176
A_55_P2182596
A_55_P2065288
A_52_P397184
A_55_P2031856
A_55_P2295762
A_55_P2140545
A_55_P2346644
A_55_P2081164
A_51_P305061
A_55_P2026809
A_51_P201400
A_66_P128139
A_55_P1966992
A_55_P1985450
A_55_P2017247
A_55_P1981265
A_51_P474498
A_55_P2344119
A_55_P2020069
A_55_P1972582
A_55_P2420353
A_52_P538412
A_52_P196097
A_51_P126089
A_55_P2083257
A_55_P2002043
A_55_P2386622
A_55_P2092561
A_55_P2007708
A_55_P2067649
A_52_P21066
A_55_P2366358
A_51_P206235
A_55_P2145626
A_52_P76988
A_66_P113735
A_55_P2027951
A_55_P2120219
A_55_P2031058
A_55_P2149946
A_55_P1978957
A_55_P2344244
A_55_P2025944
A_55_P2042855
A_55_P2121023
A_55_P2162147
A_51_P314991
A_55_P2180957
A_55_P2402312

Cyp4a29-ps
1700023G09Rik
F2
Lcn4
A_55_P2045048
Oxct2b
C430049E01Rik
Vmn1r207-ps
ENSMUST00000149488
Csf3
Gm3045
Scn3a
4930448K20Rik
A_55_P2031856
4933433G15Rik
Olfr1457
C730037M02Rik
Cd300lf
0610039K10Rik
Barhl2
Olfr912
A_66_P128139
Fam84b
Zcwpw2
Olfr915
NAP112355-1
Tac4
4930511A02Rik
AV510418
TC1691508
4930523O13Rik
Olfr610
Btn1a1
Olfr1241
A3galt2
Wdr88
ENSMUST00000164855
A_55_P2092561
Nanog
Wnt3a
E10043
AK086457
Slc39a5
Krt82
Sp2
X66649
A_55_P2027951
Rad51b
Mc2r
A_55_P2149946
Taar1
4930556H04Rik
A_55_P2025944
Disc1
4930413G21Rik
A_55_P2162147
Olfr878
Vmn2r105
ENSMUST00000181359

0.978438622
0.978446865
0.978455346
0.97845991
0.978472924
0.978572454
0.978603108
0.978613196
0.978629456
0.978656401
0.978668971
0.978721927
0.978834237
0.978887517
0.978948431
0.978985053
0.979100467
0.979102635
0.979387233
0.979396643
0.979531179
0.979562479
0.979685214
0.979718998
0.979771071
0.979786166
0.979855927
0.979969566
0.980219832
0.980264831
0.980324665
0.980330337
0.980708845
0.980780041
0.98084854
0.981082233
0.981201208
0.98122677
0.981270708
0.981309884
0.981320265
0.981582408
0.981636595
0.981676991
0.981684347
0.981778904
0.981789925
0.981948477
0.982117118
0.982320489
0.982330372
0.982610549
0.982643011
0.982770565
0.982815379
0.982910431
0.983012908
0.983038925
0.983129234
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0.001070468
0.006094191
0.002699906
0.000144345
0.000192404
0.002703564
0.002158804
0.000240395
0.002488404
0.002773335
0.002023385
0.002713733
0.000128189
0.000187149
0.007009306
3.62254E-05
0.008486652
8.62236E-05
0.000330883
0.002092369
0.000994466
0.007581896
0.006250253
0.000640117
0.000361421
0.002574521
0.003934494
0.005240646
0.008854175
0.004227842
0.000569753
0.00707349
0.000445583
0.001769421
0.000486687
0.002439857
0.000672974
0.000903824
0.007833541
0.001999308
0.000733547
0.000905332
0.002966244
0.009793145
0.0011207
0.009094396
0.005350115
0.001329975
0.001292996
0.002738069
0.001555973
0.002224731
0.002250139
0.002410098
0.00354743
0.003585138
0.002897086
0.004579952
0.003990836

A_55_P2348579
A_55_P2285397
A_55_P2423393
A_55_P2107682
A_55_P1966630
A_55_P2029673
A_51_P423290
A_55_P1960896
A_66_P129958
A_55_P2075549
A_52_P358720
A_55_P2011071
A_55_P2116515
A_51_P283507
A_55_P2390604
A_55_P2139077
A_66_P103474
A_52_P313020
A_52_P302071
A_55_P1959421
A_55_P2037439
A_55_P2126880
A_66_P107416
A_52_P206998
A_55_P2098156
A_55_P2063538
A_51_P369311
A_51_P198453
A_55_P2173670
A_55_P2072872
A_55_P2003703
A_55_P2178337
A_55_P1958146
A_52_P679935
A_55_P2017207
A_55_P2397090
A_66_P121502
A_55_P1959146
A_55_P2013223
A_55_P2179691
A_55_P2179027
A_55_P1976769
A_55_P2257076
A_55_P1975486
A_55_P2067041
A_55_P2069144
A_52_P611771
A_66_P110172
A_55_P2177448
A_55_P2090060
A_55_P2386677
A_55_P2060415
A_55_P2069955
A_55_P2029022
A_51_P170619
A_55_P2055411
A_55_P2151762
A_51_P177583
A_55_P2041894

D6Ertd160e
4930539N22Rik
4932416J16Rik
A_55_P2107682
ENSMUST00000155472
A_55_P2029673
Mmrn1
Fndc3c1
A430048G15Rik
Ube2dnl1
Olfr266
A_55_P2011071
NAP094932-001
Abca13
4930448A20Rik
Piezo2
Vmn2r26
4932438A13Rik
NP062023
A_55_P1959421
Depdc1a
Safb2
1700003E24Rik
LOC101055647
Olfr301
TC1670777
Nox4
TC1659185
A_55_P2173670
Lpin2
Arhgef7
Gm10489
Sh2d1a
Fmo6
A430078G23Rik
4930480K15Rik
Gm5485
Gm13119
S100z
Aknad1
Gem
Olfr1093
ENSMUST00000166069
Olfr1128
TC1709681
NAP057071-1
5133400J02Rik
Olfr970
A_55_P2177448
Mab21l3
A_55_P2386677
NAP114248-1
Rps12l2
Rpl34
Ddx54
Rps7
Atg7
Puf60
Gm6404

0.983159378
0.98339309
0.983514737
0.983684346
0.983684428
0.983739978
0.983836657
0.983995286
0.984069924
0.984078909
0.984178194
0.984421068
0.984493598
0.984494599
0.984627495
0.984649418
0.984745488
0.985007757
0.985170105
0.985404071
0.985761334
0.986032604
0.986167891
0.986365031
0.987438347
0.987737981
0.987813853
1.009914426
1.019644893
1.020220464
1.021440486
1.021904174
1.023772662
1.024081508
1.024316806
1.024847824
1.024969574
1.025352316
1.025910479
1.026161964
1.026193032
1.02626383
1.026282741
1.026414227
1.026745595
1.026799298
1.026835946
1.02684843
1.026853322
1.027092992
1.027094963
1.040104974
1.060751961
1.069120447
1.070523509
1.075708935
1.084678193
1.096534446
1.1063571
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0.003122877
0.002220691
0.003081295
0.003452092
0.002743688
0.002995938
0.002672421
0.003603749
0.002415504
0.003276046
0.004292107
0.005360617
0.004833695
0.007550491
0.004860158
0.004078692
0.003655581
0.008325235
0.005976648
0.005018243
0.007053163
0.007160481
0.006035326
0.006716523
0.007793635
0.009669069
0.002724696
0.009696889
0.009852399
0.008645764
0.00919585
0.008321347
0.009088198
0.008728529
0.007326654
0.008160074
0.007990574
0.00831216
0.008547035
0.009536814
0.007867975
0.008913737
0.008000447
0.007875663
0.008178722
0.008038668
0.009071035
0.007961669
0.008147662
0.008901382
0.008705932
0.009688547
0.001436671
0.003330575
0.009007141
0.005642562
0.004191301
0.003257558
0.009366224

A_55_P2052185
A_51_P432779
A_51_P384113
A_51_P211765
A_55_P2077158
A_52_P492901
A_55_P2073682
A_51_P395373
A_66_P106861
A_51_P464900
A_55_P2133225
A_51_P427663
A_51_P508088
A_55_P2058933
A_55_P2069350
A_55_P1986306
A_51_P343215
A_52_P269942
A_55_P2093013
A_52_P411331
A_52_P601688
A_52_P642488
A_55_P2062054
A_55_P2152962
A_55_P2138130
A_55_P2098558
A_55_P2029051
A_51_P407165
A_52_P456448
A_55_P2085295
A_55_P1993840
A_66_P134394
A_52_P514061
A_55_P2063465
A_52_P33014
A_55_P1970831
A_51_P503883
A_55_P2102335
A_52_P497534
A_51_P422124
A_55_P1972262
A_55_P2040260
A_55_P2083351
A_55_P1954277
A_55_P2037584
A_51_P195506
A_55_P1966958
A_51_P225224
A_55_P2049979
A_52_P169082
A_51_P337523
A_55_P2172227
A_51_P254262
A_52_P348250
A_51_P198645
A_55_P2022337
A_51_P103541
A_55_P1993358
A_55_P2027879

Lamtor1
Tmem231
Acad12
Rin1
Mro
Stx4a
Grm4
Ptprt
B3galtl
Gabbr1
Mmgt2
Cnn2
Zfp142
Kif1b
Psph
Ltv1
Ube2ql1
Cpt1c
NAP059413-1
Vac14
Abcc1
Kcnk1
Dbndd2
Mtr
A_55_P2138130
Slc39a1
Fgd3
Abhd5
Ccdc81
Inf2
Tmem132c
Pde6c
Padi4
Thbs3
Ppp1r8
Nubpl
Plekhg4
Zfp423
Wipi1
Fam126a
A_55_P1972262
Acot5
Hs3st1
Emid1
Trf
Csf1
Mef2d
Htra1
Dbi
Dbil5
Adcy2
Ubn2
Nxph3
Klhl29
Parvb
Dhcr7
Cacna1s
ENSMUST00000111423
Fbf1

1.11109865
1.115525419
1.117506144
1.136382538
1.143981427
1.150583184
1.155005057
1.159434074
1.161599994
1.165324513
1.170891727
1.171344726
1.171982095
1.183023041
1.183925019
1.185276612
1.187340671
1.190694421
1.195916296
1.19741589
1.220062822
1.220430473
1.221290718
1.230311017
1.238515727
1.242426333
1.244792801
1.247211034
1.254563904
1.258060649
1.259208277
1.264155785
1.277641281
1.279150314
1.283526478
1.283998882
1.286290598
1.287621057
1.289504441
1.296567645
1.296772679
1.299458016
1.300522403
1.302945852
1.306539841
1.312150489
1.313754473
1.316988855
1.317806736
1.317985445
1.318732864
1.323978094
1.32494126
1.325112063
1.329597333
1.330598782
1.336402696
1.336692834
1.337269532
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0.005706397
0.007880263
0.005258412
0.00140415
0.007469337
0.006765721
0.003895246
0.002371674
0.009265423
0.0022672
0.005480632
0.00463273
0.007559958
0.010002115
0.001122381
0.000419708
0.002272949
0.007771627
0.008562686
0.002845986
0.009599401
0.000979025
0.002503438
0.000667121
0.009245944
0.003655612
0.0014882
0.003605722
1.74211E-05
0.002631017
0.009333122
0.004338457
0.006428116
0.004563022
0.000534657
0.006562704
0.003789057
0.00311199
0.002659575
0.007700352
0.006577816
0.00893366
0.005118976
0.006717561
0.00938674
0.008884127
0.001958318
0.007828953
0.008010632
0.00060102
0.008932656
0.008459883
0.003825236
0.001799345
0.002994056
0.00930228
0.002029282
0.006010143
0.002540503

A_55_P2024322
A_51_P507051
A_52_P523516
A_55_P2092526
A_55_P2141938
A_55_P1979551
A_55_P2023732
A_65_P08881
A_55_P1976475
A_51_P294555
A_66_P122415
A_55_P2144641
A_55_P1961466
A_66_P119457
A_55_P2106922
A_55_P2038358
A_66_P108188
A_52_P462432
A_51_P520936
A_66_P101600
A_55_P2022971
A_55_P2147245
A_55_P2060642
A_55_P2031631
A_51_P245631
A_55_P1953920
A_51_P421140
A_52_P244637
A_55_P2037023
A_55_P2075366
A_55_P2025454
A_51_P369200
A_51_P302520
A_55_P1967168
A_52_P86353
A_51_P114005
A_52_P110052
A_55_P2037585
A_51_P472726
A_55_P2037081
A_52_P685938
A_51_P136888
A_55_P2123706
A_51_P126198
A_51_P247637
A_55_P2002723
A_52_P89567
A_55_P1974421
A_51_P282508
A_55_P2062836
A_55_P2181404
A_55_P2060158
A_55_P2066448
A_51_P208603
A_52_P89477
A_55_P1998892
A_51_P480136
A_52_P571371
A_55_P2104617

Rps27
Bhlhe22
Hapln2
Tgif1
1810058I24Rik
Pitrm1
Limch1
Pabpc1l
Tgm4
Ifitm6
Snhg6
Sdk1
Dct
Hepacam
Arfgap3
Acot1
Car5a
Copg1
Bcar3
Lamb1
Tspan9
Kcnh8
Spidr
Igf1
Rftn2
Me3
Tubb6
Fam65b
Rgs20
Tead3
Ttc12
Tpx2
Myom1
Lrp4
Cacng5
Gstm7
Darc
Trf
Pdlim2
2610305D13Rik
Efcab14
Rb1
Plekhb1
Dapk2
Rnf144a
Inpp5a
Rhob
Itga3
Rhoc
Ttf2
Dnah9
Ermn
Frmd7
Dio2
Bcl9
Smox
Cryba2
Tmem144
Kctd5

1.350264811
1.353755842
1.358041534
1.358547815
1.368147952
1.376047328
1.379918573
1.385341462
1.386232763
1.386865126
1.389041214
1.391621728
1.39513402
1.395340269
1.399688082
1.399875806
1.411893484
1.411956729
1.412957998
1.41535015
1.419746755
1.425837502
1.437663799
1.444114507
1.444328575
1.450229265
1.460238407
1.463024866
1.46643784
1.473181874
1.476771098
1.477444349
1.479895756
1.481482613
1.484000539
1.485575783
1.487441715
1.488608658
1.492420143
1.49297654
1.493222647
1.497539882
1.497632114
1.503298242
1.504283993
1.50730651
1.509262021
1.516509262
1.519704268
1.521449301
1.523586642
1.53273976
1.533278591
1.536943249
1.539914561
1.544369091
1.551734835
1.554427994
1.557771432
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0.010003186
0.000833349
0.000696628
0.006013836
0.006289515
0.009201169
0.003878559
0.002944717
0.001387682
0.008571944
0.004582603
0.000384034
0.009857839
0.001542088
0.00964654
0.007531113
0.002326386
0.004647848
0.002567227
0.007445963
0.00844527
0.002520932
0.002314206
0.005446182
0.002158338
0.002282466
0.007107885
0.006238323
0.0016555
0.008338706
0.009289365
0.009857083
0.001057562
0.000698463
0.000532479
0.007770131
0.007382902
0.001830271
0.005913195
0.003471416
0.006772713
0.004457064
0.006319433
0.001653805
0.004923615
0.002782147
0.001507456
0.007966125
0.00029772
0.0011437
0.002281723
0.009539322
0.001995192
0.009528097
0.000119402
0.001373259
0.003024233
0.005948148
0.003146124

A_66_P114627
A_52_P99807
A_55_P2106033
A_55_P2042844
A_55_P2404484
A_51_P442023
A_55_P2067942
A_52_P413646
A_51_P383399
A_51_P209280
A_52_P277104
A_55_P2116924
A_55_P1975560
A_55_P1968878
A_52_P299053
A_52_P469502
A_52_P679101
A_55_P2137828
A_51_P283473
A_66_P138999
A_55_P2039274
A_55_P2002757
A_66_P117730
A_51_P319460
A_55_P2049752
A_51_P140321
A_55_P2148478
A_55_P2062737
A_66_P111572
A_55_P2169586
A_55_P1983853
A_51_P497741
A_55_P2431118
A_55_P2019113
A_52_P700056
A_51_P341736
A_66_P140452
A_55_P2212027
A_66_P134542
A_55_P2016069
A_52_P550173
A_51_P327188
A_55_P2124791
A_55_P2382741
A_52_P495565
A_51_P164207
A_55_P2028288
A_51_P281089
A_52_P223626
A_51_P465161
A_55_P2164534
A_55_P1961968
A_55_P1970244
A_55_P2006300
A_51_P250559
A_51_P371174
A_51_P275101
A_55_P2159555
A_51_P491350

S100a16
Dpy19l3
Myo18b
Nkx2-9
1700001L05Rik
Kif17
D16Ertd472e
Bmp6
Aldh1a7
Rab31
Bank1
Dbi
Ifi204
Rhpn2
Ptplb
Cda
Tjp2
Gprc5b
Fibin
Plxna2
Hspb3
Blnk
Hapln1
Osmr
Pamr1
Mocos
Klhl25
Elovl2
Fam122b
Ccdc80
Casp12
Wdr95
Itsn1
Apol7b
Wfdc17
Mmp2
Map1a
Utrn
Anln
Adamtsl1
Slamf1
Senp1
Col18a1
AI314604
Efnb3
Mta2
Nhlrc4
S100a6
Olig2
Hoga1
Dtl
Plagl1
Dclk1
Krt12
Kcnj14
Bag3
Chst11
Adamts4
Col4a2

1.564848589
1.570560386
1.571313279
1.575932906
1.576290666
1.582948226
1.59769954
1.598092376
1.609162226
1.610146202
1.611149435
1.61239139
1.617585645
1.619105943
1.620115846
1.625203323
1.625769304
1.635024258
1.635997549
1.641129272
1.64142811
1.641851695
1.649989586
1.652829835
1.654130046
1.658215429
1.660148826
1.664611194
1.664717484
1.668925421
1.675399357
1.677008019
1.684783947
1.687719612
1.696814329
1.696877132
1.697988819
1.70319155
1.706479144
1.710711937
1.716034092
1.72599074
1.728566117
1.741932939
1.749192703
1.749879033
1.749974558
1.756815377
1.75739515
1.758734527
1.760618347
1.764510073
1.765202041
1.766141376
1.771094004
1.771434048
1.772866205
1.78698352
1.793712349
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0.001220659
0.007632669
0.002113607
0.000698787
0.001580521
0.001028202
0.002758781
0.004147918
0.00874182
0.008478719
0.002195149
0.000123195
0.001729393
0.00381341
0.008772399
0.000669809
0.005503959
0.007951179
0.000484562
0.002010269
0.000808883
0.005651032
0.000807509
0.001166209
0.008385903
0.004157572
0.004041044
0.006376051
0.004159322
0.001700784
0.00937445
0.002435877
3.72974E-05
0.002256469
0.005111763
0.009062727
0.003659455
0.009201354
0.004148527
0.007714413
8.69001E-07
0.005998988
0.00080817
0.006269683
0.00598654
0.005893805
0.006902578
0.007058524
0.002645306
0.000297591
0.008530414
0.007862886
0.009839041
0.007087185
0.00058757
0.0017122
0.006263635
0.005733243
0.008065553

A_55_P2132697
A_55_P1999715
A_51_P515684
A_55_P2252876
A_55_P2426941
A_55_P2118441
A_55_P2043718
A_51_P315682
A_51_P472287
A_52_P1174
A_55_P2101088
A_55_P1973844
A_51_P473888
A_55_P2016034
A_52_P16877
A_51_P147274
A_51_P495581
A_55_P2107502
A_55_P2146022
A_55_P2390776
A_51_P108973
A_55_P2130501
A_55_P2181738
A_55_P2183854
A_55_P2097206
A_55_P2210280
A_51_P124254
A_66_P115116
A_55_P2073694
A_55_P2030948
A_55_P2184449
A_55_P2112185
A_55_P2104422
A_55_P2035311
A_66_P100105
A_55_P2277280
A_55_P2028568
A_55_P1964568
A_51_P349546
A_52_P577662
A_66_P137911
A_55_P2094916
A_52_P60353
A_55_P1962224
A_55_P2399688
A_55_P2274837
A_55_P1954276
A_51_P285077
A_52_P497021
A_55_P1967643
A_55_P2261395
A_52_P1163599
A_51_P510882
A_52_P120813
A_55_P2035018
A_55_P2075631
A_55_P2031939
A_51_P396000
A_55_P2396335

LOC100041708
ENSMUST00000103291
1700001L05Rik
B230344G16Rik
Gprin3
Mx1
Cacna1f
Igf2bp2
Fat3
Gal3st4
Slc5a11
Sema5b
Il6st
Nlrc5
Tmcc3
Clec4a3
Tlr1
Fat1
Gm10808
1810064F22Rik
4931414P19Rik
Fndc1
Lyz1
Sctr
Camk4
TC1624885
Col4a1
Wwtr1
Gm266
5930403N24Rik
Gm10387
Nhsl1
Inadl
3110099E03Rik
Inadl
C030013G03Rik
A_55_P2028568
Megf10
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Chapter 3: Alzheimer’s disease biomarker
Chi3l1/YKL-40 is a circadian clock-regulated
neuroinflammatory mediator that modulates
amyloid pathology
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3.1 Summary
Regulation of glial activation and neuroinflammation are critical factors in the pathogenesis of
Alzheimer’s disease (AD). Circadian dysfunction is also common in AD, and has been linked to
amyloid plaque deposition and inflammation. YKL-40, a glial protein encoded by the gene
Chi3l1, is a widely studied cerebrospinal fluid biomarker of AD, which increases early in the
disease course. However, the function of Chi3l1/YKL-40 in the setting of AD is unknown. Here,
we identify Chi3l1 as a target of the circadian clock in astrocytes, and elucidate the effects of
Chi3l1 deletion in mouse models of neuroinflammation and AD. Expression of Chi3l1 was
controlled in a reciprocal manner by the positive and negative limbs of the circadian clock, while
the core clock protein BMAL1 mediated circadian gating of Chi3l1 induction in response to
lipopolysaccharide (LPS). Deletion of Chi3l1 exacerbated LPS-induced inflammatory cytokine
production in cultured astrocytes and in vivo, but did not alter astrocyte activation. In a mouse
APP/PS1 transgenic model of AD, Chi3l1 deletion caused a significant decrease in amyloid
plaque burden, which was accompanied by decreased astrocyte activation and increases in periplaque expression of the microglial lysosomal marker CD68. Finally, in a large observational
cohort of AD patients, we found that a variant in the human Chi3l1 gene, which decreases CSF
YKL-40, was significantly associated with slower AD progression. Our findings reveal
Chi3l1/YKL-40 as a modulator of AD pathogenesis both in mice and humans, and suggest a
novel mechanism linking the circadian clock with AD.

3.2 Introduction
Neuroinflammation plays a critical role in the pathogenesis of most neurodegenerative diseases,
including Alzheimer’s disease (AD)208,284. In AD, triggering of the brain’s innate immune
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response, characterized in part by activation of astrocytes and microglia, can exert both
degenerative and protective effects in a context-dependent manner84,284. While astrocytes and
microglia surround amyloid plaques and limit plaque growth through amyloid-beta degradation
and clearance, they can also exacerbate pathology via dysfunctional inflammatory responses1,284.
Thus, a deeper understanding of factors influencing glial function and neuroinflammation in
neurodegenerative conditions is needed.
Importantly, many patients with neurodegenerative diseases exhibit circadian dysfunction285,
including those with preclinical AD14. This dysfunction has been implicated as a potential
contributor to AD pathogenesis214,261. Astrocytes and microglia possess functioning circadian
clocks, and circadian timing can impact their inflammatory response140–142,199. Our group has
shown that disruption of core circadian clock transcription via deletion of the master circadian
transcription factor Bmal1 can promote neuroinflammation, and that BMAL1 regulates astrocyte
activation in a cell-autonomous manner15,286. Thus, we hypothesize that the circadian clock is a
regulator of glial function and neuroinflammation that may a play a role in AD pathogenesis.
Herein, we identify Chi3l1 as a transcript controlled by the astrocyte circadian clock. Chi3l1
encodes the protein YKL-40, which is a well-described human cerebrospinal fluid biomarker of
AD287–289, as well as other neurologic diseases including multiple sclerosis, stroke, ALS, and
frontotemporal dementia234,290–292. Chi3l1/YKL-40 is expressed primarily in astrocytes and
induced in the setting of inflammation in the brain and periphery287,293,294. Animal studies
suggest that it may mitigate inflammation and protect cells from oxidative stress230,295,296. In AD,
numerous studies show that CSF YKL-40 increases in parallel with tau and other markers of
inflammation and neurodegeneration, and that elevated YKL-40 levels predict disease
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progression287,288. While YKL-40 has been studied extensively as a biomarker, little is known
about its function in the brain and in AD. Thus, we explored the regulation of Chi3l1 by the
circadian clock, its role in neuroinflammation and amyloid plaque deposition in a mouse AD
model, and its effect on AD progression in humans.

3.3 Results
3.3.1 Chi3l1 expression is controlled by the circadian clock
We previously reported that deletion of Bmal1 caused astrocyte activation in a cell-autonomous
manner286. In order to identify circadian clock targets that may regulate astrocyte activation, we
used an existing dataset to identify the 50 most-upregulated transcripts in astrocytes after in vivo
inflammation (lipopolysaccharide (LPS) injection)77. We then examined the relative expression
of these markers in our published microarray dataset in mice with disruption of the positive
transcriptional limb of the clock (brain-specific Nestin-Cre-Bmal1 KO) or the negative feedback
limb of the clock (Per1mut;Per2mut) mice (Fig. 3.1a)286. We noted one transcript, Chi3l1, which
was strongly upregulated in LPS-activated astrocytes, but was markedly downregulated in Bmal1
KO brain and strongly upregulated in Per1mut;Per2mut mice across timepoints (Fig. 3.1a,b). In
order to evaluate Chi3l1 as a clock-controlled gene in the brain, we plotted Chi3l1 transcript
levels every 6 hours across the circadian cycle. Surprisingly, basal Chi3l1 mRNA did not
oscillate, but levels were decreased by 89% in cortex of Nestin-Bmal1 KO mice and increased by
2.3-fold in Per1mut;Per2mut mice, suggesting reciprocal regulation of Chi3l1 by the positive and
negative limbs of the circadian clock (Fig. 3.1b). Follow-up qPCR on Nestin-Bmal1 KO cortex
collected every 4 hours in constant darkness showed an average 91% loss in Chi3l1 transcript in
Bmal1 KO cortex and confirmed that Chi3l1 is expressed at constant levels (Fig. S3.1a).
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Figure 3.1. Chi3l1 is regulated by the circadian clock.
A. Microarray in Nestin-Cre;Bmal1f/f and Per1/2mut cortex from (Lananna et al, 2018) cross referenced
with 50 genes most upregulated in astrocytes with in vivo LPS treatment (Zamanian et al, 2012)
(Ct=clock time).
B. Chi3l1 expression from microarray data in (A) with 2 additional timepoints for Cre- and Per1/2mut
mice.
C. qPCR showing Chi3l1 expression from Aldh1l1-CreERT2;Bmal1f/f (Cre+) and Cre- control
hippocampus. n = 3 mice/group.
D. qPCR showing Chi3l1 expression from Cx3cr1-CreERT2;Bmal1f/f (Cre+) and Cre- control cortex. n = 68 mice/group.
E. qPCR showing gene expression from WT primary astrocytes 4-8 days after transfection with siRNA
targeting Bmal1 or non-targeting siRNA control. n = 15 samples from 5 independent experiments.
F. ELISA showing concentration of YKL-40 protein in culture medium of WT primary astrocytes 6 days
after transfection with siRNA targeting Bmal1 or non-targeting siRNA control. n =3 biological
replicates/group.
G. qPCR showing gene expression from WT primary microglia 5 days after transfection with siRNA
targeting Bmal1 or non-targeting siRNA control. n = 5-6 biological replicates/group. H. Map of Chi3l1
gene (bottom) and CANNTG E-box sequences (top) obtained from UCSC genome browser, viewed with
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IGV (Integrative Genome Viewer). E-boxes within 700bp of first ATG highlighted. Red sequences
overlap with weak BMAL1 binding in liver from (Koike et al. 2012).
All data represent mean +/- SEM. *p < 0.05, **p < 0.01, ****p < 0.0001 by two-tailed students t-test
with Holm-Sidak correction for multiple comparisons when appropriate.

CHI3L1 is highly enriched in human astrocytes297 and only negligibly expressed in other cell
types, while in mice it is highly expressed in astrocytes and OPCs, but not in microglia273,298. To
test whether the circadian clock is regulating Chi3l1 in astrocytes, we measured Chi3l1 in
inducible astrocyte-specific Bmal1 KO (Aldh1l1-CreERT2:Bmal1f/f) mice, which we have
previously shown results in the loss of approximately 70% of astrocytic BMAL1286. Chi3l1
levels were reduced by 50% in the cortex of Cre+ animals (Fig. 3.1c), while we did not observe
any change in Chi3l1 expression in microglia-specific Bmal1 KO, Cx3cr1-CreERT2:Bmalf/f mice
(Fig. 3.1d). Treating primary astrocyte cultures with siRNA targeting Bmal1 resulted in a 64%
loss in the direct BMAL1 transcriptional target Nr1d1 (REV-ERBα) and a 71% loss in Chi3l1
(Fig. 3.1e) while the secretion of CHI3L1 protein (YKL-40) decreased by 72% (Fig. 3.1f).
Knockdown of Bmal1 in primary microglia cultures resulted in a 79% loss in Nr1d1, but no
change in Chi3l1 (Fig. 3.1g). Comparison of baseline expression levels revealed that Chi3l1 is
111 times more abundant in astrocytes than in microglia cultures (Fig. S3.1b). Additionally,
while to our knowledge, binding of BMAL1 to the Chi3l1 promoter has not been evaluated in the
brain, there are 6 E-boxes (BMAL1, CLOCK heterodimer binding sequences) within 700bp of
the Chi3l1 start sequence, 3 of which displayed weak binding of BMAL1 in the liver278 (Fig.
3.1h). Taken together, these data suggest that under homeostatic conditions Chi3l1 expression
occurs primarily in astrocytes, is regulated by the circadian clock, and requires astrocytic
BMAL1.

72

3.3.2 Induction of Chi3l1 in astrocytes is gated by the circadian clock
As Chi3l1/YKL-40 has been shown to increase during inflammatory conditions294,299 and is
regulated by NF-kappaB293, we next sought to evaluate the regulation of Chi3l1 by BMAL1 in
the setting of inflammation. In cultured astrocytes, Chi3l1 was induced by LPS stimulation, but
both basal and LPS-stimulated Chi3l1 levels were much lower in Bmal1 KO cells, though some
LPS-induced increase in Chi3l1 was still observed (Fig. 3.2a). To more closely examine the
possibility that the inflammatory induction of Chi3l1 is gated by the astrocyte circadian clock,
we measured basal and LPS-induced Chi3l1 expression in synchronized primary astrocytes
across circadian timepoints. Consistent with our in vivo data, Chi3l1 transcript did not oscillate in
synchronized primary astrocytes (Fig. S3.2a). However, LPS-mediated induction of Chi3l1 was
highly dependent on circadian time, as LPS-induced Chi3l1 expression varied anti-phase to
Bmal1 mRNA expression and closely mirrored the expression pattern of Nr1d1, which is
dependent on BMAL1 transcriptional activity (Fig. 3.2b-d). These data suggest that circadian
oscillations in BMAL1 transcriptional activity gate the inflammatory induction of Chi3l1 in
astrocytes. Importantly, the induction of Chi3l1 in astrocytes was not limited to LPS as exposure
of primary astrocyte cultures to amyloid-beta-42 (Aβ42) fibrils resulted in an approximately 4.5
fold increase in Chi3l1 (Fig. 3.2e).

3.3.3 Chi3l1/YKL-40 modulates the astrocyte inflammatory response in vitro
and the neuroinflammatory response to lipopolysaccharide in vivo
We next sought to investigate the role of astrocytic Chi3l1/YKL-40 in regulating
neuroinflammation. We used siRNA to knock down Chi3l1 (siChi3l1) in primary astrocyte
cultures, achieving a 91% decrease in Chi3l1 mRNA on average (Fig. 3.2f). At baseline, loss of
Chi3l1 induced a small, but significant decrease in Gfap, demonstrating that Chi3l1 suppression
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does not mediate the astrocyte activation phenotype seen in Bmal1 KO astrocytes286. However,
we noted a small, but significant increase in Il6, similar to that seen in Bmal1 KO astrocytes286
(Fig. 3.2f), suggesting that loss of Chi3l1 may regulate some aspects of the Bmal1 KO astrocyte
phenotype.

Figure 3.2. Chi3l1 is induced during inflammation in a Bmal1-dependent manner.
A. qPCR showing gene expression from WT and Bmal1 KO primary astrocytes +/- 500ng LPS for 6
hours. n = 5 independent experiments. Two-way ANOVA with Tukey correction for multiple
comparisons.
B-D. qPCR showing gene expression from WT primary astrocytes synchronized with high serum shock,
treated with PBS (B-C) or LPS (D) at designated timepoints, and collected 3 hours after treatment. CT =
clock time. n = 6-9 replicates from 2-3 independent experiments per timepoint. Data normalized to
expression at 18 hours (B-C) or PBS control Chi3l1 expression at corresponding timepoint (D). (B) p=
0.0003 (C) p= 0.0013 (D) p= 0.0150 by one-way ANOVA with Tukey correction for multiple
comparisons. Significant multiple comparison tests depicted on graphs.
E. qPCR showing gene expression from WT primary astrocytes +/- 10uM Aβ fibrils for 48-72 hours. n =
6 replicates from 2 independent experiments.
F. qPCR showing gene expression from WT primary astrocytes treated 8-11 days after transfection with
siRNA targeting Chi3l1 or non-targeting siRNA control. n = 6-10 replicates from 3 independent
experiments.
G. qPCR showing gene expression from WT primary astrocytes treated with 500ng LPS for 6 hours, 3-6
days after transfection with siRNA targeting Chi3l1 or non-targeting siRNA control. n= 3-5 replicates
from 2 independent experiments.
All data represent mean +/- SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed students t-test with
Holm-Sidak correction for multiple comparisons when appropriate unless otherwise noted.
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Consistent with previous findings in peripheral macrophages230,2312,31, loss of Chi3l1 exacerbated
inflammatory cytokine induction by LPS with siChi3l1 treated astrocytes producing significant
increases in Ccl2 (1.4 fold), Il6 (2.4 fold), and Nos2 (1.7 fold) as well as a non-significant 1.7
fold increase in Tnfa over LPS treated control astrocytes (Fig. 3.2g). Because LPS induced large
increases in these cytokines from baseline that varied by transcript and experiment, the data is
displayed as fold change above the control LPS condition. Thus, we conclude that basal and
LPS-induced Chi3l1 expression is gated by the circadian clock in a BMAL1-dependent manner
and that loss of Chi3l1 exacerbates LPS-induced cytokine expression, but not Gfap expression,
in astrocytes in vitro.
We next explored neuroinflamamtory regulation by Chi3l1/YKL-40 in vivo, using constitutive
Chi3l1 knockout (KO) mice300. In vivo, loss of Chi3l1 slightly depressed baseline GFAP
staining, a marker of astrocyte activation, in the hippocampus (Fig. 3.3a-b) and subtly but
significantly increased staining for the microglial marker IBA1 in the cortex (Fig. 3.3a, c). This
suggested that while Chi3l1 may be produced primarily in astrocytes, it may be important for the
maintenance of both microglial and astrocytic homeostasis. In order to assess the role of
Chi3l1/YKL-40 in the setting of acute brain inflammation in vivo, WT and Chi3l1 KO mice were
injected with 2mg/kg LPS i.p., then 6 hours later were perfused and cortical tissue isolated for
analysis of a panel of inflammatory transcripts. Of note, Chi3l1 levels increased 2.1-fold in WT
cortex with LPS and were undetectable in KO tissue (Fig. S3.3a). Although there was no
significant effect of genotype on neuroinflammatory gene expression at baseline, treatment with
LPS resulted in exacerbated overall inflammation and increased expression of several
chemokines and cytokines in Chi3l1 KO mice, including Ccl2, Cxcl2, and Nos2 (Fig. 3.3D, E),
any of which could be derived from astrocytes or microglia.
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Figure 3.3. Loss of Chi3l1 exacerbates the LPS induced inflammatory response.
A. Representative images depicting GFAP (astrocyte) and IBA1 (microglia) staining in Chi3l1-/- mice and
WT controls. Scale bar = 400um.
B. Quantification of GFAP staining in (A). n = 6 mice/group.
C. Quantification of IBA1 staining in (A). n = 6 mice/group.
D. Cytokine and chemokine expression from fluidigm qPCR of 2-5mo Chi3l1-/- and WT control mouse
cortex 6 hours after PBS (left) or 2mg/kg LPS (right). All values normalized to PBS WT. Each point
represents mean of 6 mice per group (left, PBS) individual values (LPS, right) or mean of 14 mice/group
(LPS, right center). Significant main effect of genotype in LPS treated mice by two-way ANOVA with
Tukey correction for multiple comparisons. * denotes significant individual gene change after multiple
comparison correction.
E-H. Fluidigm qPCR gene expression of selected individual genes from Chi3l1-/- and WT mice from (D).
Two way ANOVA with Tukey correction for multiple comparisons.
All data represent mean +/- SEM. *p < 0.05, **p < 0.01, ***p<0.001, ****p < 0.0001 by two-tailed
students t-test with Holm-Sidak correction for multiple comparisons when appropriate unless otherwise
noted.
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In keeping with our in vitro data, no significant changes in a panel of astrocyte activation
transcripts were noted in Chi3l1 KO mice at baseline or with LPS (Fig. S3.3b). However, there
was an increase in LPS-induced, microglial-specific inflammatory transcripts, including the key
inflammasome component Nlrp3, as well as the NADPH oxidase gene Cybb (which encodes
NOX2) (Fig. 3.3e). Although there was not a significant main effect of Chi3l1 KO on a panel of
microglial activation genes, there is a significant interaction between genotype and LPS
treatment (Fig. S3.3c,d), suggesting that microglia respond differentially to LPS in the absence
of Chi3l1, with slight downregulation of several damage-associated microglial markers
(including Trem2, Spp1, and Apoe). Taken together, these data suggest that Chi3l1/YKL-40
influences the activation state of astrocytes and microglia, and potentiates LPS-induced
inflammatory cytokine expression in astrocytes and microglia without inducing typical activation
markers.

3.3.4 Deletion of Chi3l1 reduces Aβ-plaque deposition in a mouse model of AD
As YKL-40 is increased in the CSF of AD patients and is used as a biomarker of AD287,289, we
next sought to test the hypothesis that Chi3l1/YKL-40 could also be influencing pathology in a
mouse model of AD-related β-amyloidosis. We bred APP/PS1-21 mice, which express human
amyloid precursor protein gene (APP) with the KM670/671NL (Swedish) mutation and human
presenilin 1 (PS1) with the L166P mutation301, with WT or Chi3l1 KO mice. All mice were
harvested at 8 months of age when they had developed substantial plaque pathology in both the
cortex and hippocampus301. Levels of Chi3l1 mRNA were significantly increased at baseline in
APP/PS1 hippocampus at 8mo., and absent in Chi3l1 KO mice (Fig. S3.5c). Staining with X-34,
which selectively labels β–pleated sheet fibrillar Aβ plaques30243, revealed that loss of Chi3l1
diminished fibrillar plaque number by 21% (Fig. 3.4a,c) and plaque area by 17% (Fig. 3.4a,d) in
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the hippocampus, but did not significantly alter these measures in the cortex (Fig. S3.4a-c).
Staining with an antibody against Aβ (HJ3.4) revealed a much more pronounced 55% reduction
in plaque burden in the hippocampus (Fig. 3.4a,e) as well as a 42% drop in the cortex (Fig.
S3.4a,d). This discrepancy between staining methodologies led us to hypothesize that Chi3l1
deletion results in the selective reduction of non-fibrillar Aβ. Subtraction of X-34 positive
staining from total plaque staining indeed revealed a halo of non-fibrillar Aβ surrounding the
fibrillar plaque core in a majority of plaques in control APP/PS1 mice (Fig. 3.4a,b, S3.4a). The
size of this halo was greatly reduced in the Chi3l1 KO:APP/PS1 mice, especially in the
hippocampus. Additionally, while some HJ3.4-positive plaques appeared to be X-34-negative
(non-fibrillar) in control APP/PS1 mice, this type of plaque was almost completely absent in
Chi3l1 KO animals. Quantification of total non-fibrillar Aβ staining, which encompasses both
non-fibrillar plaques and the halos around fibrillar plaques, revealed an almost total (85%) loss
of non-fibrillar Aβ in the hippocampus (Fig. 3.4f) along with a 54% reduction in the cortex (Fig.
S3.4e). Loss of Chi3l1 did not result in any significant changes in the expression of several key
amyloid processing/metabolic genes (Fig. S3.4f). This, in combination with the fact that Chi3l1
is not expressed in neurons, indicates that Chi3l1/YKL-40 does not likely alter the production of
Aβ. Taken together, these data suggest that the loss of Chi3l1 mitigates the accumulation of Aβ
plaque pathology, particularly non-fibrillar plaque material.
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Figure 3.4. Loss of Chi3l1 mitigates amyloid pathology.
A. Representative hippocampal images from 8mo Chi3l1-/-:APP/PS1+ and APP/PS1+ control mice
depicting staining for X34 (fibrillar plaques), HJ3.4 antibody (total Aβ), and subtraction of fibrillar (X34)
from total (HJ3.4) Aβ. Hippocampus outlined in yellow. Yellow rectangle denotes region of inset in (B).
Scale bar = 300um
B. Representative higher magnification images depicting stains from (A). “Halo” of non fibrillar Aβ
surrounding fibrillar plaque core (X34) substantially reduced in Chi mice. Scale bar = 100um.
C. Quantification of X34+ puncta (fibrillar plaque) number from staining in (A).
D. Quantification of hippocampal area covered by X34 (fibrillar Aβ) in staining from (A).
E. Quantification of hippocampal area covered by HJ3.4 (total Aβ) in staining from (A).
F. Quantification of hippocampal area covered by non-fibrillar Aβ (total Aβ in HJ3.4-fibrillar X34) in
staining from (A).
Data points represent average of 4 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-) mice per group. All
data represent mean +/- SEM. *p < 0.05, ***p < 0.001 by two-tailed students t-test.
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3.3.5 Astrocyte activation around amyloid plaques is suppressed by Chi3l1
deletion
As astrocytes and microglia have been shown to play integral roles in both the clearance of and
neuroinflammation induced by Aβ1,111,284, we next examined the consequences of Chi3l1 deletion
on the glial response to Aβ plaques. We discovered that Chi3l1 deletion resulted in decreased
astrocyte activation as measured by GFAP staining in the hippocampus and throughout the
cortex in APP/PS1+ mice (Fig. 3.5a,c, Fig. S3.5a). Peri-plaque GFAP reductions were also
observed (Fig. 5b). Controlling for the decreased fibrillar plaque area (Fig. 3.5d) or number (Fig.
S3.5b) could not fully account for the lessened GFAP, particularly in the hippocampus, which
normally exhibits a greater amount of GFAP staining than the cortex at baseline (see Fig. 3.3a).
Thus, the amount of GFAP staining per plaque is reduced with Chi3l1 deletion. In concordance
with our staining data, transcriptional profiling of astrocyte activation markers revealed a
significant attenuation of hippocampal astrocyte activation in Chi3l1 KO; APP/PS1 mice over
that seen in APP/PS1 control mice (Fig. 3.5e, S3.5c). In combination, these data support the idea
that loss of Chi3l1 diminishes astrocyte activation in response to Aβ.
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Figure 3.5. Loss of Chi3l1 mitigates astrogliosis in the presence of amyloid-beta plaques.
A. Representative hippocampal images from 8mo Chi3l1-/-:APP/PS1+ and APP/PS1+ control mice
stained for X34 (fibrillar plaques) and GFAP (astrocytes). Yellow rectangle denotes region of inset in (B).
Scale bar = 400um.
B. Representative higher magnification images depicting stains from (A). Scale bar = 20um.
C. Quantification of GFAP coverage from mice in (A).
D. Quantification of GFAP coverage from mice in (A) normalized to X34+ area in same section.
E. Astrocyte activation marker gene expression from fluidigm qPCR of 8 mo Chi3l1-/-:APP/PS1-,
WT:APP/PS1-, Chi3l1-/-:APP/PS1+ and APP/PS1+ control mouse hippocampus. All values normalized to
WT:APP/PS1-. Each point represents mean of 4 mice (APP/PS1-) or 6-10 (APP/PS1+) mice per group.
Two-way ANOVA with Tukey correction for multiple comparisons. Significant main effect of genotype
on gene expression in APP/PS1+ mice.
Data points represent average of 2 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. *p < 0.05, **p < 0.001, ***p < 0.001 by two-tailed students t-test unless
otherwise noted.
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3.3.6 Chi3l1 deletion promotes plaque-related microglial phagocytosis without
exacerbating the inflammatory response
To address the possibility that Chi3l1 could also be regulating the microglial response to Aβ we
utilized IBA1 to label microglia and the microglial lysosomal marker CD68 to assess microglial
phagocytic activation. We did not observe any significant changes in absolute coverage of IBA1
in the hippocampus or retrosplenial cortex, but found a significant reduction in the motor cortex
(Fig. 3.6a,c, Fig. S3.6a). This decrease in the motor cortex appeared to reflect the decrease in
plaque burden as no IBA1 differences were observed in any region measured when controlling
for X-34+ plaque area (Fig. S3.6a-b). Similarly, we did not observe any alterations in absolute
levels of CD68 (Fig. S3.6a,c). However, the amount of CD68 staining normalized to X34+
plaque area was significantly elevated across all regions examined in Chi3l1-deficient APP/PS1
mice (Fig. 3.6d) indicating increased microglial phagocytic activity relative to plaque burden.
This effect appeared to be driven by increased CD68 staining around amyloid plaques (Fig.
3.6b). Indeed, colocalized IBA1/CD68 area per X34+ plaque area was also increased in Chi3l1
deficient mice (Fig. 3.6e). These changes seem to be CD68 specific as there were no significant
differences observed in transcript expression of other lysosomal markers (Fig. S3.6d). These
data suggest that loss of Chi3l1 results in increased plaque-associated microglial phagocytosis.
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Figure 3.6. Loss of Chi3l1 alters microglial activation and phagocytosis.
A. Corresponding representative hippocampal images from Fig. 3.5a of 8mo Chi3l1-/-:APP/PS1+ and
APP/PS1+ control mice stained for X34 (fibrillar plaques), IBA1 (microglia), and CD68 (phagocytic
microglia). Yellow rectangles denote regions of inset in (B). Scale bar = 400um.
B. Representative higher magnification images depicting stains from (A). Scale bar = 20um.
C. Quantification of CD68 coverage from mice in (A) normalized to X34+ area in same section.
D. Quantification of colocalized IBA1/CD68 from mice in (A) normalized to X34+ area in same section.
E. Microglia activation marker gene expression from Fluidigm qPCR of 8 mo Chi3l1-/- and WT control
mouse hippocampus. All values normalized to WT. Each point represents mean of 4 mice. Two-way
ANOVA with Tukey correction for multiple comparisons.
F. Microglia activation marker gene expression from fluidigm qPCR of 8 mo Chi3l1-/-:APP/PS1+ and
APP/PS1+ control mouse hippocampus. All values normalized to WT:APP/PS1-. Each point represents
mean of 6 (Chi3l1+/+) and 10 (Chi3l1-/-:) mice. Two-way ANOVA with Tukey correction for multiple
comparisons.
Data points represent average of 2 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed students t-test unless
otherwise noted.
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As it has been reported that gene expression changes, such as those seen in disease associated
microglia (DAM), correlate with AD-associated microglial phagocytic activity54, 212we
performed transcriptional analysis on hippocampal tissue for a selection of DAM and other
known microglia activation markers. Interestingly, this analysis revealed a significant overall
dampening of microglial activation marker expression with Chi3l1 deletion (Fig. 3.6f). This may
be due to diminished plaque burden in Chi3l1 KO;APP/PS1 mice, or could be a primary effect of
Chi3l1 deletion. Taken together, our data demonstrate that Chi3l1 deletion leads to decreased
amyloid plaque burden and increased microglial phagocytic activation, with decreased astrocyte
activation and minimal effects on microglial DAM gene expression.

3.3.7 A human CHI3L1 genetic variant causing decreased YKL-40 is
associated with slower disease progression in human AD patients
Our mouse model data suggests that decreased CHI3L1 levels might be associated with
decreased AD pathology in humans. First, we examined a human single nucleus RNAseq dataset
derived from parietal cortex, and observed that CHI3L1 expression was strongly associated with
the astrocyte cell cluster, though a few CHI3L1-expressing microglia were present (Fig. 3.7a,b).
This confirms that CHI3L1 is expressed almost exclusively in glia in the human brain, and
primarily in astrocytes. We have previously reported that CSF YKL-40 levels in humans are
strongly controlled by genetic variation in the CHI3L1 locus, and have described a common
genetic variant in the CHI3L1 locus (TT minor allele at rs10399931), which is associated with
decreased CSF YKL-40 levels303. We next examined data from 798 participants enrolled in
longitudinal observational studies of aging and dementia at the Knight Alzheimer’s Disease
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Research Center at Washington University for an association between the rs10399931 TT minor
allele and any changes in AD progression.

Figure 3.7. A genetic variant in the human CHI3L1 gene linked to decreased YKL-40 levels
is associated with slower AD progression in humans.
A. tSNE plot of cell clusters derived from single nucleus RNAseq from postmortem human brain. 30,000
nuclei purified from the parietal cortex of 3 autopsied brains were sequenced using 10X Genomics 5’ V2
protocol. Cell clusters are coded by color.
B. CHI3L1 (purple) is expressed primarily in astrocytes (solid circle), and a few microglia (dashed circle).
C. Slower rate of disease progression, as assessed by change in Clinical Dementia Rating-Sum of Boxes
(CDR-SB) over time, in AD patients carrying the minor allele (CC_TT, pink line) of SNP rs10399931 in
the CHI3L1 locus. P=0.031, N=798 participants, 26% are CC_TT positive. The TT minor allele is
associated with decreased CSF YKL-40 levels (44).

We included only participants with AD (confirmed by clinical assessment and CSF biomarker
profile), 26% of whom carried rs10399931. We examined clinical progression of AD in this
cohort, as assessed by the rate of increase in the Clinical Dementia Rating Sum-of-Boxes score
(CDR-SB). We found that the rs10399931 SNP was significantly associated with a 16% slower
rate of AD progression, suggesting that people with genetically lower CHI3L1/YKL-40 have
slower disease progression (Fig. 3.7c). For comparison, pathogenic variants in the Trem2 gene
were previously associated with a 23% increased rate of progression using the same methods304.
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This human data supports our mouse experiments demonstrating that CHI3L1/YKL-40 is not just
a biomarker of AD, but is also a potential modulator of human disease pathogenesis.

3.4 Discussion
As glia can exert either protective or degenerative influences on the brain, including in AD,1,
striking a delicate balance of glial activation and inflammatory signaling is critical for
maintaining brain health. Thus, factors that alter glial activation state may disrupt this balance
and promote neurodegeneration. Research into the relationship between circadian disruption and
neurodegenerative disease has begun to uncover a novel role for the clock in regulating
astrogliosis286 and plaque deposition261. Additionally, we and others have demonstrated clock
protein regulation of immune function in microglia141,198,199, complementing reports detailing the
critical role for the circadian clock in regulating the peripheral immune response16,180,184.
Here, we have identified the inflammation and AD biomarker Chi3l1/YLK-40 as a target of the
astrocyte circadian clock. We show that Chi3l1/YKL-40 regulates the astrocytic response to LPS
in vitro, and potentiates LPS-induced cytokine expression in vivo. We demonstrate that Chi3l1
deletion leads to diminished amyloid plaque deposition in APP/PS1 Tg mice and alters the glial
response to amyloid plaques, with decreased astrocyte activation, but increased microglial
phagocytic activation. Finally, we observed that CHI3L1 is primarily expressed in human
astrocytes in vivo, and that a genetic polymorphism causing lower CHI3L1/YKL-40 levels in
humans was associated with slower AD progression. Taken together, our findings demonstrate
that Chi3l1 induction is gated by the astrocytic circadian clock and plays a pivotal role in the
glial neuroimmune response across multiple settings. Moreover, our human and mouse data
suggest that increased Chi3l1/YKL-40 has a detrimental impact on AD pathogenesis. Thus, this
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study demonstrates a novel role for clock-regulated Chi3l1/YKL-40 in the modulation of glial
activation, neuroinflammation, and AD pathogenesis.
As Chi3l1 is strongly suppressed in Bmal1 KO astrocytes, it is important to reconcile the
reduction in Aβ plaque burden we have observed in Chi3l1 KO mice with our previous data in
which global Bmal1 deletion increased fibrillar plaque burden261. In general, the changes
resulting from global Bmal1 deletion are widespread, affecting every cell type in the brain in a
variety of ways. Bmal1 deletion also affects peripheral clocks, the sleep-wake cycle, and wholeanimal rhythmicity. The resultant phenotype in Bmal1 KO mice is thus a summation of many
smaller and possibly divergent effects, of which Chi3l1 suppression is one. One especially
relevant difference between Bmal1 and Chi3l1 deletion is that ApoE, which can drive fibrillar
plaque formation305, is markedly increased in Bmal1 KO mice261, but is unchanged with Chi3l1
deletion. Thus, manipulation of specific BMAL1 targets should not be expected to recapitulate
the overall phenotype of the global Bmal1 knockout mouse. Within astrocytes, it is notable that
that Bmal1 deletion increases astrocyte activation (as evidence by GFAP expression)286, while
loss of Chi3l1 mitigates it (see Fig. 3.5). BMAL1 presumably regulates multiple pathways in
astrocytes in addition to Chi3l1, which mediate different effects. However, we observed
increases in Il6 expression in both Bmal1-286 and Chi3l1-deficient astrocytes, suggesting that
Chi3l1 suppression may mediate the increased cytokine expression, but not the activation
phenotype seen in Bmal1 KO astrocytes. Elucidating the intricacies of these competing cellspecific pathways regulated by the clock is vital in understanding the inherently complex
mechanisms by which circadian dysfunction may impact the course of neurodegeneration.
We observed that Chi3l1 is reciprocally regulated by the positive and negative limbs of the
astrocytic clock, but that the mRNA does not oscillate at baseline in vitro or in vivo. This could
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occur if Chi3l1 mRNA were long-lived, or if rhythmic mRNA degradation was out of phase with
BMAL1 driven transcription, greatly dampening amplitude306. Such dual regulation may be
prudent to maintain tight control of Chi3l1/YKL-40-mediated inflammation. We show that
circadian oscillations in BMAL1 gate the induction of Chi3l1 in astrocytes, as the amount of
Chi3l1 induction with LPS is greatest at times when BMAL1 transcriptional activity, evidenced
by expression of the BMAL1 transcriptional target Nr1d1, is highest. Thus, while basal Chi3l1
levels do not show circadian oscillation, BMAL1 transcriptional activity may be required for
maximal induction, revealing a role for circadian timing in Chi3l1 regulation.
Our data suggest that in the setting of amyloid plaques, Chi3l1 is needed for full astrocyte
activation, and that astrocytic Chi3l1/YKL-40 may signal to microglia to restrain phagocytic
activity. Loss of Chi3l1 leads to decreased astrocyte activation, but promotes phagocytic activity
in peri-plaque microglia without potentiating cytokine production. Attenuation of astrocyte
activation in APP/PS1 mice has previously yielded mixed results, as Gfap:Vimentin double KO
increases202, while Stat3 KO decreases204 plaque burden. Interestingly, both studies reported
increased microglial plaque clustering with decreased astrocyte activation, which is consistent
with our data. It’s possible that the decreased astrocyte activation in Chi3l1 KO (and these other
models) either relents a physical barrier that limits the clustering of microglia or actively
promotes microglial clustering at plaques. While the details of astrocyte-microglia crosstalk
around amyloid plaques are not currently well understood, our data supports a role for
Chi3l1/YKL-40 in modulating both astrocyte and microglial activation states to promote plaque
accumulation.
Our experiments do not distinguish an effect of astrocyte-derived Chi3l1/YKL-40 on microglia
from a cell-autonomous effect in microglia. Indeed, our single nucleus RNAseq data indicates
88

that CHI3L1 is indeed expressed in human microglia, though at a much lower levels than in
astrocytes. Furthermore, Chi3l1 is not regulated by BMAL1 in microglia. However, it is
possible that microglia strongly upregulate Chi3l1 in the setting of inflammation. A similar
scenario has already been documented in the case of Apoe, which is expressed primarily in
astrocytes at baseline, but strongly upregulated by microglia in AD212. Previous reports have
demonstrated that Chi3l1 is expressed in macrophages and is an important suppressor of the
macrophage inflammatory response in the periphery230,231, suggesting that Chi3l1 may be
important in microglia. Indeed, the exacerbated upregulation of inflammatory mediators specific
to microglia, such as Nlrp3 and Cybb, in Chi3l1 KO mice treated with LPS suggests that Chi3l1
impacts microglial activation either directly or indirectly. Additionally, peripheral macrophages
could play a key role in this peripheral LPS injection model. In future studies, tissue-specific
Chi3l1 knockout mice may be needed to precisely assess the relative contributions of astrocytic
and microglia Chi3l1 to neuroinflammation.
One remaining and important question is whether Chi3l1/YKL-40 is a detrimental or beneficial
factor in neurodegenerative disease. Glial activation is thought to be a double-edged sword in
AD, as activated glia can phagocytose Aβ and tau and prevent proteopathy, while excessive
inflammatory factor production by activated glia can accelerate plaque accumulation and
synapse loss. Our data suggest that the effect of Chi3l1 may depend on both the stimulus and on
the cell type in question. Several studies find Chi3l1 to be anti-inflammatory and/or
neuroprotective in the setting of bacterial infection231, traumatic brain injury296 and EAE295.
Moreover, pharmacologic inhibition of Chi3l1 has also been reported to suppress Aβ deposition
in a rat Aβ infusion model, albeit through a purported anti-inflammatory mechanism307. Our
observation that Chi3l1 deletion dampened astrocyte activation in the setting of amyloid plaques
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but not LPS suggests stimulus-specific effects of Chi3l1 on astrocyte activation. Chi3l1/YKL-40
may exert differential effects on chronic, low level inflammation induced by amyloid than it does
on acute, LPS-mediated inflammation. Similarly, Chi3l1 deletion enhances microglial cytokine
production in response to LPS, but not amyloid. Indeed, the transcriptional signature of microglia
activation in response to LPS versus amyloid plaques is very different, with opposite regulation
of key mediators such as Trem2284. In the setting of AD pathology, our data show that lower
levels of Chi3l1/YKL-40 are protective, both against amyloid deposition in mice, and against
AD disease progression in humans. Chi3l1 deletion appears to promote plaque-related
phagocytic function of microglia while also slightly tempering the inflammatory response of
both astrocytes and microglia. Thus, the effect of Chi3l1/YKL-40 on the balance of glial
activation and neuroinflammation appears to be context dependent, and Chi3l1 deletion could be
neuroprotective in AD and destructive in other disease models which employ more acute
inflammatory stimuli. Further studies will be needed to determine if the beneficial effects of
Chi3l1 deletion on Aβ pathology come at the cost of exacerbation of acute neuroinflammation.
In AD patients, we observed that a common variant in the CHI3L1 gene which causes decreased
CSF YKL-40 levels is associated with slower AD progression. This observation was made in a
cohort of extremely well-characterized individuals confirmed to have AD by both clinical
evaluation (as adjudicated by expert clinicians) and biomarkers (based on CSF Aβ/tau or
amyloid PET imaging). Because CSF YKL-40 levels increase in response to inflammation and
neurodegeneration, it is difficult to determine how YKL-40 might itself be impacting these
processes simply by measuring it in CSF. By examining disease progression in carriers of this
genetic variant, which lowers CHI3L1/YKL-40 levels, we can assume that changes in
progression are likely caused by diminished CHI3L1/YKL-40 signaling, providing a unique
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opportunity to assess the function of this gene in human AD. Our human data do not demonstrate
specifically how YKL-40 alters AD progression, and future studies will be needed to address the
effects of Chi3l1/YKL-40 on AD pathology which occurs downstream of plaque accumulation,
such as tau aggregation, synaptic loss, and neuronal death. Our results suggest that inhibition of
Chi3l1/YKL-40 may be a potential future therapeutic target for limiting plaque accumulation
without inducing inflammation, optimizing the glial response, or slowing progression of AD.
In summary, we have provided evidence that Chi3l1 is regulated by the astrocytic circadian
clock, both responsive to and a regulator of neuroinflammation, and that deletion of Chi3l1
alleviates Aβ plaque pathology by optimizing glial function. These findings provide insights into
the role of the circadian systems in AD pathogenesis, reveal a novel regulator of glial activation
and amyloid clearance in AD, and identify Chi3l1/YKL-40 as a potentially viable therapeutic
target for slowing disease progression in AD.

3.5 Materials and Methods
3.5.1 Study design
The goal of the study was to identify circadian clock-controlled targets that may influence
neuroinflammation and Alzheimer’s disease pathogenesis. Chi3l1/YKL-40 was identified from a
microarray experiment of Nestin-Bmal1 KO and Per1/Per2 mutant mice due to its expression
profile. Cell culture experiments and tissue-specific Bmal1 KO mice confirmed Chi3l1 to be
regulated by the circadian clock protein BMAL1. Once identified, the study focused on
elucidating the effects of Chi3l1 deletion in LPS-induced neuroinflammation and an APP/PS1
mouse model of AD. We subsequently used data from a large observation study of Alzheimer’s
disease to determine if a known genetic variant in the CHI3l1 gene in humans, which was
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associated with lower CSF YKL-40 levels, might influence the rate of AD progression. This
analysis method was based on previous work by members of our group in identifying the variant
in CHI3L1 which affects YKL-40 levels303, and in developing a method to accurately detect
single-gene influences on clinical AD progression304.
Mouse and cell experiments were performed on a variety of tissue-specific Bmal1 knockout mice
(Nestin-Cre-, CAG-CreERT2-, Aldh1l1-CreERT2-, and Cx3cr1-CreERT2;Bmal1flox/flox mice), Chi3l1
knockout mice, APP/PS1 transgenic mice, and primary mouse—derived cultures of astrocytes
and microglia. Sample size for APP/PS1 experiments was determined at the outset and based on
power calculations derived from previous analysis of amyloid plaque pathology in our lab. Mice
were not randomized but were grouped based on genotype. When LPS injections were given,
mice within a given genotype were randomly selected for LPS vs. PBS control. Mouse tissue
samples were all processed together and analyzed to prevent batch effects. All mice were housed
in the same facility, and cohorts of mice were bred at the same time such that they aged together.
After tissue harvest, mice were assigned a number and the investigators were blinded to
genotype throughout the analysis process. QPCR and imaging data was analyzed in a blinded
manner. For human studies, data was collected as part of several ongoing longitudinal
observational studies of aging and dementia, carried out at the Knight Alzheimer’s Disease
Research Center. Participants are evaluated annually by clinical staff who are blinded to the
participant’s previous diagnosis and all previously collected data, allowing an unbiased
assessment of the Clinical Dementia Rating each year. The inclusion/exclusion criteria for our
analyses were pre-determined, and only data from participants meeting these criteria were
queried. Inclusion required a clinical AD diagnosis at the last visit, available CSF biomarkers
with a profile compatible with AD (based on CSF Aβ/tau profiles with established cutoffs), a
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Clinical Dementia Rating >0 at last assessment, and at least 1.5 years of followup. Exclusions
included a clinical diagnosis of a non-AD form of dementia, or diagnoses of other co-existent
neurological diseases.

3.5.2 Experiment details
Mice. All mouse experiments were conducted in accordance with protocols approved by the
Washington University IACUC. Global Bmal1 KO, Aldh1L1-CreERT2+, CX3CR1-CreERT2+, and
Bmal1f/f mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred at
Washington University. Chi3l1-/- mice were obtained from Dr. Jack Elias (Brown University,
Providence, RI). APP/PS1-21 mice were obtained from Dr. Mathias Jucker (University of
Tübingen, Tübingen, Germany). Timed-pregnant wildtype CD1 mice for culture experiments
were obtained from Charles River (Wilmington, MA). All mice except those used for perinatal
cultures were maintained on a C57Bl6 background and housed under 12-hour light/12-hour dark
conditions, unless otherwise specified. Aldh1L1-CreERT2+ and CX3CR1-CreERT2+ mice were
given tamoxifen (Sigma, dissolved in corn oil, 2mg/mouse/day for 5 days) by oral gavage at 1mo
or 2mo, respectively, to induce Bmal1 deletion in the applicable tissue.
Antibodies: Immunohistochemistry antibody information is listed with target (host, company,
product number, and dilution): GFAP (rabbit, Dako/Agilent Z0334, 1:3000), IBA1 (goat, Abcam
ab5076, 1/500), CD68 (rat, BioRad MCA1957, 1/500), Aβ (HJ3.4b, biotinylated mouse
monoclonal, generated by the Lab of Dr. David M. Holtzman, 1/1000).
Immunohistochemistry and imaging: Mice were anesthetized with i.p. pentobarbital (150mg/kg),
then perfused for 3.5 minutes with ice-cold Dulbecco’s modified PBS (DPBS) containing 3 g/l
heparin. One hemisphere was dissected into regions, flash frozen, and stored at -80o C for RNA
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analysis as described below. The other hemisphere was post-fixed in 4% paraformaldehyde for
24 hours (4°C), then cryoprotected with 30% sucrose in PBS (4°C) for 48 hours. Brains were
then sectioned on a freezing sliding microtome in 50-micron serial coronal sections and stored in
cryoprotectant solution (30% ethylene glycol, 15% sucrose, 15% phosphate buffer in ddH20).
For fibrillar plaque staining, sections were washed in PBS, incubated in PBS+0.04% Triton X100 (PBSX) for 30 min at RT, incubated in X34 staining buffer (10µM X34 (Sigma-Aldrich
SML 1954, St. Louis, MO) in 60% PBS, 40% ethanol, +20mM NaOH) for 20 min at RT, and
washed in 60% PBS, 40% ethanol, then washed in PBS. After X34 staining, sections were
immediately blocked for 60 minutes in PBSX (PBS with 0.4% Triton X-100 (Sigma-Aldrich, St.
Louis, MO)) containing 3% donkey serum, then incubated overnight in PBSX containing 1%
donkey serum plus primary antibodies at 4°C. On day 2, sections were washed with PBS,
incubated for 1 hour at room temperature in PBSX with 1:1000 donkey fluorescent secondary
antibody and mounted on slides using Prolong Gold (Invitrogen P36930, Carlsbad, CA). Images
were obtained by a blinded experimenter. Plaque co-stain epiflourescent images were obtained
on a Nikon Eclipse 80i fluorescent microscope using the 10x objective for quantification and 20x
for insets. For wide-field plaque and glia co-staining, a Zeiss Axio Imager Z2 fluorescent
microscope was utilized. The 10x objective was used to take 12-30, 1024x1024 pixel tile images
to cover the entire hippocampal and upper cortical region, which were then stitched together
using Zeiss Zen software. Inset images were taken on a Zeiss LSM 700 laser scanning confocal
microscope using a 63x objective. Insets consist of maximum intensity projections from z-stacks
of 28-32um (0.5 um step size).
Image quantification: GFAP, IBA1, CD68, X34, and HJ3.4 staining were quantified from 10x
images using ImageJ software (NIH). ROIs corresponding to the designated regions were drawn
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on 8-bit images by a blinded experimenter then thresholded by hand to encompass all
immunoreactivity for a particular antibody. A threshold value was set and maintained for all
sections for each stain. Percent area coverage (and particle number in the case of X34) was then
calculated for each image for each stain. For X34 images, a minimum plaque size of 50 square
pixels (~21um2) was set. Each data point corresponds to one mouse and consists of averaged
values from 2-4 coronal sections/mouse.
qPCR: RNA isolation from flash-frozen brain tissue, cDNA library preparation, and qPCR were
performed as previously described286. Briefly, tissue was mechanically homogenized in lysis
buffer plus 1% β-mercaptoethanol, and RNA extracted using the PureLinkTM RNA Mini Kit
(Life Technologies, Carlsbad CA) according to manufacturers instructions. RNA concentration
was measurement on a Nanodrop spectrophotometer, then cDNA was made using a high
capacity RNA-cDNA reverse transcription kit (Applied Biosystems/Life Technologies) with 1
μg RNA per 20μL reaction. Real-time quantitative PCR was performed with ABI TaqMan
primers and ABI PCR Master Mix buffer on ABI StepOnePLus or QuantStudio 12k
thermocyclers. mRNA measurements were normalized to β-actin (Actb) mRNA levels for
analysis. For larger experiments, microfluidic qPCR array measurements were performed by the
Washington University Genome Technology Access Center using a Fluidigm Biomark HD
system.
Microarray data: Transcriptomic data was analyzed from our previously-published microarray.
The microarray dataset is publicly available on the EMBL-EBI ArrayExpress repository
(https://www.ebi.ac.uk/arrayexpress), accession # E-MTAB-7151.
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Primary cell cultures: Primary glia were extracted from post-natal day 1-2 mouse pups (CD1
WT, or C57Bl/6 Bmal1f/f control, or CAG-CreER+; Bmal1f/f mice) per experimental designation.
Cortices were dissected, stripped of meninges in ice-cold DMEM (Life Technologies), and
incubated in 0.05% Trypsin-EDTA (Life Technologies) at 37oC for 20 minutes. 37oC DMEM
plus 10% FBS and 1% penicillin/streptomycin (Gibco) was then added to neutralize trypsin,
cortices were spun down at ~300g and gently triturated in 37oC DMEM plus 10% FBS and 1%
penicillin/streptomycin (Gibco). For both microglia and astrocyte cultures, cells were then were
plated on 10cm or T75 tissue culture plates (coated for 2 hours at 37oC with 50 μg/mL poly-Dlysine (PDL- MP Biosciences, Santa Ana, CA), then rinsed twice with ddH2O) at a concentration
of 2 cortices (1 brain) per plate. 5ng/mL G-MCSF was added to plates designated for microglial
cultures and was maintained in all subsequent media changes until siRNA transfection (see
below). After reaching 100% confluence (~10 days), cells were shaken in a heated shaker at 225
rpm for 2 hours to lift adherent microglia. After shaking, media, including microglia, was
discarded from plates intended for astrocyte cultures. Media from plates with G-MCSF intended
for microglia cultures was immediately replated in 12-well plates at a ½ dilution. Astrocytes
were later lifted using Trypl-E dissociation reagent (Life Technologies) for 5 minutes at 37oC,
washed with DMEM plus 10% FBS and 1% penicillin/streptomycin, and replated on 12-well
plates (coated with PDL as above) at a ½ dilution for mRNA and ELISA experiments. In
synchronized astrocyte experiments, astrocytes were treated with high serum (50% FBS in
DMEM) for 30 minutes which synchronizes clock gene expression308. After 30 minutes media
was changed to DMEM plus 2% FBS and 1% penicillin/streptomycin. Starting at 18 hours, cells
were treated with 500ng/mL LPS or vehicle PBS for 3 hours then collected with TRIzol as
described above. Amyloid-β oligomers (10uM, Anaspec human beta-amyloid (1-42) AS-20276,
96

Fremont, CA, prepared as previously described309) were added to designated astrocyte cultures in
DMEM plus 2% FBS and 1% penicillin/streptomycin for 48-72 hours and collected in TRIzol as
described above.
siRNA transfections: Astrocytes and microglia were transfected with siRNA using lipofectamine
RNAiMAX (Life Technologies) in Optimem (LifeTechnologies) per manufacturer’s instructions
24-48 hours after replating. 48 hours after transfection, media was changed to DMEM plus 10%
FBS and 1% penicillin/streptomycin (G-MCSF no longer added to microglial cultures). SiRNAs
targeting mouse Bmal1, Chi3l1 or non-targeting (targeting no known mouse gene) were obtained
from Dharmacon (Lafayette, CO). ON-TARGETplus SmartPool siRNA was used, which
contains 5 separate siRNAs targeting the gene of interest which are pooled together (Bmal1:
product L040483-01-005, non-targeting: D-001210-01-05). An siRNA:RNAiMAX ratio of
1:1.25) was used, and 40 pmol of siRNA (2uL of 20uM stock) was added to each well of 12-well
plates. All media was changed to DMEM containing 2% FBS and 1% penicillin/streptomycin
24-48 hours before collection of cells to reduce FBS-induced glial activation.
qPCR: Of note, cell culture lysates were homogenized in TRIzol (Life Technologies). After
chloroform extraction (1 part chloroform:5 parts sample/TRIzol, spun at 13000xg for 15
minutes), the aqueous layer was removed and RNA isolated using the kit protocol as described in
above.
ELISA: 6 days after siRNA transfection, astrocyte cultures were treated with 500ng/mL
lipopolysaccharide or vehicle PBS in fresh media for 6 hours. After 6 hours, media was
collected and placed at -20oC. Media (diluted 1/30 in sample diluent) was then used in a Mouse
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Chi3l1/YKL-40 Picokine ELISA kit (SKU: EK0975 Bosterbio, Pleasanton, CA) and analyzed
per manufacturer instructions.
Single-nucleus RNAseq: The Neuropathology Core of the Knight-Alzheimer’s Disease Research
Center (ADRC) provided the postmortem brains. AD neuropathological changes were assessed
according to the criteria of the National Institute on Aging-Alzheimer’s Association (NIA-AA).
The data displayed are combined from 3 brain samples from patients with autopsy-confirmed
AD. These three European-American females were family related subjects (one ADAD and two
LOAD), for whom we have information about clinical dementia rating (CDR), plaque and tangle
counts, APOE genotype, postmortem interval (PMI), age at onset, gender and age at death. One
subject carried a PSEN1 p.A79V pathogenic mutation and the two family related samples do not
carry any autosomal mutation (sporadic AD). Nuclei were isolated from frozen tissue using a
sucrose gradient, then libraries were made using the 10x Genomics Chromium platform.
The software CellRanger (v1.3.1 10X Genomics) was employed to align Illumina reads and
quantify gene expression. We aligned the reads to a custom “pre-mRNA” reference that was
generated as describe by 10X genomics technical manuals
(https://support.10xgenomics.com/single-cell-gene
expression/software/pipelines/latest/advanced/references). The gene expression matrices were
combined in R independently for further processing using the Seurat (version 2.20, 2.30)
pipeline. We normalized the data employing the LogNormalize function that normalizes the gene
expression measurements for each cell by the total expression; scales by a factor equal to the
median counts of all genes and log-transforms the expression. The data was regressed out using
the ScaleData function on nUMI, percent mitochondrial and Origin Sample. We applied
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FindVariableGenes with default selections and cut-offs values (x.low.cutoff = 0.0125,
x.high.cutoff = 3, y.cutoff = 0.8), for each library. We identified the common set of genes highly
variable among the samples by calculating the intersection among them. This number was 1434
genes, which were part of the function FindClusters to identify the clusters with a resolution
parameter 0.6. In addition, we corrected for drop-out events that lead to an exceedingly sparse
depiction of the single cell transcriptome. Instead of removing genes containing missing values
that restricts the analysis to only highly expressed genes, we imputed missing gene expression
values using scImpute {Li, 2018 #1340}. After imputing gene expression, we reclustered the
nuclei. Finally, we learned similarity relationships among the expression profile of the cells
included in the clusters by using the function BuildClusterTree.
Rate of Progression determination: The recruitment, assessment, and exclusion criteria methods
for the Memory and Aging Project at the Knight ADRC have been published previously310.
Participants were followed longitudinally and were evaluated annually by Clinical Core
personnel at Washington University. Briefly, cases received a clinical diagnosis of AD in
accordance with the standard criteria311 and presence or absence of dementia. The severity of
dementia was staged with the Clinical Dementia Rating (CDR) where 0 indicates cognitive
normality, 0.5 is defined as very mild dementia, 1 is mild dementia, 2 is moderate dementia, and
3 is severe dementia312. The scores in each of the six cognitive and functional domains surveyed
by the CDR are summed to yield a Sum of Box scores (CDR-SB) ranging from 0 (no
impairment) to 18 (maximal impairment). Sample selection was done as follow: only participants
that had an AD diagnosis at the last visit and had a CSF profile compatible with AD (based on
CSF Aβ/tau profiles with established cutoffs) were included in our analyses. Non-AD dementia
was excluded, as well as individuals in which the CDR at last assessment was equal to 0.
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Individuals with diagnoses of neurological diseases other than AD were excluded. After
removing the non-informative data points, only individuals with at least 1.5 year of follow-up
were included. A total of 778 participants were included in the analyses304. Statistical analysis
was carried out using R statistical software and the package nlme was used for linear mixed
model. A linear mixed-model repeated measure framework was used to account for correlation
between repeated measures in the same individual. Disease progression was modeled as follows:
(Y)=β_1 〖[SNP*Time]+β〗_2 [〖CDR_baseline8*Time]+β〗_3 〖AGE_baseline β〗_4 〖
Gender+β〗_5 Education+β_6 SNP+β_7 CDR_(baseline+) β_8 〖Time+β〗_9 PC1〖+β〗_10
PC2
Where: Y was CDR-SB, the change in CDR Sum of Boxes per year baseline CDR, baseline Age,
Gender, follow-up time, level of education, and, to avoid the possibility of spurious association
due to population substructure, the two first principal components scores were included as
covariates.
Statistics: Statistical analyses were performed using GraphPad Prism v8.02. When multiple ttests were performed, Holm-Sidak correction test for multiple comparisons was applied unless
otherwise noted. Fluidigm qPCR data was analyzed by two-way (individual gene or gene groups
given no baseline change in PBS or APP/PS1- mice) or three-way (if a significant main effect of
genotype was found by two-way ANOVA at baseline in PBS or APP/PS1- mice) analysis of
variance (ANOVA) with Tukey correction for multiple comparisons. In mouse and cell
experiments, datapoints were determined to be outliers (and thus excluded) based on the ROUT
method in Prism 8, Q=1%, performed post-hoc.
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3.6 Supplementary Materials

Figure S3.1. Chi3l1 is regulated by the circadian clock and expressed in astrocytes.
A. qPCR depicting Chi3l1 expression in cortical tissue from Nestin-Cre;Bmal1f/f and Bmal1f/f control
mice taken every 4 hours across circadian day. CT = Clock Time.
B. Change in Ct (cycle to threshold) between Chi3l1 and Actin obtained from qPCR data conducted on
WT primary astrocytes or WT primary microglia. n = 9 samples from 3 independent experiments
(astrocytes) and 5 biological replicates (microglia).
All data represent mean +/- SEM. ****p < 0.0001 by two-tailed students t-test

Figure S3.2. Chi3l1 expression does not oscillate in cultured astrocytes.
A. qPCR showing gene expression from WT primary astrocytes treated as in Fig. 3.2b-d. Data normalized
to expression at 18 hours. n = 6-9 replicates from 2-3 independent experiments per timepoint. No
significant difference based on time by one-way ANOVA with Tukey correction for multiple
comparisons. Data represent mean +/- SEM
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Figure S3.3. Loss of Chi3l1 does not change astrocyte reactivity gene signature, but does
modulate the microglial response to LPS
A. Chi3l1 expression levels from fluidigm qPCR of 2-5mo WT mouse cortex +/- 2mg/kg LPS from Fig.
3.3d-h, normalized to PBS controls. n = 6 (PBS) or 14 (LPS). Bar represents mean +SEM. ****p<0.0001
by two-tailed students t-test.
B. Astrocyte activation marker expression from fluidigm qPCR of 2-5mo Chi3l1-/- and WT control mouse
cortex from Fig. 3.3d-h. All values normalized to PBS WT. Each point represents mean of 6 mice per
group (left, PBS) individual values (LPS, right) or mean of 14 mice/group (LPS, right center). Two-way
ANOVA with Tukey correction for multiple comparisons.
C. Microglia activation marker expression from fluidigm qPCR of 2-5mo Chi3l1-/- and WT control mouse
cortex from Fig. 3.3d-h. All values normalized to PBS WT. Each point represents mean of 6 mice per
group (PBS) or mean of 14 mice/group (LPS). As PBS groups were significantly different by two-way
ANOVA, significance of entire cohort was evaluated by three-way ANOVA with Tukey correction for
multiple comparisons. No overall significant effect of genotype was detected, but there was a significant
interaction between genotype and LPS treatment, ****p<0.0001.
D. Individual mouse values from C.
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Figure S3.4. Loss of Chi3l1 mitigates amyloid pathology in cortex.
A. Representative cortical images from Chi3l1-/-:APP/PS1+ and APP/PS1+ control mice depicting
staining for X34 (fibrillar plaques), HJ3.4 antibody (total Aβ), and subtraction of fibrillar (X34) from total
(HJ3.4) Aβ. Cortex outlined in yellow. Scale bar = 300um
B. Quantification of X34+ puncta (fibrillar plaque) number from staining in (A).
C. Quantification of cortical area covered by X34 (fibrillar Aβ) in staining from (A).
D. Quantification of cortical area covered by HJ3.4 (total Aβ) in staining from (A).
E. Quantification of cortical area covered by non-fibrillar Aβ (total Aβ in HJ3.4-fibrillar X34) in staining
from (A).
F. Amyloid processing gene expression from fluidigm qPCR of 8 mo Chi3l1-/-:APP/PS1-, WT:APP/PS1-,
Chi3l1-/-:APP/PS1+ and APP/PS1+ control mouse hippocampus. All values normalized to WT:APP/PS1-.
Each point represents mean of 4 mice (APP/PS1-) or 10 (APP/PS1+) mice per group. Two-way ANOVA
with Tukey correction for multiple comparisons.
Data points represent average of 4 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. *p < 0.05 by two-tailed students t-test unless otherwise noted.
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Figure S3.5. Loss of Chi3l1 mitigates astrogliosis in the presence of amyloid-beta plaques.
A. Representative wide-field images from 8mo Chi3l1-/-:APP/PS1+ and APP/PS1+ control mice in Fig.
3.5a stained for X34 (fibrillar plaques) and GFAP (astrocytes). Scale bar = 400um.
B. Quantification of GFAP coverage from mice in (A, Fig 3.5a) normalized to X34+ plaque number in
same section.
C. Individual mouse values of astrocyte activation marker gene expression from fluidigm qPCR from Fig.
3.5e. All values normalized to WT:APP/PS1-. Two-way ANOVA with Tukey correction for multiple
comparisons. Significant main effect of genotype on gene expression in APP/PS1+ mice.
Data points represent average of 2 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. **p < 0.001 by two-tailed students t-test.
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Figure S3.6. Loss of Chi3l1 alters plaque-related microglial activation.
A. Representative wide-field images from 8mo Chi3l1-/-:APP/PS1+ and APP/PS1+ control mice in Fig.
3.6a stained for X34 (fibrillar plaques), IBA1 (microglia), and CD68 (phagocytic microglia). Scale bar =
400um.
B. Quantification of IBA1 coverage from mice in (A, Fig 3.6a).
C. Quantification of IBA1 coverage from mice in (A, Fig 3.6a) normalized to X34+ plaque area in same
section.
D. Quantification of CD68 coverage from mice in (A, Fig 3.6a).
Data points represent average of 2 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. *p < 0.05 by two-tailed students t-test unless otherwise noted.
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Figure S3.7. Loss of Chi3l1 alters microglial activation and reduces inflammation.
A. Individual mouse values of microglia activation marker gene expression from Fluidigm qPCR of from
Fig. 3.6f. All values normalized to WT:APP/PS1-. Significant main effect of genotype on gene expression
in APP/PS1+ mice by two-way ANOVA with Tukey correction for multiple comparisons.
B. Cytokine and chemokine gene expression from Fluidigm qPCR of 8 mo Chi3l1-/-:APP/PS1-,
WT:APP/PS1-, Chi3l1-/-:APP/PS1+ and APP/PS1+ control mouse hippocampus. All values normalized to
WT:APP/PS1-. Each point represents mean of 4 mice (APP/PS1-) or 6-10 (APP/PS1+) mice per group.
Significant main effect of genotype by three-way ANOVA with Tukey correction for multiple
comparisons.
C. Individual values from B.
Data points represent average of 2 sections/mouse, 6 (Chi3l1+/+) and 12 (Chi3l1-/-:) mice per group. All
data represent mean +/- SEM. *p < 0.05 by two-tailed students t-test unless otherwise noted.
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Chapter 4: The circadian clock protein
BMAL1 regulates microglial activation and
inflammation
Adapted from an ongoing study:
Brian V. Lananna, Collin J. Nadarajah, Melvin King, Erik S. Musiek, 2019. The circadian clock
protein BMAL1 regulates microglial activation and inflammation.
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4.1 Introduction
Alzheimer’s Disease (AD) is the most common form of dementia and the 6th leading cause of
death in the United States201. Aging is the most prominent risk factor for AD213. Chronic
inflammation and oxidative stress are both characteristic features of aging313,314 and can drive
damage in AD206,213,284. Although it has become evident that microglia play many roles in brain
homeostasis including in synaptic maintenance and pruning315–317, they are the brain’s resident
macrophage-like immune cells317. Thus, they are tasked with protecting the brain during
infection or during a wide array of injuries such as with TBI or protein aggregation206,317,318.
However, aged microglia can become hyperactive, producing higher levels of constitutive
proinflammatory cytokines and reactive oxygen species (ROS)319–323 while also overreacting in
response to immune challenge322–324. Although somewhat controversial237, recent evidence
suggests that microglia are capable of both destructive and protective roles in
AD206,211,212,228,325,326. The strongest evidence for this notion stems from microglial genetic risk
factors for AD248–250 and demonstrated impacts of microglial manipulations on pathology and
neurodegeneration in AD207,211,226,243,251,327.
Although circadian rhythm dysfunction is also common both to aging328,329 and as a symptom of
AD9,14, studies investigating a causative role of circadian dysfunction in the pathological
progression or neurodegenerative aspects of AD have been sparse and inconclusive10,214.
However, our lab has shown that global circadian disruption can exaggerate Aβ-plaque
deposition in a mouse model of β-amyloidosis261. Additionally, the output of the circadian
pacemaker, the suprachiasmatic nucleus of the hypothalamus (SCN)11,12,172,330 and clock gene
expression in certain tissues215–217,279,331, possibly including microglia195, decline with age and in
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AD. Circadian clock dysfunction can drive inflammation and oxidative stress in the brain15 and
in the peripheral immune system16,17,180,190. Some initial evidence from our lab198 and
others141,199 shows circadian regulation of these same systems in microglia and suggests that this
regulation may be impaired with advanced age195. However, complete characterization of the
link between the microglial clock and regulation of the neuroimmune response as well as
possible implications for AD are unknown. Thus, this study seeks to evaluate the role of the
microglial molecular clock in regulating inflammation and the pathogenesis of AD. Uncovering
a link between a hyperactive microglial immune responses and the molecular clock in microglia
would complement our studies in astrocytes (see Chapters 2 and 3) in identifying manipulation
of the molecular clock as a potentially viable option for treatments to slow or prevent
neurodegeneration in AD.

4.2 Results
We first sought to establish a potential influence of circadian regulation on immune factor
expression in the cortex as shown in the periphery17,180,184,200 and in an initial study in the
hippocampus141. Thus, we examined both clock gene and selected cytokine expression in mouse
cortex across the circadian day. Importantly, mice were housed in constant darkness beginning
24 hours before the first collection to avoid any potential masking effects of light271 on cytokine
production. As expected, clock genes displayed time of day differences in the cortex (Fig. 4.1a,
S4.1a-c). Consistent with data from the hippocampus141, we observed significant timedependency in expression levels of several cytokines including Nos2 (Fig. 4.1b), Il-1b (Fig.
4.1c), and Ptgs2 (COX2, p=0.0610, Fig. S4.1d). However, contrary to the data obtained in
cultured hippocampal microglia141, Il-6 expression levels did not vary according to time of day in
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the cortex (Fig. S4.1e). These data suggest that the microglial circadian clock may be regulating
production of some, but not all, inflammatory cytokines.

Figure 4.1. The microglial clock regulates inflammation and oxidative stress.
A-C. mRNA expression in WT mouse cortex across the circadian day, normalized to CT12. CT12 double
plotted at CT36. n = 2-4 biological replicates/timepoint from 2 independent experiments. (A) p = 0.0263
(B) p = 0.0486 (C) p = 0.0451 by one-way ANOVA with Tukey correction for multiple comparisons.
*p<0.05 for significant multiple comparison test depicted on graph.
D. Expression of microglial activation markers in Cag-CreERT2;Bmal1f/f primary microglia treated with
tamoxifen in vitro. Harvested 6 DIV after tamoxifen. n = 2 biological replicates per group. *p<0.05 by 2tailed student’s t-test.
E. Oxidative stress measured every 10 minutes by DCF assay in primary microglia treated with siRNA
targeting Bmal1 or siSCR. PBS control, 80uM H2O2, or 1mM N-acetylcysteine (NAC). n = 6 biological
replicates per group per timepoint. *p<0.05, **p<0.01 by two-way, repeated measures ANOVA of siSCR
vs. siBmal1 in each condition.
All data represent mean +/- SEM

To test a possible role for the microglial clock in microglial activation, we cultured primary
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microglia from Cag-Cre;Bmal1f/f mice. The microglia were treated with tamoxifen in vitro to
eliminate the influence of molecular clock disruption in other cell types on microglial activation.
Tamoxifen treatment resulted in a 95% reduction in Bmal1 and an 80% reduction in BMAL1
target Nr1d1 (Fig. S4.1f). Loss of a functioning microglial clock induced increases in C3, a
complement component implicated in pathogenesis of AD92,93,211,332, Apoe, which is linked to
AD risk333,334 and Aβ deposition305, and Cybb (NADPH oxidase NOX2), an ROS-producing
enzyme potentially associated with AD209, as well as a non-significant increase in complement
component C4b (Fig. 4.1d). To evaluate the dependence of oxidative stress on the microglial
clock, we conducted a dichlorofluorescin (DCF) oxidative stress assay in WT primary microglia
treated with siRNA targeting Bmal1 or a non-targeting scramble siRNA control. siBmal1 treated
microglia produced significantly higher reactive oxygen species per cell than siSCR treated
controls. This effect was exacerbated in cells treated with hydrogen peroxide (Fig. 4.1e). Cells
treated with the anti-oxidant N-acetylcysteine as a negative control produced very little reactive
oxygen species (Fig4.1e). Taken together, these data suggest that loss of microglial Bmal1
induces activation and overproduction of ROS.
Next, we investigated the regulation of the microglial inflammatory response by BMAL1 in the
presence of LPS. WT and Bmal1 KO mice were injected intraperitoneally with LPS (2mg/kg)
and after 8 hours microglia were extracted and sorted by FACS for microarray analysis.
Consistent with our in vitro data, loss of Bmal1 induced a number of changes in microglial gene
expression including in pro-inflammatory cytokines and chemokines (Tables 4.1, 4.2). To probe
a possible exacerbation of the LPS-induced inflammatory response, we sorted genes upregulated
at least 1.4 fold or downregulated at least 30% in Bmal1 KO, LPS-treated microglia from WT,
LPS-treated controls (Tables 4.3, 4.4). Genes associated with inflammation and oxidative stress,
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many of which are associated with AD, appeared preferentially upregulated in Bmal1 KO
microglia (Fig. 4.2a).

Figure 4.2. Loss of Bmal1 exacerbates the microglial immune response to LPS
A. Selected gene expression changes with associated pathways from microarray of FACS-sorted WT and
Bmal1 KO microglia +/- 2mg/kg LPS for 8 hours in vivo. DR = downregulated (>30% decrease), UR =
upregulated (>40% increase) in LPS treated Bmal1 KO microglia. Clock genes Nr1d1, Nr1d2 are direct
BMAL1 targets, Cry1, Fabp7 suppressed by BMAL1 target REV-ERB . Normalized to WT PBS. * =
putative association with AD.
B. Gene ontology (GO) analysis on all genes upregulated (>40%) in LPS-treated Bmal1 KO microglia.
Affected pathways with FDR corrected p-value<0.001 displayed.

Surprisingly, however, genes typically upregulated in the LPS-induced “M1” activation state335
or in the AD-associated “DAM” state212 were unchanged by loss of Bmal1 (Fig. S4.2a-d). Gene
Ontology (GO) analysis336,337 confirmed that the regulatory pathways altered in LPS-treated
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Bmal1 KO microglia were preferentially involved in immune processes (Fig. 4.2b, Tables 4.5,
4.6). Together, these data suggest that loss of microglial Bmal1 exacerbates the microglial
immune response, without altering the M1/M2 or DAM polarization states, in the setting of LPS.

4.3 Discussion and future directions
As central players in the neuroimmune response, microglia play an important role in recovery
after injury or infection284,317,318. Accordingly, microglial dysfunction can incur exacerbated
inflammation and damage84,92,198,207,211,323. Data from the periphery illustrate clock regulation of
the macrophage immune response16,17,180,190 and initial data suggest this same relationship may
exist in the brain141,198. While preliminary, our data suggest that disruption of the microglial
clock by loss of Bmal1 induces a pro-inflammatory, pro-oxidative stress activation state at
baseline and in the setting of LPS.
As BMAL1 directly drives transcription of Nr1d1, our data are consistent with a previous
investigation from our lab in which REV-ERBα (Nr1d1) was shown to regulate the microglial
immune response198. The increased ROS production and complement factor expression observed
with loss of Bmal1 shown here were not measured in the previous study. That being said, REVERBα is a transcriptional inhibitor. As such, Bmal1 deficiency could induce hyperinflammation,
oxidative stress, and complement activation via the loss of REV-ERBα-mediated inhibition.
Interestingly, we recorded two different patterns of cytokine expression in WT mouse cortex
with varying peak expression times. For instance, Nos2 expression peaks near CT24 while
expression of Il-1b and Ptgs2 peaks near CT12 (Fig. 4.1b,c, S4.1d). These data imply the
existence of multiple, cytokine-dependent regulatory mechanisms. Altogether, our data suggest
it is possible that the loss of REV-ERBα transcriptional inhibition is only one of several
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contributions to the overactive neuroimmune phenotype described here.
With the exception of our DCF experiment, one limitation of the REV-ERBα study198 and the
work presented here is that global deletion models were utilized. Thus, we cannot currently rule
out contributions of other cell types to these phenotypes. For instance, as seen in chapters 2 and
3, as well as in previous work1,2, astrocytes contribute substantially to neuroimmune regulation.
In order to more thoroughly characterize the purported regulation of the microglial immune
response by BMAL1 and identify any potential divergence from regulation by REV-ERBα,
follow-up experiments will examine tamoxifen-inducible, microglia-specific Bmal1 KO
(CX3CR1-CreERT2;Bmal1f/f) mice. LPS will be given to these mice in vivo and, guided by data
from the current microarray, microglial expression of immune factors will be evaluated.
Complementary measurements of functional consequences, such as neurotoxicity assays, will be
crucially important given the apparent distinction between the pro-inflammatory phenotype
described here and the M1335 and DAM212 microglia states.
Many of the genes upregulated by LPS-treated Bmal1 KO microglia are associated with AD
pathogenesis (Fig. 4.2a). Given the convergence of factors overproduced in cultured Bmal1 KO
microglia with these microarray changes on AD-related factors, CX3CR1-CreERT2;Bmal1f/f mice
have been crossed with APP/PS1 mice. These mice will be evaluated for pathological changes
such as Aβ deposition, glial activation, and oxidative stress. Given the preliminary data
presented here, we expect an exacerbation of these phenotypes in Bmal1-deficient APP/PS1
mice. While loss of Chi3l1 via disruption of the astrocytic clock results in amelioration of Aβ
pathology (See chapter 3) this does not mean that astrocyte clock dysfunction is beneficial (for
instance, see chapter 2 and Figure 2.5). Additionally, consistent with our data presented in
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chapter 3, our microarray did not identify any change in Chi3l1 with LPS or with loss of Bmal1
in microglia (see tables 4.1-4.4). Together, these data imply that microglial clock disruption in
AD would exacerbate complement expression, inflammation, and oxidative stress without the
benefit of dampened Chi3l1, leading to worsening of AD-associated pathology. Thus, this study
underscores the importance of investigating microglial clock function in further elucidating the
link between circadian dysfunction and AD.

4.4 Materials and Methods
Mice. All mouse experiments were conducted in accordance with protocols approved by the
Washington University IACUC. Global Bmal1 KO, CAG-CreERT2+;Bmal1f/f mice, and wildtype
C57Bl/6 (circadian harvest) mice were obtained from The Jackson Laboratory (Bar Harbor, ME)
and bred at Washington University. These strains were maintained on a C57Bl6 background.
Timed-pregnant wildtype CD1 mice for culture experiments were obtained from Charles River
(Wilmington, MA). All mice were housed under 12-hour light/12-hour dark conditions, unless
otherwise specified. All wildtype C57Bl/6 mice used in circadian collection experiment were
housed in constant darkness beginning 24 hours before the first collection time. At each
collection timepoint mice were perfused and cortical tissue frozen as described in section 3.5.
Primary cell cultures: Primary glia were extracted from post-natal day 1-2 mouse pups (CD1
WT, CAG-CreERT2+;Bmal1f/f, or C57Bl/6 Bmal1f/f control mice) per experimental designation.
Dissections, cells culture maintenance, and cell collections were performed as in section 3.5
except as specified below. 10 days after dissection and initial plating, astrocyte cultures from
CAG-CreERT2+;Bmal1f/f and Bmal1f/f controls were shaken as in section 3.5. Microgliacontaining media was then re-plated in 12-well plates (coated for 2 hours at 37oC with 50 μg/mL
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poly-D-lysine (PDL- MP Biosciences, Santa Ana, CA), then rinsed twice with ddH2O). 3 days
after plating, all cells were treated with 1.5uM 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich, St.
Louis, MO) in standard culture medium (DMEM plus 10% FBS and 1% penicillin/streptomycin
(Gibco, Thermo Fisher, Waltham, MA)). After cultures were exposed to 4-OHT for 48 hours to
ensure Bmal1 deletion in Cre+ cells, medium of all cells were changed to standard culture
medium. 4 days after media change each well was homogenized in 500ul TRIzol (Life
Technologies, Carlsbad, CA) for RNA extraction, processing and qPCR analysis as in section
3.5.
Dichlorofluorescin oxidative stress assay. After extraction, culture and shaking as in section 3.5,
microglia were re-plated in 96-well plate for dichlorofluorescin (DCF, Sigma-Aldrich, St. Louis,
MO) assay in standard microglia culture medium (DMEM plus 10% FBS and 1%
penicillin/streptomycin (Gibco) plus 5ng/mL GM-CSF (BD Pharmingen, San Jose, CA) at a
concentration of 5000 cells/well. 48 hours after re-plating, cells were transfected with siRNA as
in section 3.5. 72 hours after transfection, media was changed using standard microglia medium.
DCF assay was performed 48 hours after removal of lipofectamine (RNAiMAX). Media was
changed in all wells to standard culture medium (no GM-CSF) and negative-control wells were
pre-treated with 1mM N-acetylcysteine (Sigma-Aldrich, St. Louis, MO). After 6 hours, medium
was again changed using standard culture medium containing 30uM DCF plus the following
additions per siRNA condition: negative control - 1mM fresh N-acetylcysteine; positive control –
80uM H2O2; untreated – PBS vehicle. After 45 minute incubation, media was changed to phenol
red-free DMEM plus 10% FBS and 1% penicillin/streptomycin and read on a heated (kept at
37oC throughout measurements) fluorescent plate reader (480/525 Ex/Em) every 10 minutes for
120 minutes. Untreated wells containing cells, but not given DCF were used as blanks. Cells
117

were then fixed in 4% paraformaldehyde for 10 minutes, washed 3 times with PBS, stained for
10 minutes with DAPI, rewashed 3 times in PBS and imaged at 4x for cell counts. Cells were
counted using FIJI (Fiji is just ImageJ) software (NIH).
Microarray: 3mo Global Bmal1-/- or WT C57Bl/6 control mice were injected intraperitoneally
with LPS (2mg/kg) or PBS vehicle control at 2am (2 mice/condition). Mice were perfused with
ice-cold PBS at 10am (8 hours after injection). One hemisphere per mouse was collected and
microglia isolated using a MACS microglia isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to Harms and Tansey, 2013338 using CD11b beads (Miltenyi Biotec). Cells
were then fluorescence activated cell-sorted (FACS) using CD45low as a marker into RNA
collection buffer. RNA was isolated from cells as in section 3.5 and submitted to the Genome
Technology Access Center at Washington University for quality control, MessageAmp RNA
library preparation, and Affymetrix Mouse 1.0 microarray. Raw data was analyzed using Gene
Pattern to isolate gene changes with uncorrected p-values<0.01. Gene changes were then sorted
according to upregulation (>1.4 fold) or downregulation (>30%) between Bmal1 KO and WT in
either condition. These changes are presented in tables 4.1-4.4. Each list of altered genes was
then utilized in Gene Ontology (GO) analysis (http://geneontology.org/)336,337 with FDR
correction (cutoff p<0.05). GO analysis did not reveal any pathways significantly altered after
FDR correction from microglia in PBS-treatment condition. Complete lists of pathways
significantly altered in LPS treatment conditions are displayed in tables 4.5 and 4.6.
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4.5 Supplementary Materials

Figure S4.1. Time of day dependence of clock genes and cytokines in cortex.
A-E. mRNA expression in WT mouse cortex across the circadian day, normalized to CT12. CT12 double
plotted at CT36, not included in statistical analysis. n = 2-4 biological replicates/timepoint from 2
independent experiments. (A) p = 0.0381 (B) p = 0.0132 (C) p = 0.0357 (D) p = 0.0610 (E) not
significant, by one-way ANOVA with Tukey correction for multiple comparisons. *p<0.05 for significant
multiple comparison test depicted on graph
F. mRNA expression in CreERT2;Bmal1f/f primary microglia treated with tamoxifen in vitro. Harvested 6
DIV after tamoxifen. n = 2 biological replicates per group. *p<0.05, ***p<0.001 by 2-tailed student’s ttest.
All data represent mean +/- SEM
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Figure S4.2. Selected “M1” and “DAM” markers unchanged in Bmal1-deficient microglia.
A-D. Selected gene expression changes associated with TLR4-induced “M1” macrophage activation (AB) or disease associated microglia “DAM” (C-D) from microarray in Fig. 4.2 of FACS-sorted WT and
Bmal1 KO microglia +/- 2mg/kg LPS for 8 hours in vivo.
All data represent mean +/- SEM

Table 4.1: Related to Figure 4.2; Transcripts upregulated in PBS-treated Bmal1 KO
microglia.
Microarray data is sorted by ratio of mean expression in PBS-treated Bmal1 KO/WT microglia. All
transcripts upregulated from controls by >1.4 fold in PBS-treatment with an uncorrected p value <0.01
by 2-tailed student’s t-test were included. Mean expression of N = 2 mice/condition in relative units in
columns 2-5.
Ratio
BMALKO
BMALKO
Log2(Fold
Gene/ID
WT PBS
WT LPS
PBS
PBS
LPS
change)
KO/WT
Fabp7

35.40440543

199.1627934

53.4281373

253.8491775

5.62536755

2.491947362

Tcte3

109.3667311

295.1096973

Rpl9

176.2661315

416.5436239

115.5606954

91.3795426

2.698349802

1.432077385

281.4626975

337.0940092

2.363151788

1.240712298

Gm2799

32.16395533

70.97885024

45.26262241

43.86612629

2.206782391

1.141944374

Cpe

35.81995734

75.74659753

72.54843248

86.86259553

2.114647899

1.080417466

Ifnb1

68.20851005

140.3301845

64.08361208

34.4846758

2.057370619

1.040801707

Hist1h4k

27.43615629

55.70071788

32.61008102

34.19885754

2.030193927

1.021617542

Prps1l1

23.61622698

45.94286458

13.07226675

11.23813196

1.945393928

0.96006232

Cry1

122.2253063

235.6403925

210.328588

233.8012779

1.927918199

0.94704384

Eps8l1

31.70764388

60.00164429

28.97114907

33.41236288

1.892340047

0.920171359

Xlr4b

40.97090977

76.44248067

59.53850318

50.40799144

1.865774548

0.899774668
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Szt2

48.41294186

86.81852414

54.2496205

53.58654425

1.793291645

0.842610134

Apoe

1645.303529

2817.601462

2244.685019

2122.68212

1.71251165

0.776113803

4931406H21Rik

45.14107087

76.82847274

39.14119426

37.07090115

1.701963894

0.767200431

Pou5f2

21.66006923

35.98284364

32.53556917

39.90906418

1.661252476

0.73227135

Xlr4c

64.44336827

106.2878626

92.23653965

82.66303507

1.649321962

0.721873053

Tfb2m

51.70622984

83.40337007

124.0795434

158.8569531

1.613023621

0.689767565

Lilra5

81.13319849

130.2515232

44.32230172

59.68858203

1.605403529

0.682935974

Niacr1

31.55683735

50.27434572

421.9108698

525.8739024

1.593136383

0.671869777

Fat3

243.6699168

382.9239632

358.510569

155.3642576

1.571486412

0.652129797

4930451G09Rik

39.84539498

62.28570052

39.85464977

43.7067478

1.563184417

0.644487991

9430025M13Rik

36.49983362

56.97947858

56.47406382

44.41809055

1.561088721

0.642552532

75.4537665

117.7814847

79.27762926

85.82184971

1.560975551

0.642447941

Slc25a18
Mir674

70.73787532

109.7901147

113.5166049

102.5398159

1.552069726

0.634193371

Rmnd5a

97.96254505

151.6653668

79.25629646

80.52942388

1.548197494

0.630589519

Eif2c4

31.09957141

47.89637676

14.93780875

15.09283475

1.540097647

0.623021826

1600012F09Rik

39.48746735

60.7800172

51.82155058

54.92616264

1.539222981

0.622202244

Gjb4

24.16726724

36.85417056

23.49381011

25.41643458

1.524962264

0.608773543

Gpr77

114.616001

174.7692982

133.2981156

103.7098461

1.524824604

0.608643303

Vmn2r29

28.61811323

43.577081

40.179486

46.37678814

1.522709783

0.606641002

Ifna14

25.32612268

38.47944182

34.3401577

30.90566272

1.519357791

0.603461648

Apol8

42.69588627

64.70741909

51.0999942

37.81891283

1.515542239

0.599834062

Emx1

64.84550428

98.19656433

82.93101203

77.58519472

1.514315687

0.598665993

Fat3

87.79080265

131.5823147

147.4738855

79.23630323

1.498816627

0.583823887

Olfr1373

145.9959064

218.2328069

168.9212532

117.3669746

1.494787164

0.57994008

Fads2

27.75269361

41.38434036

30.35460419

31.95990001

1.491182836

0.576457159

Tmed2

24.80771757

36.89749301

52.18676563

23.6583907

1.487339289

0.57273379

Pln

42.23595786

62.63241237

42.47198135

44.92850121

1.482916821

0.568437677

Serpind1

27.61150196

40.9220439

26.7988676

30.39198061

1.482065118

0.567608837

34.3168096

50.82451829

34.33855912

24.24539838

1.48103856

0.566609203

Efcab4b

30.71379086

45.22727547

55.14622805

55.95394245

1.47253967

0.558306501

3110040N11Rik

49.61346231

72.86322974

55.70811106

50.32093814

1.46861812

0.554459305

Slc1a5

54.69840248

79.9063746

246.2275685

236.2153796

1.4608539

0.546811902

E330020D12Rik

Ankrd13d

44.65027063

65.20251333

48.23931579

47.16864057

1.460293799

0.546258657

Ifitm1

46.23828701

67.37560807

110.5059253

137.7742809

1.45713893

0.543138437

Cdk14

65.31084347

95.13982867

157.5374014

76.00602515

1.456723319

0.542726887

1600029D21Rik

31.78828809

46.30231587

551.1857609

619.2078471

1.456584128

0.542589029

EG665031

71.15379573

103.3593417

50.80610565

67.3754298

1.452618805

0.538656162

Usp35

61.70501698

89.24358953

51.29492114

38.95226515

1.446293898

0.532360749

Ppia

116.6194023

167.8585259

144.9162682

130.7226148

1.439370487

0.525437983

Ncoa4

190.8064199

274.6051726

207.4918547

167.9067238

1.43918204

0.525249088

Hs3st3b1

69.60694765

99.49122305

117.5759698

130.7873352

1.429328916

0.515337947

162.863542

232.1987843

270.3447025

228.1443965

1.425725988

0.511696735

Zfp106
Dnajb1

720.2620293

1025.959178

468.793319

442.602888

1.424424913

0.510379573

Hsd3b7

46.74237616

66.16581715

47.22210787

65.0353673

1.415542439

0.501355003
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Lipt2

30.46872953

42.98383567

50.29336483

62.17057019

1.410752477

0.496464883

D130062J21Rik

48.30297944

67.94147573

16.73935934

15.39249048

1.406569046

0.492180374

Ceacam2

26.14655524

36.76966537

44.58229773

46.9896478

1.406291002

0.491895161

Mslnl

44.69320266

62.81031726

61.68418299

51.69623028

1.405366219

0.490946126

S1pr1

332.3415367

466.9186818

113.5928921

97.2626599

1.404936279

0.490504698

Table 4.2: Related to Figure 4.2; Transcripts downregulated in PBS-treated Bmal1 KO
microglia.
Microarray data is sorted by ratio of mean expression in PBS-treated Bmal1 KO/WT microglia. All
transcripts downregulated from controls by >30% in PBS-treatment with an uncorrected p value <0.01 by
2-tailed student’s t-test were included. Mean expression of N = 2 mice/condition in relative units in
columns 2-5.
Ratio
BMALKO
BMALKO
Log2(Fold
PBS
Gene/ID
WT PBS
PBS
WT LPS
LPS
change)
KO/WT
Rps13

797.6063608

21.92611304

707.9310617

32.19080275

0.027489892

-5.1849549

Nr1d2

611.9028822

109.9795486

168.1572068

70.40161715

0.179733667

-2.4760674

Cxcl9

72.11444148

14.88249794

414.7726556

477.5864546

0.206373337

-2.2766715

S100a8

74.50460879

18.66442796

149.7773044

379.0463218

0.250513737

-1.9970384

Nr1d1

216.4745069

56.46659642

54.54002838

41.41874491

0.260846403

-1.9387276

S100a9

73.78825073

20.8303329

28.12062182

40.87963662

0.282298777

-1.8247052

Gm11428

133.3782053

50.51679048

422.0045544

436.3616326

0.378748465

-1.4006881

Atg4a

144.6986059

65.52991529

132.64036

167.8975281

0.45287178

-1.1428255

Tmc7

263.2721393

121.4289699

54.27103429

29.67181356

0.461229852

-1.1164422

H2-Aa

314.0217406

146.5948382

339.3656342

283.0735839

0.46683022

-1.0990301

Serpine1

701.0266748

334.3781073

660.9261533

344.9484948

0.476983429

-1.0679889

Cd36

69.30909974

33.11117319

27.14830811

21.85369968

0.477731976

-1.0657267

6720489N17Rik

154.5668038

75.15472785

107.6356538

116.1951923

0.486228129

-1.0402947

Rnase12

67.81928336

34.24677282

33.81109854

23.74892494

0.504971022

-0.9857275

Hmgb1

62.63030711

33.62732396

41.52099706

28.21997675

0.536917756

-0.8972270

Plac8

37.45734628

20.32771864

135.3189465

179.1528572

0.54268977

-0.8818004

71.7243111

39.12220665

44.45250928

53.17389606

0.545452526

-0.8744745

D430042O09Rik
Pira1

99.44466503

55.53034032

114.7927988

168.235397

0.558404418

-0.8406177

H2-Ab1

266.6276663

150.4679808

401.4683608

326.5514779

0.564337463

-0.8253700

Nlrc5

95.43795865

54.50691393

165.1529845

196.4217173

0.571124055

-0.8081239

Qprt

104.0259374

60.70351041

53.81916513

54.17461723

0.583542066

-0.7770914

Tmx2

115.6668229

67.80605629

138.5028865

96.18947003

0.586218715

-0.7704891

Enkur

65.84140677

39.02878086

25.53761848

20.27878634

0.592769547

-0.7544568

Szt2

96.75231575

58.2300285

53.82991997

42.68960153

0.601846354

-0.7325329

Dusp18

182.6405858

110.3050182

47.37712327

33.73026726

0.603945819

-0.7275090

9130019O22Rik

73.74558745

44.65579985

38.72276996

46.19991241

0.605538601

-0.7237092

Rpl11

208.8244107

126.6262371

253.8688377

298.7603918

0.606376605

-0.7217140

Idi1

34.96003676

21.43225727

44.59252474

43.08833057

0.613050193

-0.7059229

140.425562

86.21610232

33.27884897

27.81602033

0.613963021

-0.7037763

Dyrk4

122

Taf9b

85.73838458

52.68211876

142.9974947

172.4403149

0.614451964

-0.7026279

Fyn

71.55930842

44.57594469

146.4617882

90.47683392

0.622923078

-0.6828741

Cdk5rap1

59.87404373

37.40747679

32.26279722

36.42431698

0.624769507

-0.6786041

Zfp30

59.10233249

37.07381381

31.07553777

31.59880427

0.627281737

-0.6728145

Spry2

26.28832526

16.64181023

32.71545295

19.90442519

0.633049464

-0.6596099

Actn1

108.8011582

69.42358174

27.31299611

38.28995413

0.638077599

-0.6481962

Casc4

121.0441657

77.36912637

140.1853847

148.6498138

0.639180963

-0.6457037

Scarna13

124.8201104

79.99012245

73.08663106

60.2595341

0.640843228

-0.6419566

Suox

83.20427339

53.55007133

62.20685138

69.99509466

0.643597608

-0.6357691

Wipi1

79.69723189

51.40198914

77.06690221

92.15541848

0.644965803

-0.6327054

Lphn2

348.1297261

224.7706752

119.0848496

98.17136683

0.645652061

-0.6311712

Glipr2

36.38163788

23.53246225

36.21042547

40.53169686

0.646822508

-0.6285582

Myo18b

285.6509112

185.0807706

47.60087368

35.98162691

0.647926414

-0.6260981

Nlrc5

84.77815865

54.96557482

134.452031

150.7013745

0.648345938

-0.6251643

Pdpr

62.74991137

40.92786825

63.7525657

59.22335798

0.652237865

-0.6165299

Rny3

212.8172166

138.9587208

91.03853357

94.21390563

0.652948681

-0.6149585

2310008H09Rik

87.41443483

57.21599257

115.3221604

97.46668098

0.654537122

-0.6114531

Ppp2r5c

45.16984358

29.59950938

40.33897086

34.15212565

0.655293599

-0.6097867

Snord57

90.1271893

59.06908416

137.9248648

101.1550803

0.655396941

-0.6095592

Gimap6

292.0893078

192.1332146

126.1008233

121.7388778

0.657789277

-0.6043026

BC022687

31.13110884

20.50187137

31.69042322

25.4807858

0.658565407

-0.6026014

Fahd2a

50.12072974

33.06694648

39.19502801

31.2076964

0.659745911

-0.6000176

Serpinf1

296.0834728

196.0504157

129.5441804

98.63976484

0.662145759

-0.5947793

Prps1

214.306467

142.0382082

364.4959091

352.2647428

0.662780784

-0.5933963

Dub2a

69.94850232

46.57884435

57.21381807

46.87311771

0.665901954

-0.5866183

Macrod2

95.69253042

63.73780437

72.56964806

63.47611897

0.666068753

-0.5862570

Cd97

67.39919484

45.15376693

102.1278561

106.8332515

0.669945198

-0.5778850

Iqgap1

78.08058273

52.54763538

178.1777318

121.6559029

0.672992357

-0.5713380

Nup35

93.82761485

63.2316542

77.6207538

78.23438611

0.673913051

-0.5693656

Rcn1

67.57644876

45.60857736

183.4519679

197.7386584

0.674918233

-0.5672154

Lancl2

35.22783287

23.78140837

46.18839814

43.42021064

0.675074407

-0.5668816

Pls3

63.75140881

43.05642544

38.25756463

34.53822215

0.675379984

-0.5662287

Vcpip1

61.80826522

41.77097939

40.17842175

39.42211607

0.675815431

-0.5652988

Gtf2ird1

65.74824651

44.45237219

36.66272084

37.45817966

0.676099737

-0.5646920

Trp53i11

147.2948899

99.67727175

106.7885946

117.4762757

0.676719143

-0.5633709

Gpr165

1536.272542

1041.687257

82.51233582

54.8094503

0.678061496

-0.5605120

Rnf122

184.0863653

124.951341

68.32161245

56.60121113

0.678764779

-0.5590164

Slc44a1

176.6089738

120.1939212

154.6964346

171.099929

0.680565198

-0.5551947

123

Table 4.3: Related to Figure 4.2; Transcripts upregulated in LPS-treated Bmal1 KO
microglia.
Microarray data is sorted by ratio of mean expression in LPS-treated Bmal1 KO/WT microglia. All
transcripts upregulated from controls by >1.4 fold in LPS-treatment with an uncorrected p value <0.01 by
2-tailed student’s t-test were included. Mean expression of N = 2 mice/condition in relative units in
columns 2-5. Gene Ontology (GO) analysis presented in Figure 4.2 was performed with this list.
Ratio
BMALKO
BMALKO
Log2(Fold
LPS
Gene/ID
WT PBS
PBS
WT LPS
LPS
change)
KO/WT
Fabp7

35.40440543

199.1627934

53.4281373

253.8491775

4.75122642

2.24829996

Marco

22.38481557

31.1000102

136.96005

543.67223

3.969567988

1.988982006

Sprr2d

15.55971745

16.07813334

20.21623407

70.66246934

3.495332964

1.805429893

Ptges

24.72483099

18.49258682

104.6578898

363.6717686

3.474862423

1.79695586

Pilrb1

25.80435171

26.5058712

115.1585743

364.8073651

3.167869759

1.663513023

48.1944767

36.02464274

277.1027043

868.9452004

3.135823602

1.648844407

Cp
Fpr1

14.42695319

15.36090881

339.8723217

1041.347816

3.063938278

1.615387235

Ly6i

22.24524169

23.12177263

51.56424828

155.2868484

3.011521617

1.590492615

9230105E10Rik

33.87539905

25.31348284

33.88176034

91.24356509

2.692999542

1.429213985

Aoah

29.87895508

21.16131553

266.1362073

691.9874631

2.600125214

1.378581101

C3

45.84990531

54.18391428

111.0703887

288.2245293

2.594971825

1.375718875

Vnn3

17.65170892

18.39644478

27.56009814

71.14199641

2.581340461

1.368120435

Pilrb2

15.49841231

13.11807603

60.27017178

153.7967691

2.551789128

1.351509114

Tarm1

45.99383945

50.08851247

239.1404978

558.6227312

2.335960393

1.224015813

Gpr18

69.76492224

52.69146992

306.722903

715.9086595

2.334056741

1.222839633

Tnfsf10

19.71725297

31.45914957

23.5762341

53.75280191

2.279957083

1.189006668

Eef1g

96.20928409

46.73872477

107.1149531

243.2323619

2.270760103

1.183175299

Ifit1

18.53855967

14.1149534

233.2184089

526.1525243

2.25605057

1.173799406

Irg1

48.56432769

47.82525331

811.8995373

1830.924536

2.255112181

1.173199202

11.1179018

77.50286764

33.97935548

76.21066148

2.242851885

1.16533435

133.9589167

144.7112432

237.2325606

525.0729728

2.213325909

1.146215902

Ccl19
Fam49a
Pilra

104.8433529

108.9548508

456.4933737

1003.907058

2.199171151

1.136959887

Ccl22

32.29926936

31.73354453

289.0735116

621.8762075

2.151273577

1.105191004

Susd2

27.52916629

29.4451413

41.26698616

88.11410373

2.135220231

1.09438488

Gapdh

105.1963874

91.00521049

66.44780994

141.1526277

2.124263054

1.086962431

Rpl15

149.5929627

106.3993304

180.3543975

378.5090825

2.098696166

1.069493319

Dtx2

64.30725172

72.31268283

130.5593928

273.7885687

2.097042296

1.06835596

Plin2

250.8855923

291.5772094

622.1777145

1287.671065

2.069619395

1.049365479

Clec4a1

119.1646504

105.12449

638.8066261

1309.682081

2.050201152

1.035765464

Ppap2a

170.8232059

168.4680019

192.2746526

391.8956854

2.038207742

1.027301104

Rpl13

37.24121622

45.37673905

77.59130866

157.6590787

2.031916737

1.022841285

Il1rn

46.83700061

43.70298587

776.7511164

1542.680677

1.986068181

0.989915151

AW112010

71.35783368

76.48932052

1215.328079

2410.083566

1.983072396

0.987737347

Pstpip2

35.21939532

29.44395341

144.8716594

286.3716926

1.976726806

0.983113496

Car13

20.8441862

18.41996986

86.84182965

171.5522337

1.975456234

0.982185884

162.4289991

132.2299097

314.0668561

615.1119344

1.958538198

0.969777266

6330409N04Rik
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Agtrap

135.6146765

109.1761881

241.2553401

469.5720915

1.946369731

0.96078579

Nlrc5

38.15820051

44.21337164

48.88467188

94.57861515

1.934729467

0.952131848

Hdac9

165.64933

162.4512421

152.7044067

292.6402921

1.916384068

0.938386724

Flnb

101.7603814

103.8953442

92.07380081

174.9219273

1.899801309

0.925848542

Traf1

18.27481868

14.41968653

32.8624943

62.12649341

1.890498415

0.91876664

Asb2

142.4292315

113.9245416

46.05108406

86.52943104

1.878987928

0.909955798

Irak3

86.45761909

77.25206319

472.2723435

880.8926742

1.865221807

0.899347202

Cybb

138.0634378

93.18317101

1211.208087

2258.926105

1.865019008

0.899190334

Il4i1

53.1529934

41.95559971

48.67292999

90.05088525

1.850122548

0.887620835

Clec4a3

436.3295938

507.2122168

589.1621795

1088.970224

1.848336946

0.88622778

Pid1

135.9022407

152.061448

172.392929

317.62436

1.842444245

0.881620962

Plp2

161.399885

182.5954543

92.51241276

168.4002924

1.820299432

0.864175787

Cd80

120.6384123

125.6611136

149.2633393

269.109574

1.802918086

0.85033385

Ebi3

183.1445694

202.9233319

277.2437909

497.0172765

1.792708413

0.842140851

Rassf4

391.9795817

457.3139322

467.9535918

836.6041924

1.787793078

0.838179767

Pgm2

62.79689296

59.45513007

74.85647974

133.6605853

1.785557987

0.836374987

Mrps27

29.40497031

28.85035211

36.23369508

64.20140422

1.771870191

0.825272914

Ms4a4c

27.30360064

30.16527981

292.8569422

514.3129542

1.756191779

0.812450398

Ikbke

60.08008648

67.11507835

89.41746079

156.7149925

1.752621816

0.809514722

Samd9l

34.90045843

17.43517119

186.2694085

326.3660882

1.752118562

0.809100403

LOC625360

67.81743385

45.36141465

47.68624793

82.63042837

1.732793666

0.793099874

Rab11fip1

17.24946869

20.8573222

60.47426229

104.2715919

1.724230903

0.785952988

74.9059323

57.40493644

304.1072913

522.8340616

1.719242111

0.781772726

Ppargc1b

Usp18

24.28175122

25.85714801

36.21976261

61.80379824

1.706355696

0.770918413

Bnip3

250.4622317

238.2506765

242.2140358

411.8189449

1.700227419

0.765727731

Sod2

146.7552187

140.4842827

1292.860335

2191.762343

1.695281605

0.761524941

Zfp87

91.8344238

79.18854103

48.55439123

81.88105068

1.686377866

0.753927837

Cd80

145.7629609

157.7883683

194.37119

324.150114

1.667686009

0.737847684

Gbp5

54.8650519

58.88780075

188.0789008

313.2308398

1.665422535

0.73588825

Oasl1

72.71447167

76.31928807

316.7999736

527.0779388

1.663756259

0.734444093

Bnip3

231.0247007

198.2238214

195.5911679

325.0179048

1.661720763

0.732677971

333.904719

287.079183

669.7754737

1108.472264

1.654990825

0.726823219

Bst2
Rsad2

37.64566653

31.17917702

209.7493857

345.9343672

1.649274757

0.721831761

Nlrc5

32.31785082

37.33524081

54.94752397

90.38678254

1.644965523

0.718057347

Zc3h12c

204.1679362

201.6034547

717.4620636

1179.654067

1.644204101

0.717389397

Napepld

28.40512908

23.05369683

66.70267495

109.2435832

1.637769149

0.711732017

Snord34

35.47190569

45.36960504

67.11420741

109.6577151

1.633897193

0.70831721

Gm885

157.5265316

190.6523045

509.1917713

830.8155401

1.631635833

0.706319096

Trdmt1

59.4433485

57.24289631

64.75568446

104.8808446

1.619639194

0.69567246

103.8871915

91.40175441

60.06158733

96.60690922

1.608464137

0.685683769

Cnp
Ddx60

73.51734102

69.1837114

129.0616995

206.9261422

1.603311773

0.681054993

4930506M07Rik

28.77861538

31.18773117

45.54596997

72.60016651

1.593997593

0.672649451

Zc3h12c

346.9465355

304.8787286

912.204387

1449.698089

1.589225079

0.668323466

Cd274

82.56642646

85.29896093

402.1747728

638.5733717

1.587800665

0.667029806
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Rilpl2

196.7432175

165.3552362

139.634723

221.2754842

1.58467378

0.664185878

Pyhin1

35.57416425

32.1958138

393.9963334

624.0562198

1.583913775

0.6634938

Oasl2

73.47961942

50.0394506

328.2756002

519.5935662

1.58279679

0.662476044

Ifit3

109.4767366

82.49796159

458.6771077

725.9362842

1.582673894

0.662364022

Epb4.1l3

65.52598923

78.26266177

76.9906333

121.839279

1.582520805

0.662224466

Rpl28

858.6050672

801.9918012

732.2872245

1157.524438

1.580697299

0.660561121

Gas7

53.86430191

47.17229131

105.5296168

166.6689201

1.579356821

0.659337153

Mesdc1

56.74992624

59.38672521

73.1731639

115.3883298

1.576921423

0.657110774

Ift57

73.55193405

62.9094313

264.6615037

417.0853941

1.57592014

0.656194428

Cd72

52.7568693

69.63466581

421.7463549

663.7454902

1.573802553

0.654254554

32.01090096

34.89768232

35.83478479

56.33273137

1.572012549

0.652612734

41.8035241

48.52521686

51.0952185

80.2498636

1.570594391

0.65131065

Setbp1
2310003L22Rik
Ifi204

85.22367861

64.13202606

755.0023916

1185.632357

1.570369009

0.651103606

Ctla2a

17.62796027

20.68778733

124.0633056

194.2205056

1.565495169

0.646619057

Brp16

26.92649957

34.26336971

53.70184628

83.66200126

1.557898044

0.63960082

Malt1

154.1411403

155.0224952

321.6371102

500.6544436

1.556581712

0.638381312

Rnf213

52.26534972

57.88413586

207.7102524

322.9616015

1.554865963

0.636790218

Gbp2

82.53658673

88.91154578

690.4388906

1072.631661

1.553550467

0.635569108

Cenpt

86.5053316

70.3831908

78.90142366

122.2079827

1.548869171

0.631215289

Dmxl2

36.33328903

51.80452218

60.81518875

93.98267528

1.545381626

0.62796315

H2-T24

100.6514501

104.2073479

57.48580212

88.41892103

1.538100153

0.621149447

Ccl5

182.5429864

244.893126

5469.154485

8375.01876

1.531318741

0.614774608

Rps28

276.6635106

254.8684541

190.1275223

290.1852262

1.52626628

0.610006684

Rnf213

68.47043706

64.51065827

254.7129133

387.9569579

1.523114603

0.607024498

Gsr

92.79503681

93.43064002

229.2155605

348.9713226

1.522459129

0.606403499

Enpp4

73.70305471

72.32756122

137.5609923

209.1193156

1.520193422

0.604254897

Nlrc5

86.69214441

101.1283334

117.0368416

177.911884

1.520135724

0.604200139

St7

65.60155476

51.84502083

167.3134997

253.953586

1.517830817

0.602010992

Sepw1

343.4335623

349.9071716

709.0224504

1073.473326

1.514018808

0.598383128

Rpl17

592.2105626

626.6410343

640.7597934

968.9760169

1.512229742

0.596677334

Cox7c

286.3785293

236.1125301

239.1208437

361.313561

1.511008222

0.595511511

Acp5

25.82462511

34.00336199

96.92182073

146.2399539

1.508844477

0.593444109

Heatr6

130.0469238

136.8893941

180.5453694

272.0598349

1.506877943

0.591562564

Ncrna00085

32.90353657

45.01819985

36.7548057

55.37939576

1.506725303

0.591416418

Bmp1

50.36414259

46.44832322

54.60313678

82.20350259

1.505472166

0.590216035

Cyp20a1

141.4376682

130.5016032

147.7296127

222.3521599

1.505129242

0.589887373

Mif

711.2184251

601.1394596

2082.81042

3133.785945

1.504594904

0.589375109

Rbpms

131.4521136

130.8032362

180.1646738

270.882123

1.503525177

0.588349026

D14Ertd668e

153.5889424

124.4022389

394.6077432

592.452193

1.501369913

0.586279477

Fhl3

339.2877827

349.9642939

412.7795391

619.0755937

1.499772966

0.584744124

Gm8587

74.92459882

67.45606461

74.67614886

111.8803763

1.498207634

0.583237578

Vti1a

73.75158225

66.28707776

138.8448031

207.9218461

1.497512629

0.582568169

Fam108b

148.0053157

142.0256671

192.8039105

288.1898736

1.494730438

0.57988533

Cryzl1

125.3175801

126.6716065

86.93261232

129.5718874

1.490486526

0.575783334
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Dpy19l3

103.2834647

110.616663

69.3507446

103.0447787

1.485849638

0.571288128

Gm12250

55.20402184

32.72523713

136.5058251

201.8153063

1.478437321

0.564073081

Cbwd1

41.39508646

33.38402286

65.27061683

96.29824741

1.475369042

0.561075868

N4bp1

478.6895567

482.4494628

780.8389786

1150.383825

1.473266392

0.559018318

Nus1

346.9239852

322.0408198

511.0372807

751.1311596

1.469816759

0.555636307

9030625A04Rik

1092.525092

1078.301142

1251.983668

1838.379311

1.468373237

0.554218725

Xaf1

99.9944423

96.46777079

280.7204269

411.9669092

1.467534492

0.553394412

Rtp4

114.9161383

86.08614664

597.2106192

874.84436

1.464884133

0.550786557

Itga9

270.2473984

227.5405421

142.6423261

208.5962186

1.462372525

0.548310871

Cnih4

659.6283389

743.7715261

686.550657

1002.769775

1.460591093

0.546552338

Bnip3l

360.5179437

288.6604424

253.0386316

369.5284238

1.460363666

0.54632768

Pdcd2

159.6375444

148.7071445

187.5704278

273.8391868

1.459927293

0.545896522

Pgk1

425.614954

374.5189726

1061.308057

1548.18554

1.458752272

0.544734903

1110002L01Rik

57.5351324

55.73187733

42.36083739

61.77735259

1.458360042

0.544346938

179.0956325

200.4367015

260.3008978

379.3729383

1.457439992

0.543436483

Rpl27a
Cd47

1233.470172

1144.001632

1392.336326

2027.883884

1.456461234

0.542467303

Nlrc5

38.64116114

46.38886144

75.0257556

109.2621878

1.456329055

0.542336367

Wdr24

52.76900953

45.73867458

49.20221096

71.6301043

1.455831006

0.541842896

Pfkl

136.9954563

120.0827775

215.5591006

313.6920504

1.455248466

0.541265497

78.3509486

83.60756854

107.1310484

155.868663

1.454934544

0.540954249

Sp140
Rpl21

123.3074308

106.0812365

86.27189035

125.3598713

1.45307899

0.53911313

Glrx

155.1846194

161.2258053

433.1307159

628.4457989

1.450937963

0.536985837

Cd47

740.9342833

756.3274618

1134.826998

1643.963286

1.448646611

0.534705701

Ndufb4

65.92526158

69.40735924

67.66236332

97.9282795

1.447307997

0.533371969

3110052M02Rik

46.40908441

39.71673587

43.55280916

62.8760074

1.443672833

0.529743834

Lpxn

198.5251998

185.1502978

226.3695541

325.7892651

1.439192061

0.525259134

Tbc1d1

83.44827368

91.3838807

251.6878277

362.0733448

1.438581071

0.524646526

Rapgef2

170.2704444

210.6628908

267.2790618

384.4294827

1.438307513

0.52437216

Ddhd1

103.2662652

119.8272264

153.1646778

220.099412

1.437011556

0.523071664

Stxbp3a

352.1591275

346.394877

239.8355914

344.460039

1.436234034

0.522290856

Zbp1

54.69013981

50.89863607

291.5236308

417.0886887

1.430719999

0.516741355

Abhd10

105.3420066

76.68319126

76.71164377

109.5896762

1.428592464

0.514594416

Usp31

136.4610454

125.785323

190.9603667

272.5611624

1.427317967

0.513306763

Prdx5

761.4371071

668.65016

1143.257128

1626.560671

1.422742646

0.508674722

Nhp2l1

66.10818044

77.67119466

78.29032863

111.1693434

1.419962661

0.505852994

Nln

112.8398668

91.77256784

200.0771273

283.9952016

1.419428625

0.505310306

Rps16

1022.110315

2090.310998

2438.841368

3451.8117

1.415349003

0.501157843

Gstm1

166.5417525

136.5669282

157.7870078

222.7420829

1.411663013

0.497395735

Psma3

284.1174069

249.5861676

282.7688486

398.6669239

1.409868611

0.495560721

Brcc3

192.6562479

191.6440845

273.1970938

384.7271039

1.408240105

0.493893334

Eno1

431.3238654

428.6892245

822.1283218

1155.822794

1.405890983

0.491484728

Nlrc5

48.34564837

44.60529067

105.224491

147.8821383

1.405396567

0.490977279

Agpat2

85.20687754

80.17387044

102.7267537

144.331704

1.405005988

0.490576279

Ms4a6c

186.6238572

180.0580297

1505.69089

2114.04335

1.404035426

0.489579337
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Mettl10

60.92059125

53.53357193

64.49240977

90.53225876

1.403766103

0.489302573

Smpdl3b

74.21171474

63.25149304

148.760865

208.3547779

1.400602087

0.486047142

Table 4.4: Related to Figure 4.2; Transcripts downregulated in LPS-treated Bmal1 KO
microglia.
Microarray data is sorted by ratio of mean expression in LPS-treated Bmal1 KO/WT microglia. All
transcripts downregulated from controls by >30% in LPS-treatment with an uncorrected p value <0.01 by
2-tailed student’s t-test were included. Mean expression of N = 2 mice/condition in relative units in
columns 2-5.
Ratio
BMALKO
BMALKO
Log2(Fold
LPS
Gene/ID
WT PBS
PBS
WT LPS
LPS
change)
KO/WT
Rps13

797.6063608

21.92611304

707.9310617

32.19080275

0.045471663

-4.4588884

Bin2

753.2135539

688.5698666

326.2020126

121.5894693

0.372742855

-1.4237474

Etv1

359.8076196

373.3086812

154.4901971

58.31692287

0.377479762

-1.4055288

G530011O06Rik

1625.931399

1702.392362

932.3602677

365.3322664

0.391835945

-1.3516783

4933409K07Rik

114.4150197

148.9707368

190.6640548

78.38820045

0.411132557

-1.2823245

Fat3

195.5508748

265.900212

425.2514094

176.503455

0.41505672

-1.2686196

Nr1d2

611.9028822

109.9795486

168.1572068

70.40161715

0.418665477

-1.2561301

Plau

812.3374464

878.3142806

222.034511

94.51853731

0.425693001

-1.2321147

Capn3

378.4388103

394.0097061

131.3800704

58.95689162

0.448750647

-1.1560141

Fat3

264.7795055

275.285899

234.9271962

107.1877627

0.45625949

-1.1320735

Myo18b
Fat3

154.742737

141.601267

60.40731609

28.222248

0.467199171

-1.0978904

51.51846718

54.87274422

85.28169185

40.0831413

0.470008749

-1.0892405

Nynrin

56.62437484

58.54173966

56.99837891

27.02034362

0.474054598

-1.0768749

Fat3

159.6472479

189.1211562

253.0676245

120.9184919

0.477810989

-1.0654881

Cdk14

65.31084347

95.13982867

157.5374014

76.00602515

0.482463367

-1.0515087

Fat3

91.87079194

122.9117629

154.7754365

75.32369436

0.486664396

-1.0390009

Chn2

473.0772361

439.1457017

204.1801806

99.92881179

0.489414847

-1.0308702

Itga6

874.0450099

980.9650932

426.3027655

210.4210859

0.493595404

-1.0185991

Csmd3

269.5500049

262.6713027

72.38937968

36.65291234

0.506329969

-0.9818502

Serpine1

701.0266748

334.3781073

660.9261533

344.9484948

0.521916848

-0.9381081

Tmem54

66.7698701

92.19289161

127.9349414

67.06604835

0.524219948

-0.9317558

Rapgef5

379.1264086

390.354754

189.3307822

100.1515982

0.528976836

-0.9187235

9830001H06Rik

371.6637844

347.9363649

242.0283857

128.8812933

0.532504867

-0.9091334

Plxna4

456.1121667

523.0973756

102.4316192

55.43412665

0.541181786

-0.8858148

Fat3

93.32779472

121.5104036

194.8395247

106.2448292

0.545294028

-0.8748937

Tmc7

263.2721393

121.4289699

54.27103429

29.67181356

0.546733888

-0.8710893

Map1lc3b

101.0440249

52.86059093

119.8962082

65.87422768

0.549427114

-0.8640000

Fam110a

268.798702

271.854494

213.0281486

117.3658586

0.550940612

-0.8600313

Ralgps1

163.0155299

160.9866287

151.8169858

84.58656576

0.557161409

-0.8438328

2310079N02Rik

476.9836294

533.7433627

457.4761588

257.609217

0.5631096

-0.8285123

Nav3

788.631917

902.1471951

595.0473881

335.3740572

0.56360899

-0.8272335

Tssc4

53.3297963

64.56419225

134.9313483

76.51067937

0.567034128

-0.8184925
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Tanc2

2197.342138

2247.143854

886.1513546

503.726813

0.568443314

-0.8149116

Csmd3

546.9734479

538.693526

87.99076811

50.13929467

0.569824491

-0.8114105

Trim47

252.7570113

265.7876187

131.3468736

75.08830542

0.571679427

-0.8067217

Spns2

121.4692218

87.25827144

133.5462335

76.71542155

0.57444841

-0.7997508

R74862

67.20638633

62.61441187

47.65410661

27.41360391

0.575262152

-0.7977085

Abi3

767.6111868

727.0770772

560.5580774

324.9447384

0.579680771

-0.7866695

Fam71a

256.9081531

237.0880796

116.9306093

67.8461176

0.580225469

-0.7853145

Gm16486

140.3454963

172.1458328

100.7625342

58.47383996

0.580313312

-0.7850961

Fry

149.2003641

137.9816152

70.32121861

40.8339287

0.580677205

-0.7841917

76.6373253

55.41123831

119.6947234

69.62275649

0.581669388

-0.7817287

Rasl2-9-ps

55.85136267

39.99240541

33.42946906

19.61175351

0.586660634

-0.7694019

Slc40a1

229.9969428

246.5369858

62.68778306

36.9545408

0.589501479

-0.7624327

B3galt5

Nuak1

601.4073483

668.4473071

420.2579725

249.2016659

0.592973084

-0.7539615

Stradb

71.19731593

62.16310554

50.70931487

30.14984138

0.594562191

-0.7501004

Arhgap22

291.5803716

337.8933367

213.3162502

127.6667845

0.598485978

-0.7406106

Lphn2

298.6186414

250.9921535

160.7757

96.54085237

0.600469178

-0.7358379

A930001N09Rik

207.1063288

222.1212182

101.7419169

61.19235566

0.601446852

-0.7334908

4632428N05Rik

1284.816779

1260.639572

555.1549337

333.9967147

0.601627932

-0.7330565

Selplg

4812.96383

4633.470584

2617.466566

1576.120628

0.602155018

-0.7317932

Gpr56

1090.140846

1080.999424

301.2536217

182.5390092

0.605931335

-0.7227738

Jam2

427.053796

333.9171809

75.56772694

46.09628693

0.609999649

-0.7131197

Tanc2

840.5051996

817.3913462

382.5537501

233.7288093

0.610969855

-0.7108269

Arl4c

256.8863305

269.6414598

130.9120955

80.13251825

0.612109354

-0.7081387

Tspan13

589.6603777

523.5669807

454.0537868

279.0582854

0.614593014

-0.7022967

Entpd1

2160.262459

2246.373905

833.7015551

513.3597412

0.615759606

-0.6995609

Fyn

71.55930842

44.57594469

146.4617882

90.47683392

0.617750439

-0.6949040

Hist1h4c

124.7566038

118.8517135

71.25930739

44.07712535

0.61854552

-0.6930483

Fcrl1

273.6941735

316.1583457

90.13595056

55.7961351

0.619021986

-0.6919374

Mir27a

480.8904406

399.8008043

106.326097

65.93529156

0.620123313

-0.6893730

Gm9891

93.90955601

87.28447032

60.05360034

37.31102427

0.621295377

-0.6866488

Notch4

72.00834362

60.66712658

223.577309

139.3890186

0.623448861

-0.6816569

Cdc42ep3

56.39268371

48.62773775

26.83367549

16.74832524

0.624153231

-0.6800278

Neurl3

464.0925946

529.8798022

190.6707508

119.160955

0.624956657

-0.6781720

Acox3

365.1805812

387.3615511

135.2187977

84.86755487

0.627631338

-0.6720107

Rasgrp3

1403.475069

1367.343324

585.9443906

371.0164727

0.633194

-0.6592805

Csf1

294.4534753

276.7077815

366.9121677

232.4192765

0.633446631

-0.6587050

Usp2

386.7919063

411.763931

275.5471214

174.6354043

0.633776914

-0.6579530

Ankrd44

392.8755395

450.9422053

251.7795058

159.9462975

0.635263371

-0.6545733

Alox5ap

1592.000425

1458.137389

1051.299979

669.0171378

0.636371303

-0.6520593

Atp8a2

382.7792254

472.7969204

113.20336

72.27139513

0.638420937

-0.6474201

AB124611

95.27992224

106.9014897

320.3587426

205.4311678

0.641253509

-0.6410333

Gm10603

111.9813008

123.2315001

93.48261949

60.03552341

0.642210539

-0.6388818

Med22

132.653381

132.1863709

162.9349994

104.6962027

0.642564232

-0.6380874

Pros1

1248.612307

1208.643624

686.3802012

441.2355238

0.642844189

-0.6374590
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Raf1

85.64110518

68.44571625

83.27553075

53.56187578

0.643188645

-0.6366862

Gpr3

90.58458336

79.72619132

85.94360419

55.313588

0.643603308

-0.6357564

Upk1b

548.8613982

402.0224071

63.79562763

41.15829841

0.645158609

-0.6322742

F11r

1733.884354

1532.427348

889.8246888

576.3929578

0.647760132

-0.6264684

Krtap10-4

49.58563432

40.57753762

46.85237202

30.42306648

0.649338874

-0.6229565

Nlrp1c-ps

183.5959638

167.0591681

113.1891626

73.6820073

0.650963446

-0.6193516

2410022M11Rik

111.3186461

128.3076793

138.7966464

90.40592401

0.651355248

-0.6184835

6720401G13Rik

163.1978305

173.280546

153.0202554

99.83242847

0.652413161

-0.6161422

E130112L23Rik

156.9937427

143.7689643

105.9652943

69.34676634

0.654429045

-0.6116913

Arhgap24

100.5501573

107.8216095

547.8893284

358.7353201

0.654758729

-0.6109647

Arntl

75.80244653

74.93410853

90.75204829

59.46761063

0.655275685

-0.6098261

Trem2

1203.409639

1219.430268

546.3396208

358.2703469

0.6557649

-0.6087494

Rab3il1

538.1521381

587.996736

415.8060082

272.8454258

0.656184424

-0.6078267

Tmem204

254.8217265

242.9407434

104.0215857

68.29878447

0.656582805

-0.6069511

Nova1

127.8167052

128.7485733

112.6451367

74.48604546

0.661245107

-0.5967430

Strada

165.9980738

181.8995673

151.7193774

100.4154289

0.661849729

-0.5954244

Rassf3

97.87462415

110.5345514

91.15064536

60.37988797

0.662418656

-0.5941848

Rnase4

1279.236741

1300.4103

555.1913782

368.0718338

0.662963886

-0.5929978

Iffo1

128.8403338

121.1471023

80.44487772

53.4219806

0.664081817

-0.5905671

Kitl

97.58110668

82.25120549

71.09098365

47.24765151

0.664608212

-0.5894240

Msrb2

174.0637416

161.6585642

100.1903538

66.59478454

0.664682597

-0.5892625

Ypel3

602.8882176

586.8567849

182.0194069

121.7227762

0.668735155

-0.5804931

Arsg

125.4088152

114.8374464

91.75457897

61.40412277

0.669221345

-0.5794446

Arsb

1338.63033

1279.714829

713.9952911

479.8171552

0.672017254

-0.5734298

Chst1

170.1641854

121.8215092

108.0679122

73.05378282

0.675998836

-0.5649073

Slc1a3

221.2669588

198.8980188

293.7136045

198.6244741

0.67625221

-0.5643667

Coro6

63.83903858

87.62433079

72.36424089

48.98562586

0.676931386

-0.5629185

Nup210l

59.82391826

66.99646819

71.87806045

48.72235283

0.67784735

-0.5609677

Acads

149.3867115

151.4890716

98.05123031

66.53711243

0.678595385

-0.5593765

Bhlhe41

289.7309844

245.2596573

233.9968657

158.9874229

0.679442532

-0.5575766

Rogdi

325.5503039

302.1745459

188.9329575

128.5259482

0.68027278

-0.5558147

Clcf1

180.167012

223.629263

102.6711331

69.91622965

0.680972612

-0.5543313

Slc38a9

264.4928629

266.0019047

128.6112546

87.59162016

0.681057194

-0.5541521

Man2b1

1608.50852

1786.834359

1247.732775

853.4207436

0.683977179

-0.5479799

Dnajc12

152.5783163

127.554964

129.8493652

89.1303041

0.686413091

-0.5428510

Fat3

111.7836339

93.47261262

106.1541582

72.95896694

0.687292596

-0.5410037

Tjp1

1226.296243

1193.941677

479.4731445

329.766056

0.687767521

-0.5400071

Atp8b1

53.43486919

41.69344146

25.91075119

17.83790836

0.688436558

-0.5386044

Rasgef1b

1127.808864

1023.06349

490.6373713

338.5211515

0.689962019

-0.5354111
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Table 4.5: Related to Figure 4.2; Gene Ontology (GO) analysis on transcripts upregulated
in LPS-treated Bmal1 KO microglia.
Microarray data from Table 4.3 was analylzed for pathway enrichment using GO analysis336,337 with FDR
correction cutoff of p<0.05. Table is sorted by FDR-corrected p-value.
Analysis Type:
PANTHER Overrepresentation Test (Released 20190308)
Annotation Version and
Release Date:
GO Ontology database Released 2019-01-01
Analyzed List:
UpregBmal1KOLPS (Mus musculus)
Reference List:
Mus musculus (all genes in database)
Test Type:
FISHER
Correction:
FDR

GO biological process
complete

Mus
musculus REFLIST
(22296)

Number
genes
uploaded
(total 158)

Number
genes
expected

Fold
Enrichment

Raw Pvalue

FDR
corrected
P-value

Immune system process
(GO:0002376)

2240

52

15.87

3.28

6.10E-15

9.55E-11

Defense response (GO:0006952)

1299

36

9.21

3.91

2.02E-12

1.58E-08

Response to virus (GO:0009615)
Response to biotic stimulus
(GO:0009607)
Response to external biotic
stimulus (GO:0043207)
Innate immune response
(GO:0045087)
Response to other organism
(GO:0051707)

221

16

1.57

10.22

1.24E-11

3.89E-08

1047

31

7.42

4.18

1.83E-11

4.10E-08

1024

31

7.26

4.27

1.06E-11

4.15E-08

725

26

5.14

5.06

1.78E-11

4.65E-08

1022

31

7.24

4.28

1.01E-11

5.28E-08

1370

34

9.71

3.5

1.70E-10

3.33E-07

590

22

4.18

5.26

3.70E-10

6.44E-07

727

24

5.15

4.66

5.84E-10

8.31E-07

54

9

0.38

23.52

5.75E-10

9.01E-07

307

16

2.18

7.35

1.21E-09

1.58E-06

125

11

0.89

12.42

3.37E-09

4.06E-06

100

10

0.71

14.11

5.73E-09

6.41E-06

176

12

1.25

9.62

9.48E-09

9.90E-06

1268

29

8.99

3.23

2.76E-08

2.70E-05

1969

37

13.95

2.65

3.89E-08

3.58E-05

645

20

4.57

4.38

4.90E-08

4.26E-05

1472

31

10.43

2.97

5.34E-08

4.40E-05

3053

48

21.64

2.22

7.49E-08

5.87E-05

3377

51

23.93

2.13

8.05E-08

6.00E-05

Immune response (GO:0006955)
Regulation of defense response
(GO:0031347)
Response to cytokine
(GO:0034097)
Response to interferon-beta
(GO:0035456)
Positive regulation of defense
response (GO:0031349)
Response to interferon-gamma
(GO:0034341)
Cellular response to interferongamma (GO:0071346)
Defense response to virus
(GO:0051607)
Regulation of response to stress
(GO:0080134)
Response to external stimulus
(GO:0009605)
Regulation of cytokine production
(GO:0001817)
Regulation of immune system
process (GO:0002682)
Response to stress (GO:0006950)
Response to chemical
(GO:0042221)
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Cellular response to chemical
stimulus (GO:0070887)
Cellular response to cytokine
stimulus (GO:0071345)
Cellular amide metabolic process
(GO:0043603)
Positive regulation of cytokine
production (GO:0001819)
Positive regulation of immune
system process (GO:0002684)
Regulation of inflammatory
response (GO:0050727)
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Positive regulation of response to
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Negative regulation of viral
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Negative regulation of immune
system process (GO:0002683)
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Regulation of response to external
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positive regulation of adaptive
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6.59E-03

72

6

0.51

11.76

1.87E-05

6.64E-03
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4
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Table 4.6: Related to Figure 4.2; Gene Ontology (GO) analysis on transcripts
downregulated in LPS-treated Bmal1 KO microglia.
Microarray data from Table 4.4 was analylzed for pathway enrichment using GO analysis336,337 with FDR
correction cutoff of p<0.05. Table is sorted by FDR-corrected p-value.
Analysis Type:
PANTHER Overrepresentation Test (Released 20190308)
Annotation Version
and Release Date:
GO Ontology database Released 2019-01-01
Analyzed List:
DownregBmal1KOLPS (Mus musculus)
Reference List:
Mus musculus (all genes in database)
Test Type:
FISHER
Correction:
FDR
GO biological process
complete
cell differentiation
(GO:0030154)
cellular developmental
process (GO:0048869)
anatomical structure
morphogenesis
(GO:0009653)
developmental process
(GO:0032502)
anatomical structure
development
(GO:0048856)

Mus
musculus REFLIST
(22296)

Number
genes
uploaded
(total - 93)

Number
genes
expected

Fold
Enrichment

Raw Pvalue

FDR
corrected
P-value

3616

35

15.08

2.32

6.37E-07

4.98E-03

3704

36

15.45

2.33

3.64E-07

5.70E-03

2144

24

8.94

2.68

5.95E-06

2.33E-02

5351

42

22.32

1.88

8.28E-06

2.59E-02

5070

41

21.15

1.94

5.31E-06

2.77E-02

134

multicellular organism
development
(GO:0007275)
system development
(GO:0048731)

4705

38

19.63

1.94

1.76E-05

4.59E-02

4142

35

17.28

2.03

2.15E-05

4.82E-02
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5.1 Implications for the degenerating star clock
An innovative and substantial body of work now implicates the circadian clock in regulating a
number of biological processes outside of behavioral rhythms including the peripheral immune
system and the microglial immune response141,200,214. Sleep abnormalities and other forms of
circadian disruption are common occurrences in aging and neurodegeneration8,171,172,214,339 in
which the brain’s immune response plays a central role245,246,340. Research into the relationship
between circadian dysfunction and neurodegenerative disease has begun to uncover a novel role
for the clock in regulating plaque deposition261 and for sleep in regulating Alzheimer’s-related
tau262 and amyloid259 pathology. However, the mechanisms governing this relationship as well
as the potential involvement of microglia and astrocytes remain unclear. While several groups
have now shown astrocytes as an integral player in controlling behavioral circadian rhythms30–33,
the role of astrocytic and microglial clocks in extra-circadian functions such as in neuroimmunity
and Alzheimer’s disease (AD) remains largely unexplored.
Here, we present evidence that the circadian clock cell-autonomously controls astrogliosis
through regulation of glutathione signaling. We show that loss of circadian clock function in
astrocytes impairs their ability to support neuronal health and strongly suppresses their
production of Chi3l1. We demonstrate that Chi3l1 deficiency exacerbates acute endotoxinmediated inflammation, but mitigates Aβ-plaque deposition in a mouse model of AD and is
associated with slower AD progression in humans. Therefore, we identify Chi3l1/YKL-40 as a
clock-regulated astrocytic protein and a potentially viable therapeutic target for the treatment of
AD. In a preliminary study, we demonstrate that the deletion of microglial Bmal1 induces
oxidative stress and hyperinflammation. Altogether, these studies suggest that the circadian
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clock regulates gliosis and immune function relevant to AD in both astrocytes and microglia.
Thus, disruption of this regulation as may occur in aging or neurodegenerative disease could
have significant consequences for disease pathogenesis and overall brain health. While this work
is an important step forward in elucidating the link between circadian dysfunction in disease,
glial activation, and the pathogenesis of AD, many unanswered questions remain. A selection of
the most intriguing unanswered questions along with their potential implications will be briefly
discussed at the conclusion of this chapter.
We have shown that removal of Bmal1 from astrocytes, in vitro using astrocyte cultures with
Bmal1 KO and knockdown as well as in vivo using brain-specific germline deletion, tamoxifen
inducible global deletion, viral astrocyte-specific deletion, and tamoxifen-inducible, astrocytespecific deletion, drives astrogliosis. Although Gfap mRNA and protein levels are utilized as
primary benchmarks for the identification of astrogliosis, this phenotype is not limited to changes
in Gfap. The expression of other astrocyte activation markers including a number of A1, A2,
pan reactive, and previously described markers such as Aqp4, C4b, and Pla2g3 are altered as a
result of Bmal1 deficiency. Thus, the loss of Bmal1 induces a previously undescribed
astrogliosis phenotype mediated at least in part through disruption of glutathione signaling.
In a process called glutathionylation, glutathione-s-transferases (GSTs) can catalyze the
reversible addition of glutathione to protein cysteine residues275. Glutathionylation can serve to
mitigate oxidative damage341 or as a signaling mechanic in pathways such as mitochondrial
metabolism283 and apoptosis342. Glutathionylation in the SCN varies based on time of day,
suggesting an interaction with the molecular clock276. Our data suggest that the Bmal1dependent altered pattern in glutathionylated proteins, without a change in glutathione levels or
oxidation state may be key in the induction of BMAL1-regulated astrogliosis (See Figure 2.4,
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S2.3). Recently, another report documented mitigation in astrocytic and microglial inflammation
with loss of specific GSTs343. However, it is likely that the combination of changes in
glutathione signaling documented here is not faithfully recapitulated by deleting specific GSTs
and therefore an identical outcome should not be expected. Thus, further studies should more
concretely elucidate the role of glutathione signaling and redox homeostasis in the regulation of
astrocyte and microglia activation.
One functional consequence of our described astrogliosis phenotype is diminished neuronal
support (See Figure 2.5, S2.4), though the mechanism remains elusive. Consistent with the data
documented here, others have shown that disruptions to the clock, including Bmal1 deletion, in
the periphery16,17,180,184,190, in the brain15, in microglia198 and perhaps in astrocytes197 can induce
inflammation and oxidative stress176,200. Additionally, reactive astrocytes can secrete a number
of neurotoxic factors such as C392, IL-1β, TNFα344, NO345, and others2,84. Thus, Bmal1-deficient
astrocytes may secrete factors that cause neuronal damage. It is also possible that deletion of
Bmal1 restricts the ability of astrocytes to provide neurons with crucial metabolic support61–63,
resulting in neuronal loss. The differentiation of these explanations, exploration of alternatives,
and the in vivo relevance of this phenotype should be investigated in the future.
The majority of experiments employed herein specifically involve manipulations to Bmal1.
Given this Bmal1 specificity, that Per1/2mut mice do not develop pronounced increases in Gfap,
and that the downstream effector Chi3l1 does not oscillate, it is possible that BMAL1 regulates
the astrogliosis phenotype detailed in these studies independently from its role in the circadian
clock. However, while behavioral desynchrony does result in the loss of Bmal1 oscillations, it
does not deplete Bmal1 expression in the brain (See Figure 2.2, S2.1). This loss in the Bmal1
transcription rhythm is sufficient to drive an increase in Gfap. Further, other components altered
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in the described astrogliosis, such as Chi3l1, are also altered in Per1/2mut mice, though in the
opposite direction. This suggests that locking the clock in a positive or negative limbpredominant mode (by deletion of components of the other limb) has reciprocal effects on gene
transcription. Additionally, given that Bmal1 is rhythmically expressed, that BMAL1 drives
transcription by binding to DNA E-boxes in a rhythmic manner278, and that these actions are
dependent on a functioning molecular clock121, it is difficult to completely separate regulation by
BMAL1 from regulation by the circadian clock. Taken in this context, our data suggest that
disruptions to the astrocyte circadian clock that affect Bmal1 levels or rhythmicity are sufficient
to drive astrogliosis.
Recent studies have begun to connect behavioral circadian dysfunction, such as occurs in AD,
with changes in the molecular clock215–217. Additionally, a single study purported a dampening
of microglial clock gene oscillations with age195. Despite these advances, possible alterations to
the astrocytic or microglial clocks in aging or neurodegeneration, along with any associated
pathological consequences have yet to be thoroughly investigated. The data presented here
identify substantial consequences for brain health resulting from glial molecular clock
dysfunction. For instance, Bmal1-regulated astrogliosis results in almost complete depletion of
the inflammatory regulator and AD biomarker Chi3l1, the loss of which incurs a complex set of
functional repercussions. Unlike Bmal1 depletion, Chi3l1 deficiency does not induce
astrogliosis by the markers measured in this study, including Gfap. Thus, the loss of Chi3l1 is
unlikely to be the mechanism by which Bmal1 deficiency induces astrocyte activation.
However, Bmal1 deletion also induces inflammatory factor production both in vitro and in vivo.
Overlap in inflammatory factor overproduction between Chi3l1-deficient, LPS-treated cultured
astrocytes and whole cortex, such as in the cases of Ccl2 and Nos2, suggests that astrocytes shift
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toward a pro-inflammatory state in the absence of Chi3l1. Thus, loss of Chi3l1 could be the
means by which Bmal1 depletion induces inflammation, independent of Gfap expression.
Loss of Bmal1 in astrocytes, but not microglia, depletes Chi3l1 in vitro and in vivo.
Accordingly, Chi3l1 levels are almost completely lost in Nestin-Bmal1 KO mice in which
microglial clocks remain intact. Thus, in contrast to the case of peripheral macrophages230,231,346,
microglia do not make a substantial contribution to brain levels of Chi3l1/YKL-40 at baseline.
As is the case with Apoe212, it is possible that microglia strongly upregulate Chi3l1 under certain
conditions. However, the robust and dynamic induction of Chi3l1 in primary astrocytes in
response to LPS and Aβ, the exacerbation of inflammation with astrocytic Chi3l1 knockdown,
and the dramatic drop in Chi3l1 with Bmal1 manipulations both in vitro and in vivo suggest that
BMAL1-controlled, astrocytic Chi3l1 is a major contributor to neuroimmune regulation.
Nevertheless, the exacerbated upregulation of cytokines, chemokines, and immune response
genes specific to microglia in the brain such as Nlrp3 and Cybb in Chi3l1-deficient mice treated
with LPS suggest that secreted Chi3l1/YKL-40 may also be acting through microglia. This
possibility is consistent with data from the periphery in which Chi3l1/YKL-40 suppresses
bacteria-induced expression of inflammatory factors such as Nlrp3 in macrophages231 and
mitigates apoptosis in lung tissue in the setting of oxidative stress230. Given our described
astrocytic production of Chi3l1, it is possible that secreted Chi3l1/YKL-40 represents a novel
communication signal and neuroinflammatory regulator between astrocytes and microglia in the
brain. Future studies should examine this possibility.
Further evidence of a potential role for Chi3l1/YKL-40 in facilitating astrocyte/microglia
crosstalk during a neuroimmune response stems from our investigation into Chi3l1-/-:APP/PS1
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mice. In the setting of Aβ-plaques, both astrocytes and microglia are markedly affected by the
absence of Chi3l1. Interestingly, we observed attenuation of Aβ-induced activation marker
expression in both astrocytes and microglia in these mice, implying that Chi3l1/YKL-40
promotes glial activation in these conditions. This suppression is consistent with microglia
marker suppression in our LPS-treated animals, but contrasts with the lack of change observed in
astrocyte markers in the setting of LPS. In addition, the absence of Chi3l1 induces
hyperinflammation in the setting of LPS, but not in the setting of Aβ pathology. A possible
reconciliatory explanation for these discrepancies stems from the divergent immune pathways
stimulated by LPS and Aβ. Specifically, LPS initiates an “M1” type pro-inflammatory response
through binding to the TLR4 receptor, resulting in NF-κB activation in macrophages and
microglia. This binding leads to the release of toxic factors such as TNFα and NO335,347–351. As
TLR4 is more highly expressed in microglia273, it is possible that the differences seen here can be
explained by microglia simply responding more strongly to LPS.
Along similar lines, LPS inhibits microglial expression of factors such as Trem2352 (also see
Figure S3.3), which is normally upregulated in the presence of Aβ353,354 (also see Figure 3.6).
The full induction of DAM markers, denoting a pro-phagocytic microglial state documented in
AD and other neurodegenerative diseases, requires TREM2212. Conversely, TREM2 can inhibit
the pro-inflammatory “M1” activation state355,356. As the activation state of astrocytes, especially
in the presence of LPS, may depend on microglia77,84, divergent microglial activation states may
also exert divergent effects on astrocyte activation. Together, these data suggest that our
observed differences in glial activation and inflammation between models (LPS vs. APP/PS1)
may reflect the initiation of fundamentally different neuroimmune pathways. Accordingly, the
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effect of Chi3l1/YKL-40 on these two distinct pathways/polarization states of microglia, and by
extension astrocytes, appears to be very different.
The role of astrocyte activation in regulating amyloid plaque pathology is still incompletely
understood. The seemingly dissonant previous investigations into blocking astrocyte activation
in APP/PS1 mice - Gfap:Vimentin double KO increasing202 and Stat3 suppression
decreasing204,205 plaque burden – could reflect differing methodologies. For instance, it is
possible that the severe impediment induced by removing all intermediate filaments (astrocytes
are unable to generate Nestin or Synemin filaments without Gfap and Vim357,358) causes
generalized astrocyte dysfunction, impairing a healthy immune response to Aβ. In contrast to
this dramatic functional alteration, tamoxifen-inducible Stat3 deletion as well as inhibition of the
JAK2-STAT3 pathway was able to modulate the astrocyte activation state, suppressing several
“A1” markers, upregulating several “A2” markers, and suppressing inflammation204,205. Our
findings of weakened, but still present, inflammation, astrocyte activation, and microglial
activation marker expression in Chi3l1-/-;APP/PS1 brain are more consistent with the Stat3
inhibition studies. Together, these data suggest that tempering, rather than completely
preventing astrocyte activation is beneficial in the setting of Aβ-plaques. Additionally, we show
increased microglial CD68 per plaque, which is congruous with the increased microglial plaque
clustering in both previous studies. Thus, it is likely that the astrocyte activation shift seen with
Chi3l1 deletion acts synergistically with the described microglial changes to lower both brain
inflammation and plaque burden. Relatedly, substantially limiting astrocyte function by deleting
Aqp4 amplified Aβ deposition257. However, in this case, microglial clustering was lessened.
These data further emphasize the need to more thoroughly characterize the interplay between
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astrocytic and microglial activation as well as a potential role for Chi3l1/YKL-40 signaling in the
attempted resolution of Aβ-plaque pathology.
One of the most intriguing findings of this study is the dramatic reduction of non-fibrillar Aβ
with Chi3l1 deletion. Soluble species of Aβ are thought to serve as precursor seeds for359,360 and
may incur increased toxicity over361–363 fibrillar Aβ-plaques. Thus, a therapeutic strategy in
which non-fibrillar Aβ is preferentially cleared could both slow the rate of plaque deposition and
mitigate damage. As Aβ accumulation precedes and is hypothesized to eventually trigger the
deposition of the more toxic tau aggregates219,364, such a strategy could serve to postpone
presentation of clinical symptoms. This idea is consistent with our human data in which a SNP
resulting in diminished YKL-40 is associated with a slower progression of AD clinical
symptoms in humans. This association is an important validation of the mouse work presented
here. The marked decrease in plaque pathology observed in our Chi3l1-/-:APP/PS1 mice
suggests that less human YKL-40 could influence disease progression through affecting Aβplaque deposition. However, future studies should investigate the possibility that lowered YKL40 could also affect human disease through changes to tau pathology. Data that Aβ can
exacerbate tau pathology365 suggest that an effect of YKL-40 on tau pathology could also occur
indirectly. That is, slowing Aβ-plaque deposition could depress tau deposition and thus overall
disease progression.
Targeting Aβ in clinical trials has been a complicated endeavor219. Trials have failed due to
adverse events such as meningoencephalitis366 or because of off-target effects on Notch
signaling367. However, even when trials have achieved a reduction in Aβ, there has been little
documented effect on clinical symptoms368–371. There are many possible reasons for this lack of
efficacy on disease progression, including a predominant theory that treatments were started too
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late in the disease course. Thus, current efforts are being made to refine ongoing trials to
minimize inflammatory and other off-target effects while initiating the trials at an earlier disease
stage219. In the case of antibodies targeting Aβ, follow-up reports have attributed the Aβ
reduction achieved, at least in part, to increased clearance by microglia372, which has been
documented via increases in CD68373. Here, we show increased CD68 staining per plaque and a
lack of changes in Aβ processing gene expression, suggesting unaltered Aβ production. Thus, it
is likely that Chi3l1 deletion facilitates microglial uptake and degradation of Aβ. As Chi3l1
deficiency curtails Aβ deposition without increasing inflammation, inhibition of CHI3L1/YKL40 could be an effective therapeutic substitute for Aβ antibodies. Further, our documented
slowing of human AD progression with lower CHI3L1/YKL-40 suggests that inhibiting
CHI3L1/YKL-40 may be efficacious in treating disease progression whether or not it reduces Aβ
in humans. However, our data demonstrating an exacerbation of LPS-induced inflammation in
the absence of Chi3l1 suggest that Chi3l1/YKL-40 may undertake differential signaling roles
depending on the inflammatory stimulus and other pathways that are concomitantly activated.
Thus, the viability of Chi3l1/YKL-40 inhibition as an AD treatment option should be approached
with caution and thoroughly vetted for possible side effects including implications for
comorbidities.

5.2 Next time…
As alluded to throughout this discussion, the work presented here has uncovered a number of
exciting avenues for future inquiry. While not a comprehensive list, several remaining questions
leading to potentially prosperous lines of investigation are briefly outlined below.
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1) Are changes to microglial or astrocytic molecular clocks physiologically relevant in aging
or neurodegeneration? While initial work has shown that aging195,331,374 or Aβ215–217 can affect
the molecular clock, the applicability of these studies to glial clocks, especially outside of the
SCN, in mice or humans during aging or AD remains poorly understood. Moreover, while our
data suggest that behavioral desynchrony is sufficient to disrupt cortical clock gene rhythmicity,
the specific effect on glial clocks has not been investigated. Ideally, single cell RNAseq could be
performed on cortical or hippocampal tissue from mouse models and humans of different ages
and pathologies across times of day. While “time of day” in the mouse iteration of this
undertaking is easily controlled, timing of the human tissue would be reliant on an accurate time
of death and rapid freezing of tissue, as has been done previously in a microarray study375.
Single nucleus RNAseq can be successfully performed on frozen human brain tissue376,377 and
would presumably allow analysis of clock gene oscillation fidelity in all cell types under the
chosen conditions. In addition, any abnormalities in clock gene expression and/or oscillations
could be correlated with glial activation and inflammation marker expression. Thus, this strategy
also has the potential to validate the link between the clock and gliosis documented in the present
study. Alternatively, a less robust strategy, but still theoretically possible even from frozen
human tissue378, would be to perform RNAseq on cell types of interest sorted by fluorescenceactivated cell sorting (FACS). The identification of an effect of aging or neurodegeneration on
the circadian clock would help strengthen the connection between the research presented here
and its applicability to human disease.
2) What are the downstream functional consequences for clock-controlled astrocyte or
microglia activation on learning and memory? As an initial undertaking, the potential
implications of our documented neuronal support deficit in Bmal1 KO astrocytes should be
146

investigated in vivo. The examination of synaptic integrity in Aldh1l1- CreERT2;Bmal1f/f mice via
pre- and post-synaptic marker colocalization211 would be a reasonable approach in this regard.
Functional connectivity deficits have also been observed in both Bmal115 and Nr1d1 (REVERBα)198 whole body KO mice. Therefore, a possible role for astrocytic or microglial Bmal1
KO in causing similar dysfunction should be evaluated. Given the substantial influence of
astrocytic clock function on animal behavioral rhythms30–33, circadian changes in memory
function152,153, and the possible role for astrocytes in synaptic strengthening28,29, astrocytespecific Bmal1 KO mice should be assessed for behavioral memory deficits, as well as
alterations in electrophysiological correlates of learning and memory, such as LTP and LTD.
Changes in learning and memory resulting from glial clock disruption would emphasize the need
for optimizing circadian health, including for instance, maintaining good sleep hygiene and
minimizing nighttime light exposure. These studies could also serve to inform policies
governing daily activities such as school scheduling and daylight savings time.
3) How does disruption of glial clocks impact AD pathogenesis? The ongoing investigation
into the microglial clock and neurodegeneration is discussed in Chapter 4. The astrocyte clock
regulates Chi3l1 and Chi3l1 depletion has a mitigating effect on Aβ pathology and human AD
progression. However, our lab has previously shown increased Aβ deposition in constitutive
global and brain-specific Bmal1 KO;APP/PS1 mice261. Despite this seeming discrepancy, there
are multiple possible unifying explanations. First, the exact combination of genes controlled by
the clock varies between tissues137. At the same time, we have shown specific cases of cell-typedependent gene regulation by the clock as with Chi3l1 and Gfap in astrocytes. Thus, the number
and identity of clock-controlled genes likely differ between astrocytes, microglia, and neurons.
As each of these cell types plays a unique role in AD pathogenesis, it follows that the effect of
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clock disruption on AD pathology may be cell-type specific. For instance, activation of
astrocytes in response to Bmal1 deletion might promote Aβ degradation, while altered microglial
activation in response to microglial Bmal1 deletion might enhance cytokine release and promote
plaque formation. These potential differences will need to be determined empirically, and may
provide important insights into the relative roles of different cell types in AD pathogenesis.
Moreover, the effect of global clock disruption on sleep-wake cycles and other peripheral
rhythms is likely to have a major impact on Aβ metabolism that will not be observed in other cell
type-specific mutants, and could overwhelm the effects of the clocks in astrocytes or microglia.
Second, the core clock in a given cell type may regulate multiple targets which have conflicting
effects on amyloid pathology or inflammation. For instance, enacting a single component of the
astrogliosis present in Bmal1 KO astrocytes, namely Chi3l1 depletion, may be beneficial, but
astrocytic clock disruption as a whole may be detrimental due to differential regulation of other
targets. The documented neuronal support deficit with astrocytic Bmal1 KO (see Chapter 2)
suggests that simultaneous disruption of all pathways regulated by the clock and/or BMAL1 in
astrocytes is detrimental to neuronal health, supporting the second hypothesis. Thus, it is
important to characterize the targets of the clock in a given cell type, what effect these targets
have on AD pathology, and which effects are strongest. Toward this end, similar pathological
measures contained in this study including Aβ pathology and the associated glial response should
be evaluated in astrocyte-specific Bmal1 KO;APP/PS1 (Aldh1l1- CreERT2;Bmal1f/f;APP/PS1)
mice. Understanding of the connection between glial clock dysfunction and progression of
human AD could be strengthened further through examination of the measures contained in
direction (2) in these mice and in microglia Bmal1 KO equivalents to identify potential
implications for clock-regulated gliosis on learning and memory in AD. In this process, we may
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gain a better appreciation of the complexity through which glial cells contribute to AD
pathogenesis.
4) Does Chi3l1/YKL-40 serve a regulatory role in microglia-astrocyte crosstalk during AD?
Concomitant changes in microglial activation, astrocyte activation, inflammation, and microglial
phagocytosis in Chi3l1-/-:APP/PS1 mice suggest that Chi3l1/YKL-40 secretion could be a
potential mechanism through which astrocytes regulate microglial activation, phagocytosis,
and/or inflammation. However, it is important to keep in mind that the effect of Chi3l1/YKL-40
on inflammation and glial activation described here seem to be perturbation-specific. Critically,
the development of a mouse with floxed Chi3l1 alleles would allow tissue specific-deletion of
Chi3l1 in astrocytes, microglia, and even peripheral macrophages. These mice would enable
parsing of the relative effects of Chi3l1/YKL-40 in these different cell types. Mechanistically,
data from the periphery highlights Chi3l1/YKL-40 signaling through a IL-13Rα2-dependent
pathway in limiting inflammation and oxidative damage in macrophages230,346. According to
existent online databases, in the human CNS, Il-13ra2 is expressed in fetal astrocytes and
neurons, while in mice expression is inconclusive37,273,298. However, Il-13ra1 is primarily
expressed in microglia37,273,298. Taken together, investigation into a role for IL-13Rα in a
possible microglial response to Chi3l1/YKL-40 is a potentially fruitful undertaking. Treatment
of both astrocytes and microglia with recombinant YKL-40 protein under various inflammatory
stresses, including Aβ, with and without Il-13ra1/2 knockdown could serve as an effective
screen for the involvement of this pathway. Positive results from this screen would then suggest
microglia-specific deletion of the applicable Il-13ra family member in vivo in the presence of
AD pathology for a potential recapitulation of the effects described here with Chi3l1 deletion.
Identification of the effector cell types and regulatory pathways involved in the phenotypes
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documented in this study have the potential to enrich our understanding of AD pathogenesis and
inform the development of relevant therapeutics.
5) Is CHI3L1/YKL-40 inhibition a viable treatment for AD progression in humans?
Although data presented here demonstrate a correlation between diminished CHI3L1/YKL-40
and slowing of AD progression in humans, a causative relationship as well as mechanistic clarity
have yet to be characterized. Our mouse data suggest that loss of Chi3l1 may be slowing AD in
humans through mitigation of Aβ-plaque pathology. However, tau pathology, and not Aβ, more
closely mirrors clinical AD progression379. As the presence of Aβ can serve as a trigger for tau
pathology365, it is possible that decreasing Aβ deposition by inhibiting or deleting Chi3l1/YKL40 could slow overall disease progression. Injection of tau lysates into Chi3l1-/-:APP/PS1 mice
would enable analysis of the possibility that Chi3l1 deletion could slow progression, in terms of
behavioral measures as well as protein aggregation and associated gliosis, in the presence of
pathology that more closely resembles that of human AD365. Thus, such an investigation has the
potential to offer further insight linking the mitigation of Aβ-plaque deposition documented here
to the slowing of the disease in humans. Because CHI3L1/YKL-40 is a secreted protein,
monoclonal antibodies targeting extracellular YKL-40 could potentially be employed as a
therapeutic to prevent YKL-40 signaling in the AD brain. Moreover, antisense oligonucleotides
or small molecule inhibitors307 could be used to target Chi3l1 expression. These studies would be
important steps toward validating CHI3L1/YKL-40 inhibition as a potential treatment for human
AD.
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5.3 Dissertation conclusion
In summary, we have shown that astrogliosis is cell-autonomously regulated by BMAL1, that
Chi3l1/YKL-40 is an astrocytic protein regulated by the circadian clock and that Chi3l1
depletion mitigates Aβ pathology in mice and AD progression in humans. In a preliminary
study, we have provided evidence that the microglial clock may regulate inflammation and
oxidative stress in mice. Thus, we have identified both Chi3l1/YKL-40 specifically and glial
circadian clocks generally as potentially viable therapeutic targets for the treatment of AD.
Taken together, these studies represent an important advancement in characterizing the link
between circadian dysfunction and neurodegenerative disease.
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